<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11900337</article-id><article-id pub-id-type="pmcid-ver">PMC11900337.1</article-id><article-id pub-id-type="pmcaid">11900337</article-id><article-id pub-id-type="pmcaiid">11900337</article-id><article-id pub-id-type="pmid">40076637</article-id><article-id pub-id-type="doi">10.3390/ijms26052012</article-id><article-id pub-id-type="publisher-id">ijms-26-02012</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine Development: Lessons, Challenges, and Future Innovations</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Santamarina-Fern&#225;ndez</surname><given-names initials="R">Rebeca</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fuentes-Valverde</surname><given-names initials="V">V&#237;ctor</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref><xref rid="af2-ijms-26-02012" ref-type="aff">2</xref><xref rid="af3-ijms-26-02012" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva-Rodr&#237;guez</surname><given-names initials="A">Alis</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0418-296X</contrib-id><name name-style="western"><surname>Garc&#237;a</surname><given-names initials="P">Patricia</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref><xref rid="af2-ijms-26-02012" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8977-3269</contrib-id><name name-style="western"><surname>Moscoso</surname><given-names initials="M">Miriam</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref><xref rid="af2-ijms-26-02012" ref-type="aff">2</xref><xref rid="c1-ijms-26-02012" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8837-0062</contrib-id><name name-style="western"><surname>Bou</surname><given-names initials="G">Germ&#225;n</given-names></name><xref rid="af1-ijms-26-02012" ref-type="aff">1</xref><xref rid="af2-ijms-26-02012" ref-type="aff">2</xref><xref rid="af4-ijms-26-02012" ref-type="aff">4</xref></contrib></contrib-group><aff id="af1-ijms-26-02012"><label>1</label>Servicio de Microbiolog&#237;a, Instituto de Investigaci&#243;n Biom&#233;dica de A Coru&#241;a (INIBIC), Complexo Hospitalario Universitario de A Coru&#241;a (CHUAC), Sergas, 15006 A Coru&#241;a, Spain; <email>rebeca.santamarina.fernandez@udc.es</email> (R.S.-F.); <email>victorfueval@gmail.com</email> (V.F.-V.); <email>alis.silva@udc.es</email> (A.S.-R.); <email>patricia.garcia.fernandez@sergas.es</email> (P.G.); <email>german.bou.arevalo@sergas.es</email> (G.B.)</aff><aff id="af2-ijms-26-02012"><label>2</label>CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain</aff><aff id="af3-ijms-26-02012"><label>3</label>&#193;rea de Medicamentos Biol&#243;gicos, Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios (AEMPS), 28022 Madrid, Spain</aff><aff id="af4-ijms-26-02012"><label>4</label>Departamento de Fisioterapia, Medicina y Ciencias Biom&#233;dicas, Universidad de A Coru&#241;a, 15006 A Coru&#241;a, Spain</aff><author-notes><corresp id="c1-ijms-26-02012"><label>*</label>Correspondence: <email>mirian.moscoso.naya@sergas.es</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>26</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">484054</issue-id><elocation-id>2012</elocation-id><history><date date-type="received"><day>11</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-14 06:25:22.633"><day>14</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-02012.pdf"/><abstract><p><italic toggle="yes">Pseudomonas aeruginosa</italic> is an opportunistic pathogen with a multidrug-resistant profile that has become a critical threat to global public health. It is one of the main causes of severe nosocomial infections, including ventilator-associated pneumonia, chronic infections in patients with cystic fibrosis, and bloodstream infections in immunosuppressed individuals. Development of vaccines against <italic toggle="yes">P. aeruginosa</italic> is a major challenge owing to the high capacity of this bacterium to form biofilms, its wide arsenal of virulence factors (including secretion systems, lipopolysaccharides, and outer membrane proteins), and its ability to evade the host immune system. This review provides a comprehensive historical overview of vaccine development efforts targeting this pathogen, ranging from early attempts in the 1970s to recent advancements, including vaccines based on novel proteins and emerging technologies such as nanoparticles and synthetic conjugates. Despite numerous promising preclinical developments, very few candidates have progressed to clinical trials, and none have achieved final approval. This panorama highlights the significant scientific efforts undertaken and the inherent complexity of successfully developing an effective vaccine against <italic toggle="yes">P. aeruginosa</italic>.</p></abstract><kwd-group><kwd><italic toggle="yes">Pseudomonas aeruginosa</italic></kwd><kwd>virulence factors</kwd><kwd>vaccines</kwd><kwd>adaptative immunity</kwd><kwd>preclinical development</kwd><kwd>antigen</kwd><kwd>antibody</kwd><kwd>cytokines</kwd><kwd>nanoparticles</kwd><kwd>clinical trials</kwd></kwd-group><funding-group><award-group><funding-source>SERGAS-Galician Healthcare Service</funding-source></award-group><award-group><funding-source>CIBERINFEC</funding-source><award-id>CB21/13/00055</award-id></award-group><award-group><funding-source>Ministry of Economy and Competitiveness</funding-source><funding-source>Institute of Health Carlos III</funding-source><award-id>PI18/00501</award-id><award-id>PI21/00704</award-id></award-group><award-group><funding-source>Conselleria de Cultura</funding-source><award-id>IN606A-2019/012</award-id></award-group><funding-statement>This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program &#8220;Innova Sa&#250;de&#8221;), CIBERINFEC (CB21/13/00055), and the projects PI18/00501 and PI21/00704 to G.B., integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013&#8211;2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. V.F-V. is funded by a predoctoral fellowship from Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-ijms-26-02012"><title>1. <italic toggle="yes">Pseudomonas aeruginosa</italic>: A Clinically Relevant Pathogen</title><p>The rapid rise of antimicrobial resistance (AMR) is among the top 10 global health threats identified in the 13th General Programme of Work 2019&#8211;2023 (GPW13) [<xref rid="B1-ijms-26-02012" ref-type="bibr">1</xref>]. Abban and Ayerakwa estimated that 4.95 million deaths worldwide are associated with AMR, warning that underdeveloped countries experience higher mortality rates [<xref rid="B2-ijms-26-02012" ref-type="bibr">2</xref>]. There is therefore an urgent need to consider AMR a critical global public health and socio-economic problem. <italic toggle="yes">P. aeruginosa</italic> is one of the main pathogens associated with AMR-related deaths [<xref rid="B2-ijms-26-02012" ref-type="bibr">2</xref>,<xref rid="B3-ijms-26-02012" ref-type="bibr">3</xref>].</p><p><italic toggle="yes">P. aeruginosa</italic> is an aerobic, nonfermenting, Gram-negative bacillus in the <italic toggle="yes">Pseudomonadaceae</italic> family and is characterized by polar flagellum-driven motility. It is found in almost all environments, ranging from water and soil to humans, and it is a pathogen of medical relevance due to its resistance mechanisms and ability to infect vulnerable populations [<xref rid="B4-ijms-26-02012" ref-type="bibr">4</xref>]. The National Healthcare Safety Network (NHSN) and the U.S. Centers for Disease Control and Prevention (CDC) have identified <italic toggle="yes">P. aeruginosa</italic> as a prevalent pathogen in healthcare-associated infections, with particularly high incidence rates in long-term care hospitals [<xref rid="B5-ijms-26-02012" ref-type="bibr">5</xref>]. This trend highlights the global challenge, with the American and African continents being particularly affected by this pathogen [<xref rid="B6-ijms-26-02012" ref-type="bibr">6</xref>,<xref rid="B7-ijms-26-02012" ref-type="bibr">7</xref>].</p><p>The opportunistic nature of <italic toggle="yes">P. aeruginosa</italic> allows it to colonize healthy skin and hospital environments. The bacterium can contaminate various surfaces and can be transmitted by healthcare workers to immunosuppressed patients such as burn victims, cancer patients, and transplant recipients [<xref rid="B8-ijms-26-02012" ref-type="bibr">8</xref>]. This pathogen is associated with a broad range of infections, including bloodstream infections, folliculitis, otitis, urinary tract infections, and ventilator-associated pneumonia (VAP) [<xref rid="B8-ijms-26-02012" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-02012" ref-type="bibr">9</xref>]. VAP, the most common nosocomial infection, affects the lung parenchyma of patients who have been intubated for at least 48 h. Between 9% and 29% of such patients are affected by VAP, depending on the duration of the intubation and the underlying cause of the mechanical ventilation (e.g., surgery, disease, transplantation) [<xref rid="B8-ijms-26-02012" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-02012" ref-type="bibr">9</xref>,<xref rid="B10-ijms-26-02012" ref-type="bibr">10</xref>,<xref rid="B11-ijms-26-02012" ref-type="bibr">11</xref>,<xref rid="B12-ijms-26-02012" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-02012" ref-type="bibr">13</xref>]. <italic toggle="yes">P. aeruginosa</italic> is the leading cause of VAP and is also one of the most common pathogens in community-acquired and hospital-acquired pneumonias, particularly in intensive care units (ICUs) [<xref rid="B11-ijms-26-02012" ref-type="bibr">11</xref>,<xref rid="B12-ijms-26-02012" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-02012" ref-type="bibr">13</xref>,<xref rid="B14-ijms-26-02012" ref-type="bibr">14</xref>]. Patients with cystic fibrosis (CF) comprise another susceptible group frequently colonized by <italic toggle="yes">P. aeruginosa</italic>. CF is a recessive genetic disease that is most prevalent in Europe, North America and Australia. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which impair chloride ion transport and mucus clearance in the airways. Approximately 360 variants of the CFTR gene have been identified and classified into six main classes of CFTR mutations based on their functional effects, including defects in protein synthesis, processing or transport within the cell. The most common mutation, present in approximately 66% of CFTR alleles, is F508del, which results in CFTR misfolding and improper chloride channel function [<xref rid="B15-ijms-26-02012" ref-type="bibr">15</xref>]. Patients with CF experience chronic inflammation of the airways and are predisposed to persistent infections by pathogens such as <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B16-ijms-26-02012" ref-type="bibr">16</xref>], which has a prevalence of approximately 24.5% in this population. The genetic adaptability of <italic toggle="yes">P. aeruginosa</italic> allows it to establish chronic infections that, together with airway inflammation, contribute to morbidity and mortality in these patients [<xref rid="B17-ijms-26-02012" ref-type="bibr">17</xref>,<xref rid="B18-ijms-26-02012" ref-type="bibr">18</xref>].</p></sec><sec id="sec2-ijms-26-02012"><title>2. Pathogenesis and Virulence Factors of <italic toggle="yes">P. aeruginosa</italic></title><p>Pathogenesis in <italic toggle="yes">P. aeruginosa</italic> is mediated by a wide range of virulence factors (VFs) that facilitate adhesion, modulate host cell signaling pathways and degrade the extracellular matrix, causing severe invasive disease or persistent infections that are extremely difficult to eradicate. <italic toggle="yes">P. aeruginosa</italic> infection progresses through three key stages: adhesion/colonization, local invasion and systemic dissemination (<xref rid="ijms-26-02012-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B19-ijms-26-02012" ref-type="bibr">19</xref>]. In the initial adhesion phase, <italic toggle="yes">P. aeruginosa</italic> attaches to epithelial surfaces using flagella, type IV pili and outer membrane proteins (e.g., OprF), which interact with specific galactose- or mannose- or sialic-acid-containing receptors and also contribute to biofilm formation. During invasion, <italic toggle="yes">P. aeruginosa</italic> utilizes the type III secretion system (T3SS) to inject cytotoxins like ExoS and ExoU directly into host cells, which disrupt the cytoskeleton, induce apoptosis and impair immune responses. In addition, proteases, elastases (LasB) and phospholipases degrade epithelial barriers, including the glycocalyx, allowing deeper tissue penetration. During the dissemination phase, the bacterium utilizes its flagellum and rhamnolipids to spread, while quorum-sensing (QS) mechanisms coordinate VFs production. QS systems, which regulate gene expression in a cell-density-dependent manner (e.g., AHLs, DKPs, LuxR, PQS, HHQ), are a clear example of the intricate regulatory networks that connect the pathogenic mechanisms of this bacterium [<xref rid="B20-ijms-26-02012" ref-type="bibr">20</xref>,<xref rid="B21-ijms-26-02012" ref-type="bibr">21</xref>]. Moreover, siderophores like pyoverdine enable iron acquisition, promoting bacterial survival in the bloodstream and proliferation within the host, leading to extensive tissue damage, characteristic of acute infections. However, in chronic infections, <italic toggle="yes">P. aeruginosa</italic> undergoes adaptive changes (loss of flagella and pili, alterations in LPS, increased biofilm formation, etc.) to persist in the host environment. These adaptations allow the bacterium to adhere to the respiratory epithelium, avoid immune recognition and contribute to a sustained inflammatory state [<xref rid="B19-ijms-26-02012" ref-type="bibr">19</xref>].</p><p>Among the major VFs considered as potential targets for vaccine development against <italic toggle="yes">P. aeruginosa</italic> are (<xref rid="ijms-26-02012-f002" ref-type="fig">Figure 2</xref>) the following.</p><p>Lipopolysaccharide (LPS) is a key component of the outer membrane (OM) and is composed of lipid A, a core region, and the O-antigen (OPS) [<xref rid="B22-ijms-26-02012" ref-type="bibr">22</xref>]. The OPS can produce two distinct antigens: the common polysaccharide antigen (CPA) and the variable O-specific antigen (OSA), which is used for serotyping [<xref rid="B23-ijms-26-02012" ref-type="bibr">23</xref>]. LPS plays a crucial role in interactions with host receptors, evasion of host defense mechanisms, biofilm formation and antimicrobial resistance. Specifically, lipid A has endotoxic properties that induce inflammation, stimulate the production of reactive oxygen species (ROS) and contribute to tissue damage during infections [<xref rid="B23-ijms-26-02012" ref-type="bibr">23</xref>].</p><p>Outer membrane proteins (OMPs), such as OprF, maintain membrane integrity, regulate membrane permeability, and facilitate the acquisition of ions and nutrients. These proteins can also participate in biofilm formation and the secretion of other VFs. Additional porins, such as OprH, OprI, OprD, OprG, and OprL, contribute to antibiotic resistance, molecular transport, adhesion and membrane biogenesis [<xref rid="B22-ijms-26-02012" ref-type="bibr">22</xref>].</p><p>Biofilm formation is a well-known characteristic of <italic toggle="yes">P. aeruginosa</italic>. An increase in c-di-GMP levels in response to environmental factors promotes secretion of adhesive molecules and matrix components, enabling the bacteria to adhere to surfaces and to each other; the bacteria then adapt physiologically until detachment of the biofilm is activated by various metabolic or environmental factors [<xref rid="B24-ijms-26-02012" ref-type="bibr">24</xref>]. The biofilm matrix is formed by exopolysaccharides (e.g., alginate, levan, PsI, and PeI), extracellular DNA (eDNA), other polysaccharides and various proteins that act as adhesives and stabilizers, protect bacteria against external threats and impair antibiotic penetration [<xref rid="B24-ijms-26-02012" ref-type="bibr">24</xref>,<xref rid="B25-ijms-26-02012" ref-type="bibr">25</xref>]. Studies have demonstrated that low concentrations of aminoglycosides can induce biofilm formation [<xref rid="B26-ijms-26-02012" ref-type="bibr">26</xref>], while alginate overproduction enhances resistance by limiting antibiotic penetration into the biofilm [<xref rid="B27-ijms-26-02012" ref-type="bibr">27</xref>].</p><p>The type III secretion system (T3SS) is a membrane-associated system that assembles an injection complex, commonly known as the injectisome, which excretes proteins from the bacterial cytosol into the extracellular environment. The classical effector proteins are ExoS, ExoT, ExoU, and ExoY, and other molecules such as PemA/PemB and the flagellar filament. These factors disrupt immune responses, inhibit DNA synthesis and induce cell death [<xref rid="B28-ijms-26-02012" ref-type="bibr">28</xref>,<xref rid="B29-ijms-26-02012" ref-type="bibr">29</xref>], leading to epithelial damage and promoting bacterial persistence in the lung [<xref rid="B22-ijms-26-02012" ref-type="bibr">22</xref>]. The type VI secretion system (T6SS) also plays a role in virulence by targeting the host microbiota and facilitating epithelial cell invasion [<xref rid="B30-ijms-26-02012" ref-type="bibr">30</xref>].</p><p>The polar flagellum enables <italic toggle="yes">P. aeruginosa</italic> to swim in aqueous or low-viscosity environments, and it also plays an important role in chemotaxis and adhesion to mucosal surfaces, such as the pulmonary epithelium, which is protected by a thick layer of mucus [<xref rid="B31-ijms-26-02012" ref-type="bibr">31</xref>,<xref rid="B32-ijms-26-02012" ref-type="bibr">32</xref>].</p><p>Type IV pili are flexible, retractile appendages involved in biofilm formation, contractile motility and adherence. They are composed of pilin proteins that participate in pilus assembly (major pilins) and can have additional roles in DNA uptake and aggregation (minor pilins) [<xref rid="B31-ijms-26-02012" ref-type="bibr">31</xref>,<xref rid="B33-ijms-26-02012" ref-type="bibr">33</xref>].</p><p>Other secreted VFs include exotoxins and proteolytic enzymes such as elastases and alkaline protease (AprA). Exotoxin A (ETA), which is secreted via the type II secretion system (T2SS), binds to host cells and is internalized in clathrin-coated vesicles, where it induces apoptosis and necrosis and modulates inflammatory responses. Pyocyanin generates oxidative stress by increasing ROS levels, leading to cell damage and reduced lung function. Finally, the iron acquisition systems in <italic toggle="yes">P. aeruginosa</italic> include siderophores, such as pyoverdine, pyochelin and yersiniabactin, among others [<xref rid="B34-ijms-26-02012" ref-type="bibr">34</xref>]. Overexpression of these systems is often associated with hypervirulence [<xref rid="B22-ijms-26-02012" ref-type="bibr">22</xref>].</p><p>The various VFs associated with <italic toggle="yes">P. aeruginosa</italic> are potential targets for vaccine development (<xref rid="ijms-26-02012-f001" ref-type="fig">Figure 1</xref>). Detailed studies of these factors are therefore essential for designing effective strategies to combat infections caused by this pathogen.</p></sec><sec id="sec3-ijms-26-02012"><title>3. Immunology of <italic toggle="yes">P. aeruginosa</italic> Infections</title><p>As an opportunistic pathogen, <italic toggle="yes">P. aeruginosa</italic> triggers a robust immune response while simultaneously developing evasion strategies. The immune response to this pathogen is therefore complex and multifactorial, involving both innate and adaptive immunity.</p><p>The innate immune response, which serves as the first line of defense, depends on pattern recognition receptors (PRRs), e.g., Toll-like receptors (TLR), to detect bacterial elements. Upon recognition, TLRs activate a signaling cascade that leads to the release of pro-inflammatory cytokines, tumor necrosis factor (TNF), and interleukins (ILs), and to the recruitment of phagocytic immune cells [<xref rid="B35-ijms-26-02012" ref-type="bibr">35</xref>]. <italic toggle="yes">P. aeruginosa</italic> is known to express agonists for TLR2, TLR4, TLR5, and TLR9, which recognize lipopeptides, LPS, flagellin, and unmethylated CpG DNA, respectively [<xref rid="B36-ijms-26-02012" ref-type="bibr">36</xref>]. In particular, TLR4 and TLR5, which recognize LPS and flagellin, are essential for triggering the immune response in respiratory infections [<xref rid="B37-ijms-26-02012" ref-type="bibr">37</xref>,<xref rid="B38-ijms-26-02012" ref-type="bibr">38</xref>]. The phagocytic immune cells activated in this response to respiratory infections include neutrophils, which destroy bacteria through proteolytic enzymes, ROS [<xref rid="B39-ijms-26-02012" ref-type="bibr">39</xref>], and macrophages. However, <italic toggle="yes">P. aeruginosa</italic> evades this response by forming biofilms and using T3SS effectors like ExoS, which can lyse macrophages and inhibit the phagocytic absorption of both neutrophils and macrophages [<xref rid="B36-ijms-26-02012" ref-type="bibr">36</xref>,<xref rid="B40-ijms-26-02012" ref-type="bibr">40</xref>]. Likewise, the ability of this pathogen to form biofilms further enhances its persistence in the host [<xref rid="B24-ijms-26-02012" ref-type="bibr">24</xref>,<xref rid="B25-ijms-26-02012" ref-type="bibr">25</xref>,<xref rid="B41-ijms-26-02012" ref-type="bibr">41</xref>].</p><p>On the other hand, the adaptive immune response is activated when antigen-presenting cells (APCs) present <italic toggle="yes">P. aeruginosa</italic> antigens to T lymphocytes, initiating a cascade that activates B lymphocytes to produce specific antibodies. These antibodies facilitate the clearance of bacteria through phagocytosis and/or opsonization [<xref rid="B35-ijms-26-02012" ref-type="bibr">35</xref>,<xref rid="B39-ijms-26-02012" ref-type="bibr">39</xref>]. However, persistent <italic toggle="yes">P. aeruginosa</italic> cells can survive macrophage attacks and even redirect them toward an anti-inflammatory M2-type response (<xref rid="ijms-26-02012-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B42-ijms-26-02012" ref-type="bibr">42</xref>]. Th17 cells, a subtype of CD4+ T lymphocytes, secrete IL-17, IL-21, IL-22, and IL-26, which are crucial cytokines for mucosal immunity, particularly in pulmonary infections [<xref rid="B43-ijms-26-02012" ref-type="bibr">43</xref>,<xref rid="B44-ijms-26-02012" ref-type="bibr">44</xref>]. IL-17 and IL-22 stimulate the release of pro-inflammatory cytokines from mucosal cells [<xref rid="B45-ijms-26-02012" ref-type="bibr">45</xref>] and play a key role in controlling bacterial loads during the early stages of infection. However, Th17 differentiation is controlled by both interferon-gamma (IFN-&#947;) (Th1) and IL-4 (Th2) [<xref rid="B45-ijms-26-02012" ref-type="bibr">45</xref>]. In chronic infections, such as those observed in patients with chronic obstructive pulmonary disease (COPD), excessive release of IL-17 has a dual effect: it contributes to bacterial clearance and can also lead to prolonged inflammation and tissue damage [<xref rid="B46-ijms-26-02012" ref-type="bibr">46</xref>]. Other cytokines, such as IL-1&#946; and IL-18, are also responsible for the exacerbated damage in acute pneumonia through activation of inflammasomes [<xref rid="B47-ijms-26-02012" ref-type="bibr">47</xref>].</p><p>The immune response to <italic toggle="yes">P. aeruginosa</italic> in patients with CF is mediated by exacerbated chronic inflammation and ineffective bacterial clearance. It is characterized by the massive recruitment of neutrophils to the lungs, where elastases and ROS are released. However, these responses cause tissue damage without effectively eliminating the bacteria. The biofilm formation and antigenic variability of <italic toggle="yes">P. aeruginosa</italic> enable the bacteria to evade phagocytosis and antibiotics, thus contributing to the persistence of the infection. The continuous release of cytokines and proteases by neutrophils results in progressive deterioration of tissue, worsening the condition of patients with CF and making <italic toggle="yes">P. aeruginosa</italic> infection a key factor in the progression of lung disease [<xref rid="B39-ijms-26-02012" ref-type="bibr">39</xref>,<xref rid="B41-ijms-26-02012" ref-type="bibr">41</xref>,<xref rid="B48-ijms-26-02012" ref-type="bibr">48</xref>,<xref rid="B49-ijms-26-02012" ref-type="bibr">49</xref>]. Further studies are required in regard to achieving elimination of the pathogen from the organism or preventing <italic toggle="yes">P. aeruginosa</italic> infections, for which effective vaccines would play a key role.</p></sec><sec id="sec4-ijms-26-02012"><title>4. Vaccination Against <italic toggle="yes">P. aeruginosa</italic></title><p>Historical successes, such as the eradication of smallpox [<xref rid="B50-ijms-26-02012" ref-type="bibr">50</xref>] and the development of the SARS-Cov-2 vaccine [<xref rid="B51-ijms-26-02012" ref-type="bibr">51</xref>,<xref rid="B52-ijms-26-02012" ref-type="bibr">52</xref>] in record time, have inspired both past and future efforts to develop a vaccine against <italic toggle="yes">P. aeruginosa</italic>. Different strategies targeting VFs have been explored for more than 50 years, but no successful vaccine against this pathogen has yet been approved for human use. <xref rid="ijms-26-02012-f004" ref-type="fig">Figure 4</xref> shows the number of studies conducted using different technologies to develop vaccines against <italic toggle="yes">P. aeruginosa</italic>, including those in the preclinical stages and those that have advanced to the clinical phases. <xref rid="app1-ijms-26-02012" ref-type="app">Tables S1&#8211;S4</xref> summarize the key characteristics of the experimental vaccines evaluated in different animal infection models, including pneumonia, burns, sepsis, and others. <xref rid="app1-ijms-26-02012" ref-type="app">Table S5</xref> lists the vaccine candidates targeting <italic toggle="yes">P. aeruginosa</italic> that have advanced to phase I, II, and III clinical trials.</p><sec id="sec4dot1-ijms-26-02012"><title>4.1. Live-Attenuated Vaccines</title><p>Live-attenuated vaccines use pathogenic strains with reduced virulence while preserving immunogenicity to provoke an effective immune response [<xref rid="B53-ijms-26-02012" ref-type="bibr">53</xref>]. Moreover, these vaccine candidates contain multiple antigenic components, which stimulate multiple immune effectors in the host, thereby reducing the selective pressure for the emergence of resistant strains. The development of resistance could occur when vaccine candidates include antigens that are not essential for causing acute pneumonia or system invasion [<xref rid="B54-ijms-26-02012" ref-type="bibr">54</xref>]. Unfortunately, this vaccination strategy is highly reactogenic and is associated with side effects such as weight loss and lesions at the injection site in mice [<xref rid="B55-ijms-26-02012" ref-type="bibr">55</xref>,<xref rid="B56-ijms-26-02012" ref-type="bibr">56</xref>]. While these vaccines often elicit stronger cellular immune responses than inactivated vaccines, providing long-lasting protection, safety concerns, such as the potential reversion to virulence, require careful evaluation and optimization.</p><sec id="sec4dot1dot1-ijms-26-02012"><title>4.1.1. Live Auxotrophic Vaccines</title><p>Mutants of <italic toggle="yes">P. aeruginosa</italic> PAO1 with a deletion of the <italic toggle="yes">aroA</italic> gene, rendering the strains auxotrophic for aromatic amino acids, have shown some effectiveness in pneumonia models with mice and rabbits [<xref rid="B57-ijms-26-02012" ref-type="bibr">57</xref>,<xref rid="B58-ijms-26-02012" ref-type="bibr">58</xref>]. Intranasal vaccination (IN) with PAO1 &#916;<italic toggle="yes">aroA</italic> induced high titers of opsonizing antibodies and provided protection against homologous LPS strains [<xref rid="B57-ijms-26-02012" ref-type="bibr">57</xref>], with no dissemination to other organs observed [<xref rid="B58-ijms-26-02012" ref-type="bibr">58</xref>]. Modified PA14 &#916;<italic toggle="yes">aroA</italic> strains provided broader protection, inducing IL-17 secreted by T cells [<xref rid="B59-ijms-26-02012" ref-type="bibr">59</xref>]. Finally, a multivalent live-attenuated mucosal vaccine with &#916;<italic toggle="yes">aroA</italic> strains covering diverse O-antigen epitopes in the O2/O5 serogroup generated multifactorial immunity against <italic toggle="yes">P. aeruginosa</italic> lung infections, with opsonophagocytic antibodies targeting LPS O-antigens, the LPS core, and surface proteins [<xref rid="B54-ijms-26-02012" ref-type="bibr">54</xref>].</p><p>On the other hand, PAO1 mutants lacking the <italic toggle="yes">murI</italic> gene, which encodes glutamate racemase, generated a D-glutamate auxotrophic strain with attenuated virulence, capable of inducing robust antibody responses and providing protection against heterologous strains [<xref rid="B60-ijms-26-02012" ref-type="bibr">60</xref>]. This vaccine elicited IL-17 and IL-4 secretion by T cells, enhancing mucosal immunity when administered IN and providing protection against lethal pneumonia [<xref rid="B56-ijms-26-02012" ref-type="bibr">56</xref>]. However, for the PAO1 &#916;<italic toggle="yes">murI</italic> mutant, some variants regained D-glutamate auxotrophy. Additionally, D-alanine auxotrophy in the alanine racemase-defective triple mutant PAO1 &#916;<italic toggle="yes">murI</italic> &#916;<italic toggle="yes">alr</italic> &#916;<italic toggle="yes">dadX</italic> improved the safety of the vaccine candidate [<xref rid="B55-ijms-26-02012" ref-type="bibr">55</xref>].</p><p>A novel live auxotrophic vaccine for p-benzoyl-L-phenylalanine (BzF) demonstrated protection against <italic toggle="yes">P. aeruginosa</italic> sepsis and acute pneumonia, eliciting higher IgG responses than the inactivated PAO1 and showing cross-reactivity against several strains [<xref rid="B61-ijms-26-02012" ref-type="bibr">61</xref>].</p></sec><sec id="sec4dot1dot2-ijms-26-02012"><title>4.1.2. Recombinant Vaccines with Attenuated Carriers</title><p>Recombinant vaccines using attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Thyphimurium (SL3261/pLPS2) as carriers to express <italic toggle="yes">P. aeruginosa</italic> antigens (e.g., LPS O-antigens) have been evaluated in animal models. Oral administration (PO) of the construct expressing the <italic toggle="yes">P. aeruginosa</italic> (PA103) serogroup O11 in acute pneumonia models provided better protection than intraperitoneal (IP) administration and induced strong immunoglobulin G (IgG) and IgA responses [<xref rid="B62-ijms-26-02012" ref-type="bibr">62</xref>]. IN administration was also effective, even in patients with corneal lesions and burns [<xref rid="B63-ijms-26-02012" ref-type="bibr">63</xref>]. The efficacy of the vaccine was also demonstrated in immunocompromised mice susceptible to pneumonia, improving survival [<xref rid="B64-ijms-26-02012" ref-type="bibr">64</xref>]. A similar vaccine expressing the <italic toggle="yes">P. aeruginosa</italic> serotype O9 required a higher dose for immunization but showed comparable efficacy, increasing the IgG2a and IgG2b levels, as well as enhancing the opsonophagocytic killing capacity [<xref rid="B65-ijms-26-02012" ref-type="bibr">65</xref>]. However, the same procedure using <italic toggle="yes">Salmonella</italic> Typhimurium SL1344 &#916;<italic toggle="yes">wecA</italic>, an attenuated mutant strain with a disruption in the enterobacterial common antigen biosynthesis pathway, failed to protect against IN infection in pneumonia models when administered PO, although it was successful via IP injection [<xref rid="B66-ijms-26-02012" ref-type="bibr">66</xref>].</p></sec><sec id="sec4dot1dot3-ijms-26-02012"><title>4.1.3. Killed but Metabolically Active (KBMA) Vaccines </title><p>An approach involving the photochemical inactivation of <italic toggle="yes">P. aeruginosa</italic> strains that do not cause disease but retain metabolic activity to elicit a potent immune response has been reported [<xref rid="B67-ijms-26-02012" ref-type="bibr">67</xref>]. A KBMA vaccine against <italic toggle="yes">P. aeruginosa</italic> (PA CHA &#916;<italic toggle="yes">uvrAB</italic> &#916;<italic toggle="yes">exoS</italic> &#916;<italic toggle="yes">exoT</italic>) generated high antibody titers and specific T cell activation (Th17, Th1 and Th2). IN administration in lethal pneumonia models yielded a survival rate of 58.3% in immunized mice relative to non-immunized mice [<xref rid="B68-ijms-26-02012" ref-type="bibr">68</xref>].</p></sec></sec><sec id="sec4dot2-ijms-26-02012"><title>4.2. Inactivated Vaccines</title><p>Inactivated vaccines utilize dead pathogenic cells, obtained by different techniques, such as inactivation by formaldehyde, heat or hydrogen peroxide treatment. These vaccines are generally safer than live vaccines but tend to generate weaker immune responses, and booster doses are often required [<xref rid="B69-ijms-26-02012" ref-type="bibr">69</xref>].</p><p>Pseudostat&#174; is a prototype vaccine consisting of <italic toggle="yes">P. aeruginosa</italic> inactivated with paraformaldehyde that was tested in acute respiratory infection models using various administration routes, including PO, intratracheal (IT), intra-Peyer&#8217;s patch (IPP) and subcutaneous (SC) routes [<xref rid="B70-ijms-26-02012" ref-type="bibr">70</xref>]. The most effective method was IPP, yielding up to 96% bacterial clearance in bronchoalveolar fluid (BAL) and an associated increase in survival rates. High antibody levels were correlated with bacterial clearance, but excessive titers were linked to a poor prognosis in some studies. Remarkably, intestinal mucosal immunization provided some protection against respiratory infections [<xref rid="B70-ijms-26-02012" ref-type="bibr">70</xref>]. Pseudostat<sup>&#174;</sup> reached the phase I clinical trial stage on two occasions, reflecting scientific interest in this candidate. The initial trial demonstrated a reduced bacterial load in sputum and improved lymphocytic immunity [<xref rid="B71-ijms-26-02012" ref-type="bibr">71</xref>]. Subsequent studies in healthy volunteers showed the development of specific IgA and IgG responses. Although some adverse effects detected during the study, such as headache, gastrointestinal disorders or upper respiratory tract infections, were not considered clinically significant [<xref rid="B72-ijms-26-02012" ref-type="bibr">72</xref>], further development of this vaccine was limited.</p><p>Rodgers et al. developed microneedles loaded with heat-inactivated <italic toggle="yes">P. aeruginosa</italic> PAO1, delivering antigens quickly into the skin. This approach reduced the bacterial loads in the lungs and spleen [<xref rid="B73-ijms-26-02012" ref-type="bibr">73</xref>]. Additionally, IN administration of a heat-inactivated whole-cell vaccine with Curdlan as an adjuvant reduced the bacterial loads in the nasal lavage and lungs, although it was less effective at resolving lung inflammation than its counterpart targeting <italic toggle="yes">Bordetella pertussis</italic> [<xref rid="B74-ijms-26-02012" ref-type="bibr">74</xref>]. The humoral response was shown to play a critical role in this vaccination approach [<xref rid="B75-ijms-26-02012" ref-type="bibr">75</xref>].</p><p>PAO1 vaccines inactivated by hydrogen peroxide or heat have been evaluated in sepsis models. The surface epitopes were better preserved when hydrogen inactivation was used, generating stronger immunogenic responses. This approach enhanced IgG production and improved IFN-&#947; and IL-4 secretion, although the cells appeared to release unidentified material, possibly DNA, during vaccination [<xref rid="B76-ijms-26-02012" ref-type="bibr">76</xref>].</p><p>Bacterial ghosts (BGs), which are empty bacterial envelopes retaining all the surface structures [<xref rid="B77-ijms-26-02012" ref-type="bibr">77</xref>], have been tested with <italic toggle="yes">P. aeruginosa</italic> in both oral and topical vaccination. BGs triggered robust humoral and cellular immune responses, with increased phagocytic activity and elevated IFN-&#947; levels. These vaccines effectively reduced the bacterial loads in the organs and protected against epidermal ulcers in diabetic rat models [<xref rid="B78-ijms-26-02012" ref-type="bibr">78</xref>].</p><p>Jiang et al. (2023) have recently used X-ray-inactivated <italic toggle="yes">P. aeruginosa</italic> in a murine keratitis model. IN immunization reduced bacterial colonization in the cornea and improved the clinical severity scores following <italic toggle="yes">P. aeruginosa</italic> infection. By contrast, non-immunized mice had increased bacterial loads in the respiratory tract, suggesting translocation of the infection. The vaccine provided cross-protection against heterologous strains, induced M2 macrophage responses to reduce inflammation, and increased anti-inflammatory cytokines such as IL-10 [<xref rid="B79-ijms-26-02012" ref-type="bibr">79</xref>].</p></sec><sec id="sec4dot3-ijms-26-02012"><title>4.3. LPS-Based Vaccines</title><p>A heptavalent vaccine, designed in the 1970s, was based on seven immunotypes of antigens capable of inducing cross-protection [<xref rid="B80-ijms-26-02012" ref-type="bibr">80</xref>]. Initial safety and antigenicity studies in prison volunteers led to clinical trials under the name Pseudogen<sup>&#174;</sup>, which was used to immunize patients with CF or burns. Despite eliciting increased levels of LPS-specific antibodies, this vaccine caused high levels of toxicity, with no clinical improvement [<xref rid="B81-ijms-26-02012" ref-type="bibr">81</xref>]. Phase I and II trials, first with prisoner volunteers and later with burn patients (over 20% total body surface burned), suggested a correlation between antibody titers and infection resistance. However, positive outcomes were not achieved with severe infections [<xref rid="B82-ijms-26-02012" ref-type="bibr">82</xref>]. Further trials demonstrated that Pseudogen<sup>&#174;</sup> prevented sepsis and reduced mortality caused by <italic toggle="yes">P. aeruginosa</italic>, highlighting the critical role of neutrophils and IgG in resistance to infection [<xref rid="B83-ijms-26-02012" ref-type="bibr">83</xref>,<xref rid="B84-ijms-26-02012" ref-type="bibr">84</xref>]. Optimized dosing further reduced mortality, even in severe burns (over 40% of the body), with an overall reduction of 15.7% and an 86% for <italic toggle="yes">P. aeruginosa</italic>-related sepsis [<xref rid="B85-ijms-26-02012" ref-type="bibr">85</xref>]. Despite these findings, inconclusive results in cancer patients and several reported adverse reactions raised safety concerns [<xref rid="B86-ijms-26-02012" ref-type="bibr">86</xref>]. In addition, trials in children and adults with acute leukemia and CF also yielded disappointing results due to toxicity concerns [<xref rid="B87-ijms-26-02012" ref-type="bibr">87</xref>,<xref rid="B88-ijms-26-02012" ref-type="bibr">88</xref>,<xref rid="B89-ijms-26-02012" ref-type="bibr">89</xref>].</p><p>Around the same time, PEV-01, a polyvalent vaccine combining 16 <italic toggle="yes">P. aeruginosa</italic> serotypes, was developed [<xref rid="B90-ijms-26-02012" ref-type="bibr">90</xref>]. In sepsis models, each component induced early protection in mice. Phase II trials showed no toxicity and provision of early protection in healthy volunteers and burn patients [<xref rid="B91-ijms-26-02012" ref-type="bibr">91</xref>,<xref rid="B92-ijms-26-02012" ref-type="bibr">92</xref>]. However, subsequent studies in CF patients reported the worsening of disease in colonized and vaccinated individuals [<xref rid="B93-ijms-26-02012" ref-type="bibr">93</xref>].</p><p>Exotoxin A (ETA) is one of the most potent cytotoxins secreted by <italic toggle="yes">P. aeruginosa</italic>. ETA production is regulated by iron and its cytopathic activity stems from inhibiting protein biosynthesis and suppressing pro-inflammatory cytokines, such as TNF-&#945;, IL-10, IL-6, and IL-8, which contribute to the severity of the infection [<xref rid="B11-ijms-26-02012" ref-type="bibr">11</xref>]. A combined vaccine (Aerugen<sup>&#174;</sup>) was developed using attenuated ETA and LPS from <italic toggle="yes">P. aeruginosa</italic> 27316 (immunotype 5), adjuvanted with Al(OH)<sub>3</sub>. Experiments in rabbits and mice showed that Aerugen<sup>&#174;</sup> was non-toxic, elicited anti-LPS and anti-ETA IgG responses, and also protected against fatal sepsis caused by <italic toggle="yes">P. aeruginosa</italic> in a burn-induced sepsis model in mice [<xref rid="B94-ijms-26-02012" ref-type="bibr">94</xref>]. Aerugen<sup>&#174;</sup> advanced to phase III trials. Initial studies in healthy volunteers and non-colonized CF patients demonstrated enhanced immunity to LPS components and robust IgG responses [<xref rid="B95-ijms-26-02012" ref-type="bibr">95</xref>,<xref rid="B96-ijms-26-02012" ref-type="bibr">96</xref>,<xref rid="B97-ijms-26-02012" ref-type="bibr">97</xref>,<xref rid="B98-ijms-26-02012" ref-type="bibr">98</xref>]. However, phase III clinical trials with nearly 500 CF patients showed no differences between the vaccinated and control groups, leading to the study being suspended [<xref rid="B99-ijms-26-02012" ref-type="bibr">99</xref>].</p><p>More recently, a conjugate vaccine composed of LPS from both <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">P. aeruginosa</italic> was evaluated in a murine pneumonia model, demonstrating 100% survival and highlighting the protective potential of LPS [<xref rid="B100-ijms-26-02012" ref-type="bibr">100</xref>].</p><p>Immunization with the O-antigen of LPS triggers the production of opsonizing antibodies, which correlate with protection against <italic toggle="yes">P. aeruginosa</italic> infection in animal models and patients during acute infection. However, due to its properties, the O-antigen does not confer broad-spectrum immunogenicity or cross-protection against other serotypes [<xref rid="B101-ijms-26-02012" ref-type="bibr">101</xref>,<xref rid="B102-ijms-26-02012" ref-type="bibr">102</xref>]. These antigens, which induce a T-independent immune response, are ineffective in protecting young populations or immunocompromised individuals, and they do not generate immunological memory [<xref rid="B103-ijms-26-02012" ref-type="bibr">103</xref>]. Due to this diversity of serotypes and the lack of demonstrated clinical efficacy of these vaccine candidates, recent studies have mainly focused on developing vaccines based on conserved epitopes, outer membrane vesicles, or whole cells (inactivated or attenuated).</p></sec><sec id="sec4dot4-ijms-26-02012"><title>4.4. Alginate-Based Vaccines</title><p>The mucoid exopolysaccharide (MEP) or alginate produced by <italic toggle="yes">P. aeruginosa</italic> protects against antibiotics, inhibits the complement system and reduces phagocytosis [<xref rid="B104-ijms-26-02012" ref-type="bibr">104</xref>]. These findings suggest that the alginate could be a potential vaccine target. Pier et al. (1990) found that opsonizing antibodies against MEP were effective in models of endobronchial and chronic infections, aiding phagocytosis and reducing the bacterial load in the lungs of immunized mice [<xref rid="B105-ijms-26-02012" ref-type="bibr">105</xref>]. However, the vaccine showed limited effectiveness against strains that induce non-opsonizing antibodies. Two alginate-based vaccines from the mucoid <italic toggle="yes">P. aeruginosa</italic> strain 2192, differing in the molecular size of MEP, reached phase I trials but elicited weak opsonizing antibody responses in healthy individuals. Additionally, booster doses failed to enhance immunity, limiting their potential use [<xref rid="B106-ijms-26-02012" ref-type="bibr">106</xref>].</p><p>To improve the immune response against mucoid strains of <italic toggle="yes">P. aeruginosa</italic>, Cryz and colleagues combined alginate and ETA, demonstrating enhanced opsonizing antibody titers, improved phagocytosis, and partial neutralization of ETA toxicity. While promising for CF patients, this approach carried risks of immune hypercomplex formation, which could aggravate the clinical course of the disease [<xref rid="B107-ijms-26-02012" ref-type="bibr">107</xref>]. In animal models, a conjugate vaccine using MEP linked to keyhole limpet hemocyanin (KLH) showed increased IgG titers and cross-reactivity against heterologous mucoid strains. In addition, the vaccine induced opsonizing antibodies in the presence of non-opsonizing antibodies, a common characteristic in CF patients [<xref rid="B108-ijms-26-02012" ref-type="bibr">108</xref>]. Although KLH is considered a promising carrier, concerns about allergic reactions and variability have so far limited its widespread use in human vaccine development.</p><p>Nanotechnology has also been applied to alginate-based vaccine development. A polylactic-co-glycolic acid (PLGA)-based vaccine conjugated with alginate enhanced opsonic activity and pro-inflammatory cytokine production (TNF-&#945;, IL-4, IL-17A, and INF-&#947;). In a model of chronic infection, this vaccine significantly reduced the bacterial load in the spleen of immunized mice [<xref rid="B109-ijms-26-02012" ref-type="bibr">109</xref>]. At the same time, a combination of alginate with solid lipid nanoparticles (Alg-SLNs), administered via intramuscular (IM) injection, resulted in increased IgG, IgA and IgM titers and the production of opsonophagocytic antibodies. The conjugate provided superior protection against <italic toggle="yes">P. aeruginosa</italic> than alginate alone in an acute pneumonia model [<xref rid="B110-ijms-26-02012" ref-type="bibr">110</xref>].</p><p>Researchers have recently developed a vaccine using synthetic mannuronic acid alginate glycans conjugated with CRM-197-1, and adjuvanted with Freund&#8217;s adjuvant (FA). This vaccine elicited high IgG1 and IgG2b antibody titers and improved survival rates in a murine pneumonia model, reducing the bacterial loads in the lungs and bloodstream for both the mucoid and non-mucoid strains of <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B111-ijms-26-02012" ref-type="bibr">111</xref>].</p></sec><sec id="sec4dot5-ijms-26-02012"><title>4.5. OMP-Based Vaccines</title><p>Vaccine candidates based on OMPs typically include antigens with highly conserved and surface-exposed immunogenic domains [<xref rid="B9-ijms-26-02012" ref-type="bibr">9</xref>]. Unlike live-attenuated vaccines, OMP-based vaccines are considered safer, as they generate fewer adverse effects, which, when present, tend to be milder [<xref rid="B112-ijms-26-02012" ref-type="bibr">112</xref>]. However, they exhibit lower immunogenicity compared to attenuated whole-cell vaccines and are more susceptible to enzymatic degradation and/or mucociliary clearance on mucosal surfaces [<xref rid="B9-ijms-26-02012" ref-type="bibr">9</xref>].</p><p>OprI, a lipoprotein of the OM of <italic toggle="yes">P. aeruginosa</italic>, has been studied as a vaccine candidate. Finke and colleagues demonstrated that both recombinant OprI expressed in <italic toggle="yes">Escherichia coli</italic> and the purified OprI from <italic toggle="yes">P. aeruginosa</italic> serogroup 12, adjuvanted with Al(OH)<sub>3</sub>, increased survival rates in a sepsis model [<xref rid="B113-ijms-26-02012" ref-type="bibr">113</xref>]. Likewise, a chimeric OprI-ExoS protein encapsulated in gelatin nanoparticles enhanced both Th1 and Th2 responses, increasing IgA and IgG titers and cytokines such as IL-4, IL-17, and INF-&#947;. In a pneumonia model, immunized mice had significantly lower bacterial counts, with slightly better results in those receiving alum-adjuvanted protein than the nanoparticle-based vaccine [<xref rid="B114-ijms-26-02012" ref-type="bibr">114</xref>].</p><p>OprF, another OMP, has also been extensively studied as a protective immunogen. In a burn model, the OprF protein provided immunity and reduced mortality in infected mice [<xref rid="B115-ijms-26-02012" ref-type="bibr">115</xref>]. In a chronic pneumonia model, OprF conjugated with elastase and ETA adjuvanted with Al(OH)<sub>3</sub> provided protection against <italic toggle="yes">P. aeruginosa</italic> infection, but the combination with elastase A exacerbated lung damage [<xref rid="B116-ijms-26-02012" ref-type="bibr">116</xref>]. In acute pneumonia models, recombinant OprF activated dendritic cells (DCs), similarly to native OprF, and demonstrated a superior capacity to reduce bacterial colonization and promote production of IL-10, IL-12p70, INF-&#947;, leading to a decrease in inflammation [<xref rid="B117-ijms-26-02012" ref-type="bibr">117</xref>]. To enhance the immune response to OprF, <italic toggle="yes">P. aeruginosa</italic> epitopes (Epi8) were incorporated into adenoviral (Ad) vectors, and OprF was conjugated with the AdC7-RGD (modified with an arginine&#8211;glycine&#8211;aspartic acid sequence), promoting robust humoral and cellular responses [<xref rid="B118-ijms-26-02012" ref-type="bibr">118</xref>,<xref rid="B119-ijms-26-02012" ref-type="bibr">119</xref>,<xref rid="B120-ijms-26-02012" ref-type="bibr">120</xref>,<xref rid="B121-ijms-26-02012" ref-type="bibr">121</xref>]. The histidine-tagged OprF, adjuvanted with Bacillus Calmette&#8211;Gu&#233;rin (BCG) or alum, increased the IgG1 and IgG2a antibodies and decreased the bacterial counts in the kidneys and lungs. In addition, decreased neutrophil recruitment and reduced tissue damage in the liver of immunized mice were observed [<xref rid="B122-ijms-26-02012" ref-type="bibr">122</xref>]. Mayeux et al. generated OprF proteoliposomes, achieving 90% survival in an acute pneumonia model using the CHA strain of <italic toggle="yes">P. aeruginosa</italic>. Moreover, sera containing OprF-induced antibodies provided complete protection as a post-infection treatment [<xref rid="B123-ijms-26-02012" ref-type="bibr">123</xref>]. On the other hand, a multi-epitope vaccine derived from OprF conjugated with a TLR agonist and formulated in dipalmitoylphosphatidylcholine (DPPC)/cholesterol (Chol) liposomes, generated a balanced Th1/Th2 response and induced potent opsonophagocytic activity [<xref rid="B124-ijms-26-02012" ref-type="bibr">124</xref>].</p><p>In chronic pneumonia models, Gomi and colleagues evaluated an adenoviral vector vaccine (AdC7) expressing <italic toggle="yes">P. aeruginosa</italic> OprF fused with an integrin-binding RGD sequence. This vaccine, administered IN, generated strong humoral and cellular immune responses, successfully resolving the infection and decreasing pulmonary bacterial colonization [<xref rid="B125-ijms-26-02012" ref-type="bibr">125</xref>].</p><p>The combination of OprI and OprF with ETA, adjuvanted with aluminum phosphate, improved survival in a burn model (60% vs. 50% survival with OprF alone) while enhancing phagocytosis and neutralizing ETA&#8217;s cytotoxicity [<xref rid="B126-ijms-26-02012" ref-type="bibr">126</xref>]. Nanoparticle-based vaccines, such as polyhydroxyalkanoate (PHA) containing a combination of OprI, OprF and AlgE epitopes, administered by the SC route, increased the IgG2c levels and cytokine production (IFN-&#947;, IL-10, IL-17A, and IL-6), indicating a Th1 immune response [<xref rid="B127-ijms-26-02012" ref-type="bibr">127</xref>]. Similarly, a recombinant <italic toggle="yes">Salmonella enterica</italic> vaccine expressing OprF and OprI of <italic toggle="yes">P. aeruginosa</italic> increased the IgG and IgA levels, resulting in a balanced Th1/Th2 response. Following SC administration and subsequent challenge in a pneumoniae model, this vaccine achieved a 77.78% survival rate [<xref rid="B128-ijms-26-02012" ref-type="bibr">128</xref>].</p><p>Mannose-modified chitosan microspheres have been evaluated to improve the immunity induced by OprF-OprI vaccines. This approach increased the INF-&#947; and TNF-&#945; levels and also the IgM and IgA titers in mucosal samples following IN administration, providing 75% protection against <italic toggle="yes">P. aeruginosa</italic> infection [<xref rid="B129-ijms-26-02012" ref-type="bibr">129</xref>]. The combination of OprF, OprI and flagellin B increased specific titers against all the proteins and enhanced the phagocytosis and reduced bacterial counts in the blood. However, OprF-flagellin B failed to protect against the non-mucoid PAK strain, and its use against mucoid strains was ruled out [<xref rid="B130-ijms-26-02012" ref-type="bibr">130</xref>].</p><p>The IC43 vaccine, a fusion protein of OprF and OprI (OprF<sub>190&#8211;342</sub>&#8211;OprI<sub>21&#8211;83</sub>), combines the immunogenic properties of both proteins. Jing and colleagues evaluated an IC43 heptamer fused with alpha-hemolysin (HLA) and adjuvanted with alum, achieving 80% survival compared to 30% with IC43 alone, along with a reduced bacterial load and decreased inflammation in the lungs [<xref rid="B131-ijms-26-02012" ref-type="bibr">131</xref>]. A systemic formulation of the IC43 candidate was first evaluated in three phase I trials with healthy individuals and burn patients using different doses, demonstrating safety, tolerability, and increased specific IgG levels [<xref rid="B132-ijms-26-02012" ref-type="bibr">132</xref>,<xref rid="B133-ijms-26-02012" ref-type="bibr">133</xref>,<xref rid="B134-ijms-26-02012" ref-type="bibr">134</xref>]. Later, in phase II trials, ICU patients with mechanical ventilation maintained elevated IgG levels over time, although the study lacked statistical power to assess infection and mortality rates [<xref rid="B135-ijms-26-02012" ref-type="bibr">135</xref>]. In phase III trials, with a larger sample size, IC43 was well tolerated, but no differences in mortality or survival were observed compared to controls [<xref rid="B136-ijms-26-02012" ref-type="bibr">136</xref>]. Similarly, a mucosal formulation of IC43 was tested in phase I trials with healthy individuals, resulting in increased IgG and IgA titers without adverse effects [<xref rid="B137-ijms-26-02012" ref-type="bibr">137</xref>]. Phase I/II studies comparing systemic and mucosal formulations showed superior immune responses with the systemic formulation following a booster dose [<xref rid="B138-ijms-26-02012" ref-type="bibr">138</xref>,<xref rid="B139-ijms-26-02012" ref-type="bibr">139</xref>].</p><p>PHA microspheres presenting antigens such as OprF, OprI, AlgE, and PopB (a translocator protein) with alum generated specific immune responses and high survival rates [<xref rid="B140-ijms-26-02012" ref-type="bibr">140</xref>]. Biopolymer particles delivering multiple proteins (OprF, OprI, AlgE, OprL, PopB, PilA, PilO, FliC, Hcp1, and CdrA) adjuvanted with Alhydrogel<sup>&#174;</sup> also conferred protection [<xref rid="B141-ijms-26-02012" ref-type="bibr">141</xref>]. The combination of OprF/I with PopB improved the protection against <italic toggle="yes">P. aeruginosa</italic> pneumonia, increasing the IgG titers and survival [<xref rid="B142-ijms-26-02012" ref-type="bibr">142</xref>]. Likewise, a combination of OprF-OprI-PopB adjuvanted with granulocyte&#8211;macrophage colony-stimulating factor enhanced the production of IFN-&#947;, IL-17A, and IL-4, leading to 83.3% survival and reduced tissue damage in a burn model in rats [<xref rid="B143-ijms-26-02012" ref-type="bibr">143</xref>].</p><p>Beyond OprI and OprF, other OM components of <italic toggle="yes">P. aeruginosa</italic> have been explored as vaccine candidates. Wu et al. identified several proteins (PopB, FpvA, FptA, OprL, and PilQ) that induced IL-17 release in vitro. Purified PopB, adjuvanted with Curdlan, demonstrated protective efficacy in an acute pneumonia model caused by <italic toggle="yes">P. aeruginosa</italic>. While PopB generated a strong systemic and mucosal immune response after IN administration, the specific antibodies lacked opsonic killing capacity [<xref rid="B144-ijms-26-02012" ref-type="bibr">144</xref>]. Gao et al. also evaluated recombinant OprL with Curdlan, which activated Th1 and Th17 immune responses, reduced inflammation and provided cross-protection against multiple <italic toggle="yes">P. aeruginosa</italic> strains [<xref rid="B145-ijms-26-02012" ref-type="bibr">145</xref>]. In another study, OprH produced protective effects against infection when administered in micelles, while other proteins, such as FpvA, HasR, and FoxA, did not [<xref rid="B146-ijms-26-02012" ref-type="bibr">146</xref>]. Baker et al. tested a mucosal adjuvant, the double mutant heat-labile toxin of <italic toggle="yes">E. coli</italic> (dmLT), with an OMP vaccine, increasing IgG and IL-17A production and achieving a 53% survival rate in a pneumonia model [<xref rid="B147-ijms-26-02012" ref-type="bibr">147</xref>]. In a recent study, an extracellular polysaccharide isolated from <italic toggle="yes">Lactobacillus plantarum</italic> combined with OprH improved cytokine production (IFN-&#947;, IL-2, and IL-4) and survival rates, although not as effectively as an inactivated vaccine [<xref rid="B148-ijms-26-02012" ref-type="bibr">148</xref>].</p><p>PcrV, a component of the <italic toggle="yes">P. aeruginosa</italic> T3SS, has been widely evaluated as a vaccine candidate. Golpasha et al. found that a bivalent combination of PcrV and 3-oxo-C12-HSL increased IgG and IgG1 production and led to 86% survival in a burn model, with reduced bacterial colonization in the liver and spleen of immunized mice, although not in the skin [<xref rid="B149-ijms-26-02012" ref-type="bibr">149</xref>]. Hybrid proteins like PcrV-ExoS adjuvanted with alum or monophosphoryl lipid A (MPL) improved the immune responses (IgA, IgG and cytokines IFN-&#947;, IL-4 and IL-17) and reduced the bacterial loads in the bladder and kidneys in a murine bladder infection model with <italic toggle="yes">P. aeruginosa</italic> PAO1 [<xref rid="B150-ijms-26-02012" ref-type="bibr">150</xref>]. A recombinant protein composed of PcrV, OprF and OprI produced high IgG titers and 75% survival in a burn mouse model, with significant reductions in bacterial loads in the liver, spleen, kidney, and skin [<xref rid="B151-ijms-26-02012" ref-type="bibr">151</xref>]. Furthermore, a multi-epitope PcrV-OmpE vaccine enhanced the antibody responses and the reduced bacterial load in the bladder in a rabbit urinary tract infection model. In silico analysis confirmed its stable interaction with both TLR2 and TLR4 [<xref rid="B152-ijms-26-02012" ref-type="bibr">152</xref>].</p><p>In acute pneumonia models, Sawa and colleagues demonstrated that PcrV immunization increased IgG titers and reduced mortality, bacterial colonization, inflammation, and lung damage [<xref rid="B153-ijms-26-02012" ref-type="bibr">153</xref>]. A trivalent combination of PcrV, OprI and Hcp1 (a protein regulated by T6SS), adjuvanted with alum, provided better protection, higher survival rates, and less tissue damage and inflammation following infection [<xref rid="B154-ijms-26-02012" ref-type="bibr">154</xref>]. Further studies evaluating PcrV with different adjuvants (FA, alum, CpG ODN) via the IP route showed that FA provided the highest protection against mortality, while alum and CpG produced more balanced results. When administered IN, CpG improved survival, reduced pulmonary edema and inflammation, and enhanced Ig titers compared to alum in preventing <italic toggle="yes">P. aeruginosa</italic> infection [<xref rid="B155-ijms-26-02012" ref-type="bibr">155</xref>]. To improve the PcrV efficacy, Wan et al. identified the dominant domains for the immune response and combined them into a vaccine that increased the IgG and IgA levels, protecting against <italic toggle="yes">P. aeruginosa</italic> lung colonization [<xref rid="B156-ijms-26-02012" ref-type="bibr">156</xref>]. Additionally, a recombinant fusion protein (PaF) composed of PcrV, PopB and the A1 subunit of dmLT [<xref rid="B157-ijms-26-02012" ref-type="bibr">157</xref>,<xref rid="B158-ijms-26-02012" ref-type="bibr">158</xref>,<xref rid="B159-ijms-26-02012" ref-type="bibr">159</xref>,<xref rid="B160-ijms-26-02012" ref-type="bibr">160</xref>] induced higher IgG and IgA titers, stimulated a Th17 response, and enhanced bacterial elimination from the lungs [<xref rid="B158-ijms-26-02012" ref-type="bibr">158</xref>,<xref rid="B160-ijms-26-02012" ref-type="bibr">160</xref>]. When comparing different formulations, such as the oil-in-water MedImmune emulsion (ME), chitosan particles, TLR4 agonists and BECC438 (non-toxic lipid A analogue), researchers found BECC438/ME to be the most effective, although it failed to protect against the <italic toggle="yes">P. aeruginosa</italic> serogroup O12, which produces the exolysin A (ExlA) toxin [<xref rid="B159-ijms-26-02012" ref-type="bibr">159</xref>]. To provide broader protection, ExlA was include in the vaccine formulation [<xref rid="B157-ijms-26-02012" ref-type="bibr">157</xref>].</p><p>Th17-dependent epitopes, such as rePcrV and reAmpC, were used to construct a chimeric protein (PVAC) that strongly enhanced IL-17 production and protection against different <italic toggle="yes">P. aeruginosa</italic> strains [<xref rid="B161-ijms-26-02012" ref-type="bibr">161</xref>]. IN vaccination with rePcrV adjuvanted with Curdlan improved phagocytosis and protection, as well as immune cell recruitment and IL-17A production [<xref rid="B162-ijms-26-02012" ref-type="bibr">162</xref>]. In another study, a PcrV/OprI vaccine encapsulated in ferritin nanoparticles, and administered IM without adjuvant, increased antibody titers and INF-&#947;-producing lymphocytes, indicating a Th1 profile. This vaccine led to a 60% survival rate and reduced bacterial colonization in the spleen and lungs, and it lowered the pro-inflammatory cytokines (TNF-&#945;, IL-6, IL-12) in a pneumonia model [<xref rid="B163-ijms-26-02012" ref-type="bibr">163</xref>]. PomT, a vaccine combining PcrV, OprF and the mutated ETA, demonstrated similar efficacy to PcrV alone in a pneumonia model [<xref rid="B164-ijms-26-02012" ref-type="bibr">164</xref>].</p><p>In addition to PcrV, the chaperone protein PcrH, which directly binds the PopB translocator, has also been tested [<xref rid="B165-ijms-26-02012" ref-type="bibr">165</xref>]. The PopB/PcrH conjugate, adjuvanted with Curdlan and encapsulated in PLGA particles, enhanced Th17 cytokine and significantly reduced bacterial colonization in the lung, improving survival in acute pneumonia models [<xref rid="B166-ijms-26-02012" ref-type="bibr">166</xref>]. Another vaccine candidate, LptF (a lipotoxin related to OmpA), elicited a Th2-type response, increasing IgG1 titers and providing protection in acute pneumonia models by reducing the bacterial loads in the lungs and spleen [<xref rid="B167-ijms-26-02012" ref-type="bibr">167</xref>]. Furthermore, the chitin-binding protein D (CbpD), associated with T2SS, protected mice in both pneumonia and sepsis models [<xref rid="B168-ijms-26-02012" ref-type="bibr">168</xref>].</p></sec><sec id="sec4dot6-ijms-26-02012"><title>4.6. Pili-Based Vaccines</title><p>Pili and related molecules have been explored as vaccine candidates in acute pneumonia models. A recombinant vaccine based on PilA, a type IV pilus protein, adjuvanted with alum and naloxone, stimulated robust humoral and cellular immune responses, increasing IL-4, INF-&#947; and IL-17 production following SC administration [<xref rid="B169-ijms-26-02012" ref-type="bibr">169</xref>]. The survival rates were higher in immunized mice and bacterial counts reduced in the lungs, with elevated IgG and IgG1 levels, suggesting a Th2-biased immune response [<xref rid="B169-ijms-26-02012" ref-type="bibr">169</xref>]. A similar vaccine based on the PilY1 epitope (EP 167-193), delivered via a macrophage membrane-coated PLGA formulation (PNPS@M-EP167-193), increased the titers of epitope-specific antibodies, after IM administration, without in vitro toxicity [<xref rid="B170-ijms-26-02012" ref-type="bibr">170</xref>].</p><p>Pili-based vaccines for <italic toggle="yes">P. aeruginosa</italic> have been less frequently explored in sepsis models. A synthetic peptide consensus vaccine (C1s) targeting the type IV pilus receptor binding domain (RBD) provided cross-protection and improved survival rates, highlighting the importance of preserving the RBD receptor backbone structure in vaccine design [<xref rid="B171-ijms-26-02012" ref-type="bibr">171</xref>]. The study also demonstrated that synthetic peptide-based vaccines were more effective than those derived from pilus structural proteins [<xref rid="B172-ijms-26-02012" ref-type="bibr">172</xref>].</p><p>For burn-related skin infections, Korpi et al. combined flagellin B and PilA, eliciting a robust immune response, with increased IgG1, IL-4, INF-&#947; and IL-17 production, as well as enhanced opsonophagocytic activity. Immunization improved survival and reduced the bacterial loads in the organs (liver, spleen, bloodstream), although the skin bacterial loads remained unchanged [<xref rid="B173-ijms-26-02012" ref-type="bibr">173</xref>,<xref rid="B174-ijms-26-02012" ref-type="bibr">174</xref>,<xref rid="B175-ijms-26-02012" ref-type="bibr">175</xref>]. Additionally, these antibodies enhanced the phagocytic capacity, inhibited bacterial invasion, and led to 100% survival in passively immunized mice [<xref rid="B176-ijms-26-02012" ref-type="bibr">176</xref>]. Another bivalent vaccine, based on FlaB and PilQ (a type IV pilus secretory complex component) and adjuvanted with alum, yielded a survival rate of 83% and reduced the bacterial loads in both the organs and skin [<xref rid="B177-ijms-26-02012" ref-type="bibr">177</xref>]. Finally, a trivalent vaccine combining FlaA, FlaB and PilA induced the highest IgG production, strongly stimulated splenocyte proliferation and cytokine production (IL-4, INF-&#947;, IL-12), and also reduced IL-10 levels. Vaccine administration improved survival and decreased the bacterial loads in the liver and bloodstream but not in the skin [<xref rid="B178-ijms-26-02012" ref-type="bibr">178</xref>].</p><p>Some pili-based vaccine candidates have been developed without experimental challenges. A liposomal vaccine containing a pilin-derived B-cell epitope and an influenza hemagglutinin-derived T-helper epitope was designed with TLR agonists (Pam3CAG, Pam2CAG) as adjuvants and a mannosylated lipid for DC targeting [<xref rid="B179-ijms-26-02012" ref-type="bibr">179</xref>]. The liposomal formulation enhanced the immune response by improving drug targeting and adsorption. In animal studies, the vaccine increased the IgG levels following IP administration and the IgA levels in the pulmonary mucosa after IN administration. The PakSer epitope combined with Pam3CAG elicited a stronger response, while PakCys was more effective with Pam2CAG. However, a delayed immune response and an incomplete immune profile limited the conclusions that could be reached [<xref rid="B179-ijms-26-02012" ref-type="bibr">179</xref>]. A chimeric PilQ-PilA vaccine adjuvanted with alum significantly increased the IgG and IgG1 isotype levels, indicating a Th2-biased response. Sera from immunized mice completely inhibited <italic toggle="yes">P. aeruginosa</italic> PAO1 motility [<xref rid="B180-ijms-26-02012" ref-type="bibr">180</xref>]. Additionally, the tight adherence pili or Flp combined with the montanide ISA 266 adjuvant, stimulated T cell proliferation, cytokine production (IL-4, INF-&#947;, and IL-17), and a balanced Th1/Th2 response in murine models [<xref rid="B181-ijms-26-02012" ref-type="bibr">181</xref>].</p><p>The immunogenicity of PilS2, a type IVb pilin, has recently been evaluated. An in-silico-designed PilS2 chimera, administered with or without alum, enhanced the humoral responses in mice [<xref rid="B182-ijms-26-02012" ref-type="bibr">182</xref>]. PilS2 expressed in <italic toggle="yes">E. coli</italic> increased IgG production, with alum enhancing the IgG2b and IgG3 levels [<xref rid="B182-ijms-26-02012" ref-type="bibr">182</xref>,<xref rid="B183-ijms-26-02012" ref-type="bibr">183</xref>]. The combination with alum also stimulated splenocytes more effectively, increasing the IL-4 levels without altering the IFN-&#947; and IL-17 levels, and enhanced the phagocytic capacity (99.98% versus 97% without alum) [<xref rid="B183-ijms-26-02012" ref-type="bibr">183</xref>]. However, the efficacy of this vaccine remains unproven.</p></sec><sec id="sec4dot7-ijms-26-02012"><title>4.7. Flagellin-Based Vaccines</title><p>In the previous section, several flagellin-based vaccines were discussed [<xref rid="B173-ijms-26-02012" ref-type="bibr">173</xref>,<xref rid="B175-ijms-26-02012" ref-type="bibr">175</xref>,<xref rid="B176-ijms-26-02012" ref-type="bibr">176</xref>,<xref rid="B177-ijms-26-02012" ref-type="bibr">177</xref>,<xref rid="B178-ijms-26-02012" ref-type="bibr">178</xref>,<xref rid="B184-ijms-26-02012" ref-type="bibr">184</xref>]. Early studies from the 1980s demonstrated that flagellar antigens (FAgs) could generate protective antibodies against <italic toggle="yes">P. aeruginosa</italic>, with divalent FAgs providing protection regardless of the strain&#8217;s serotype [<xref rid="B185-ijms-26-02012" ref-type="bibr">185</xref>,<xref rid="B186-ijms-26-02012" ref-type="bibr">186</xref>,<xref rid="B187-ijms-26-02012" ref-type="bibr">187</xref>]. The FlaB flagellin, when combined with alginate and IN administered to mice, increased the IgG levels and opsonophagocytic activity [<xref rid="B188-ijms-26-02012" ref-type="bibr">188</xref>].</p><p>In murine models of acute pneumonia, multivalent vaccines combining FlaA, FlaB and <italic toggle="yes">P. aeruginosa</italic> OMPs (OprF and OprI) induced robust IgG responses, improved bacterial clearance and reduced lung damage, particularly against non-mucoid strains of <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B189-ijms-26-02012" ref-type="bibr">189</xref>]. Antibodies against polymeric flagella were more effective, but monomeric flagellin induced superior TLR5 activation, crucial for innate immunity [<xref rid="B190-ijms-26-02012" ref-type="bibr">190</xref>]. A vaccine combining FlaA and the polymannuronic acid (PMA) improved the IgG responses, inhibited motility and protected against both non-mucoid and mucoid strains, without impairing TLR5 activation [<xref rid="B191-ijms-26-02012" ref-type="bibr">191</xref>]. Bivalent vaccines with flagellins A and B produced significantly higher survival rates in pneumonia models than monovalent vaccines. This combination enhanced the phagocytic capacity and neutrophil recruitment, inhibited motility and promoted a Th2-biased immune response, including elevated IL-17 levels [<xref rid="B192-ijms-26-02012" ref-type="bibr">192</xref>]. Furthermore, a chimeric protein combining FlaA, FlaB, PcrV and OprF reduced bacterial colonization in the liver and lungs, with 100% survival rates in mice challenged with both the PAO1 and PAK strains [<xref rid="B193-ijms-26-02012" ref-type="bibr">193</xref>].</p><p>FlgE, a protein related to the flagellar hook structure, was identified as a promising antigen. When adjuvanted with alum, FlgE elicited a Th2-biased immune response and reduced both the bacterial loads in the organs and inflammation in murine pneumonia models [<xref rid="B194-ijms-26-02012" ref-type="bibr">194</xref>]. The conjugated reFliC-FN, a fusion of flagellin type A (FliC) with ferritin using nanotechnology, shifted the immune responses from the Th2 to Th1 profile, increasing survival rates by 50%, reducing bacterial colonization, and providing broader protection against strains with flagellins A and B in acute lung infections [<xref rid="B195-ijms-26-02012" ref-type="bibr">195</xref>].</p><p>In recent years, O-polysaccharides have gained attention for their immunogenic potential. Choi et al. investigated both native FlaA and its deglycosylated form (dnFlaA). Although both generated similar antibody levels, dnFlaA failed to protect against <italic toggle="yes">P. aeruginosa</italic> in a burn infection model and yielded poor results in motility inhibition assays. These findings highlight the critical role of O-glycans in vaccine efficacy [<xref rid="B196-ijms-26-02012" ref-type="bibr">196</xref>].</p><p>Two flagellin-based formulations have reached clinical trials. The monovalent vaccine advanced to phase I and II trials in healthy volunteers, and high levels of specific antibodies against <italic toggle="yes">P. aeruginosa</italic> flagellin were reported [<xref rid="B197-ijms-26-02012" ref-type="bibr">197</xref>,<xref rid="B198-ijms-26-02012" ref-type="bibr">198</xref>]. Subsequently, the bivalent formulation reached phase III trials and was tested in non-colonized CF patients, reducing the colonization rates in the vaccinated patients. Notably, 34% of patients were protected from acute infections and 51% from chronic infections [<xref rid="B199-ijms-26-02012" ref-type="bibr">199</xref>].</p></sec><sec id="sec4dot8-ijms-26-02012"><title>4.8. Other Protein-Based Vaccines</title><p>Several less-explored targets for <italic toggle="yes">P. aeruginosa</italic> vaccination include proteins such as elastase, catalase, ETA, and others. Sokol and colleagues investigated elastase epitopes (15 and 42) conjugated to KLH or tetanus toxoid (TT) as carrier proteins [<xref rid="B200-ijms-26-02012" ref-type="bibr">200</xref>]. Both formulations generated similar IgG and IgA titers, but no significant reduction in the pulmonary bacterial load was observed in acute pneumonia models in rats, suggesting protection against the proteolytic activity of elastase rather than the bacteria itself [<xref rid="B200-ijms-26-02012" ref-type="bibr">200</xref>]. Mutant elastases with reduced proteolytic activity, developed by Kawamoto et al., demonstrated promising protective effects in a sepsis model [<xref rid="B201-ijms-26-02012" ref-type="bibr">201</xref>].</p><p>Immunization with the catalase KatA protein was evaluated through a single IPP inoculation or IPP followed by an IT booster. The IPP plus IT inoculation elicited a more robust immune response, reducing the bacterial loads in both the BAL and lungs, and increased the activity of phagocytic cells [<xref rid="B202-ijms-26-02012" ref-type="bibr">202</xref>]. Later studies also assessed the immunogenic capacity of amidase, aminopeptidase, KatE, and Pa13, although the responses varied depending on the protein used [<xref rid="B203-ijms-26-02012" ref-type="bibr">203</xref>]. A peptide vaccine targeting the siderophore FpvA, conjugated with KLH and adjuvanted with Curdlan, promoted the recruitment of DCs and T cells, and induced a Th17-type immune response after IN administration, reducing pulmonary edema and bacterial colonization in a murine pneumonia model [<xref rid="B204-ijms-26-02012" ref-type="bibr">204</xref>].</p><p>Extensive research on <italic toggle="yes">P. aeruginosa</italic> ETA, a potent toxin that inhibits protein synthesis, has been conducted [<xref rid="B205-ijms-26-02012" ref-type="bibr">205</xref>]. A non-toxic ETA variant, engineered by removing Glu-553 from the active site, was administered with FA via SC or IP routes, generating specific antibodies [<xref rid="B206-ijms-26-02012" ref-type="bibr">206</xref>]. Another non-toxic ETA variant, ETA &#916;576&#8211;613, provided protection against <italic toggle="yes">P. aeruginosa</italic> infection in mice when adjuvanted with alum [<xref rid="B207-ijms-26-02012" ref-type="bibr">207</xref>]. Additionally, combining this non-toxic ETA variant with pilin enhanced both mucosal and systemic immunity, increasing the IgG and IgA levels in the serum and saliva after IN administration in mice [<xref rid="B208-ijms-26-02012" ref-type="bibr">208</xref>]. However, the variability of pilin sequences may affect the potential protective efficacy. ETA combined with flagellin also increased IgG titers and demonstrated high protective efficacy in sepsis models, although its effectiveness against multiple <italic toggle="yes">P. aeruginosa</italic> strains remains untested [<xref rid="B209-ijms-26-02012" ref-type="bibr">209</xref>].</p><p>The iron-binding periplasmic protein HitA, adjuvanted with BCG or with incomplete Freund&#8217;s adjuvant (IFA), showed some potential in reducing the bacterial load and histological damage in the lungs and liver in a sepsis model [<xref rid="B210-ijms-26-02012" ref-type="bibr">210</xref>]. Similarly, the HasAp protein adjuvanted with naloxone elicited a Th2-based immune response, reduced the inflammation and bacterial load in the liver, but had limited effects on other organs (kidneys and lungs) [<xref rid="B211-ijms-26-02012" ref-type="bibr">211</xref>].</p><p>Recent advances in nanotechnology have allowed the development of a PLGA-encapsulated ETA vaccine. This nanovaccine generated significantly higher IgG levels than uncoated ETA and induced a robust Th17 response, reducing bacterial colonization in the spleen in a sepsis model [<xref rid="B212-ijms-26-02012" ref-type="bibr">212</xref>]. Similarly, ETA encapsulated in gold nanoparticles and administered with FA produced elevated IgG titers and resulted in a 100% survival rate following a <italic toggle="yes">P. aeruginosa</italic> challenge [<xref rid="B213-ijms-26-02012" ref-type="bibr">213</xref>]. A conjugate of detoxified ETA toxoid and LPS with FA, encapsulated in gold particles, increased the IgG levels and survival rates in sepsis models without toxicity [<xref rid="B214-ijms-26-02012" ref-type="bibr">214</xref>].</p><p>Finally, Cairns and colleagues developed a vaccine system based on the trisaccharide D-rhamnan derived from the A-band of <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B215-ijms-26-02012" ref-type="bibr">215</xref>,<xref rid="B216-ijms-26-02012" ref-type="bibr">216</xref>]. This glycoconjugate vaccine elicited a good immune response, which was further improved using the diphtheria toxoid CRM197 [<xref rid="B217-ijms-26-02012" ref-type="bibr">217</xref>]. The synthetic conjugates of tetra- and pentasaccharides triggered specific immune responses in both rabbits and mice and cross-reacted with LPS from different <italic toggle="yes">P. aeruginosa</italic> serotypes and clinical isolates.</p></sec><sec id="sec4dot9-ijms-26-02012"><title>4.9. Outer Membrane Vesicle-Based Vaccines</title><p>Gram-negative bacteria, including <italic toggle="yes">P. aeruginosa</italic>, release outer membrane vesicles (OMVs) containing proteins, eDNA, RNA, and other molecules [<xref rid="B218-ijms-26-02012" ref-type="bibr">218</xref>]. The protein composition of the OMVs varies depending on their biogenesis, and these vesicles can transport bacterial materials to host cells, acting as inflammatory VFs [<xref rid="B219-ijms-26-02012" ref-type="bibr">219</xref>]. Similar to live-attenuated vaccines, OMVs contain VFs such as endotoxins (e.g., LPS), which may pose safety-related issues.</p><p>OMVs are being explored as vaccine platforms to induce immune responses. Recent studies have evaluated recombinant OMVs (rOMVs) from <italic toggle="yes">Yersinia pseudotuberculosis</italic> carrying <italic toggle="yes">P. aeruginosa</italic> antigens such as PcrV and HitA. When administered via IM injection in murine models, these vaccines generated specific IgG and IgM antibodies, enhanced T cell responses (Th1 and Th17) and increased production of TNF-&#945;, IL-17A and INF-&#947; [<xref rid="B220-ijms-26-02012" ref-type="bibr">220</xref>]. In addition, bacterial colonization in the organs (lung, liver and spleen) was reduced, particularly in the bloodstream [<xref rid="B220-ijms-26-02012" ref-type="bibr">220</xref>,<xref rid="B221-ijms-26-02012" ref-type="bibr">221</xref>]. In burn infection models, a similar vaccine combining <italic toggle="yes">P. aeruginosa</italic> OMVs with diphtheria toxoid and alum, administered via SC, achieved 100% survival in immunized mice [<xref rid="B222-ijms-26-02012" ref-type="bibr">222</xref>]. It also significantly reduced the bacterial loads in the organs (liver, spleen, blood, skin) while decreasing inflammatory cell infiltration by eight-fold. However, three doses of vaccine were required to induce the optimal immune response [<xref rid="B222-ijms-26-02012" ref-type="bibr">222</xref>]. With advances in nanotechnology, Noh and colleagues developed cellular nanodiscs derived from <italic toggle="yes">P. aeruginosa</italic> OMVs, which enhanced both cellular and humoral immune responses, protecting against pneumonia by reducing the lung bacterial loads and pro-inflammatory cytokines (IL-12, IL-17A and TNF-&#945;) [<xref rid="B223-ijms-26-02012" ref-type="bibr">223</xref>].</p><p>Despite these promising results, OMV-based vaccine development is still in the preliminary stages. Recent work by Bi et al. revealed that X-ray irradiation could induce OMV release, which reduced edema, lesions and pulmonary inflammation in a sepsis mouse model. Preventive treatment with irradiated OMVs reduced peritoneal bacterial colonization by 39.5%, while post-infection treatment yielded a 50.9% reduction [<xref rid="B224-ijms-26-02012" ref-type="bibr">224</xref>]. A novel approach using hybrid membrane vesicles (HMVs), composed of macrophage membranes fused with bacterial OMVs and incorporated in gold nanoparticles, effectively stimulated B-cell proliferation in the spleen and antibody production. In sepsis and pneumonia models, prophylactic vaccination produced significant reductions in lung bacterial colonization and the levels of pro-inflammatory cytokines (IL-6, TNF-&#945; and IL-1&#946;), resulting in 100% survival over 14 days [<xref rid="B225-ijms-26-02012" ref-type="bibr">225</xref>]. Furthermore, Takahara et al. examined the differences in vesicle production between biofilm and planktonic cultures. Biofilm-derived OMVs contained higher concentrations of LPS and phospholipids, suggesting a more pronounced inflammatory profile and more efficient macrophage recognition [<xref rid="B226-ijms-26-02012" ref-type="bibr">226</xref>].</p></sec><sec id="sec4dot10-ijms-26-02012"><title>4.10. Autoinducer Vaccines</title><p>Quorum sensing (QS) is a bacterial communication process that relies on extracellular signaling molecules, known as autoinducers. These molecules, which include acyl-homoserine lactones (AHLs), enable bacteria to respond collectively to changes in population density [<xref rid="B227-ijms-26-02012" ref-type="bibr">227</xref>] and have been explored as potential vaccine components. In this context, N-3-oxododecanoyl homoserine lactone (3-oxo-C12-HSL) was conjugated to bovine serum albumin (BSA) as a carrier protein to stimulate antibody production in murine models of acute lung infection. This vaccine generated antibody titers over 100-fold higher than those in the controls and improved the survival rates in some vaccinated mice 48 h post-infection after IN challenge. Although administration of the vaccine reduced the TNF-&#945; levels and modulated lung inflammation, it did not effectively decrease bacterial colonization or enhance bacterial clearance by the immune system [<xref rid="B228-ijms-26-02012" ref-type="bibr">228</xref>].</p></sec><sec id="sec4dot11-ijms-26-02012"><title>4.11. Nucleic Acid Vaccines</title><p>Nucleic acid vaccines have gained importance in recent years, particularly during the SARS-Cov2 pandemic, due to their safety profile and ability to elicit both humoral and cellular immune responses [<xref rid="B229-ijms-26-02012" ref-type="bibr">229</xref>].</p><p>OprF has been investigated as a DNA vaccine against <italic toggle="yes">P. aeruginosa</italic> by testing the pVR1020 plasmid in chronic pneumonia models. Immunization reduced the lung lesions and bacterial loads, with strong opsonizing antibodies and a predominant Th2-biased response. Gene gun administration produced higher and faster antibody responses than IM injection [<xref rid="B230-ijms-26-02012" ref-type="bibr">230</xref>]. A multivalent DNA vaccine combining OprF, OprI, PcrV and PilA, administered via IM electroporation, reduced the bacterial loads in the lungs and bloodstream in acute pneumonia models, generating a Th1-biased immune response with elevated levels of IFN-&#947; and microphage inflammatory protein-2 (MIP-2) in BAL, as well as increased phagocytic cell infiltration. In this case, gene gun delivery yielded suboptimal results, highlighting the importance of delivery methods in the efficacy of the vaccine [<xref rid="B231-ijms-26-02012" ref-type="bibr">231</xref>]. A bivalent DNA vaccine containing OprF and PcrV epitopes, delivered with a polyaspartamide/polyethylene glycol di-aldehyde (PSIH/PEG DA) hydrogel, allowed controlled antigen release, higher specific IgG titers and cytokine levels (INF-&#947;, IL-4, TNF-&#945;, IL-2, and IL-17), and improved survival rate (83%) with reduced bacterial loads and inflammation in a pneumonia model [<xref rid="B232-ijms-26-02012" ref-type="bibr">232</xref>].</p><p>The TLR5 receptor plays a fundamental role in pathogen recognition and activation of innate immune responses by detection of flagellin. However, excessive TLR5 activation can hinder the innate immune response to <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B233-ijms-26-02012" ref-type="bibr">233</xref>]. To address this challenge, the researchers engineered a DNA vaccine using a mutant flagellin (FliC R90A) to minimize TLR5 activation. The mutant successfully induced high levels of cross-reactive antibodies against type A (FlaA) and B (FliC) flagellins, while minimizing TLR5 interference. However, the reduction of TLR5 activation may impact long-term immunity [<xref rid="B234-ijms-26-02012" ref-type="bibr">234</xref>].</p><p>In mouse sepsis models, the recombinant pVAX1-OprF-VP22 vaccine, combining OprF with the VP22 protein from herpes simplex virus type 1, induced higher IgG2a levels (indicating a Th1-biased response) and increased IFN-&#947;, providing enhanced protection against infection [<xref rid="B235-ijms-26-02012" ref-type="bibr">235</xref>]. However, the VP22 protein lost its structural conformation when it fused to the amino terminus of OprF due to the location at this end of its cell-penetrating peptide. In chicken models, divalent and fusion vaccines combining <italic toggle="yes">oprL</italic> and <italic toggle="yes">oprF</italic> genes of <italic toggle="yes">P. aeruginosa</italic> provided 80% protection and induced high IFN-&#947; and IL-2 levels, while monovalent vaccines were less effective (40&#8211;50% protection) [<xref rid="B236-ijms-26-02012" ref-type="bibr">236</xref>]. Further optimization of the OprL/OprF divalent vaccine dosage revealed that a dose of 100 &#181;g was optimal [<xref rid="B237-ijms-26-02012" ref-type="bibr">237</xref>]. A trivalent vaccine combining OprL, OprF and FlgE improved the survival rates by 10%, reaching 90% protection after challenge in chickens. However, its efficacy was slightly lower compared to an inactivated vaccine control [<xref rid="B238-ijms-26-02012" ref-type="bibr">238</xref>].</p><p>Two mRNA vaccines encoding PcrV and a fusion protein OprF-I have recently been evaluated in murine models of burns and sepsis [<xref rid="B239-ijms-26-02012" ref-type="bibr">239</xref>]. The PcrV-based vaccine generated a higher specific IgG titer than the OprF-I vaccine, although the combined vaccine enhanced both responses. The mRNA-PcrV vaccine was more effective in activating CD4+ T cells, promoting IL2 and IL4 secretion, opsonizing antibody production and also activating IFN-&#947; secreting cells. However, neither vaccine significantly activated CD8+ T cells. While all the vaccines provided protection against different <italic toggle="yes">P. aeruginosa</italic> strains by reducing bacterial colonization in the organs and inflammation, the mRNA-PcrV and the combined vaccine were the most effective against severe <italic toggle="yes">P. aeruginosa</italic> infections [<xref rid="B239-ijms-26-02012" ref-type="bibr">239</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-26-02012"><title>5. Conclusions and Future Prospects</title><p><italic toggle="yes">P. aeruginosa</italic> is an important pathogen that poses a serious health threat, especially to individuals with CF and bronchiectasis, due to its ability to infect the respiratory tract. Additionally, <italic toggle="yes">P. aeruginosa</italic> is one of the most prevalent pathogens in ICU infections associated with mechanical ventilation and nosocomial infections. It has a broad clinical spectrum, affecting both immunocompetent patients and especially those with some degree of immunosuppression. Furthermore, it easily develops resistance to antimicrobials, including next-generation drugs, and exhibits notable virulence. This pathogen has attracted great attention from the scientific community over the past five decades, with efforts aimed at developing effective antimicrobials and vaccines. Regarding vaccines, a broad spectrum of vaccine strategies has been developed; however, due to safety concerns and limited evidence of efficacy against chronic pulmonary infections, few vaccine candidates have progressed to clinical trials. To date, no vaccine against <italic toggle="yes">P. aeruginosa</italic> has received marketing authorization approval. Despite this, previous studies have provided valuable insights into the mechanisms that can guide the future development of vaccines. Understanding how <italic toggle="yes">P. aeruginosa</italic> interacts with the immune system is crucial for designing vaccines that elicit both humoral and cellular immune responses.</p><p>Most vaccine candidates reviewed have been effective in increasing the serum IgG antibody levels specific to <italic toggle="yes">P. aeruginosa</italic>, regardless of the administration route. However, for optimal protection, especially against pathogens targeting mucosal surfaces, vaccines should prioritize stimulating IgA production at these sites. The Th17 immune responses are particularly promising, as they enhance mucosal immunity through cytokine production and neutrophil recruitment, while the Th1 responses triggered by specific adjuvants, such as alum, combined with naloxone or adenovirus vectors, may offer protection against acute infections.</p><p>Whole-cell vaccines, including inactivated or live-attenuated variants, and particularly auxotrophic variants, have shown high immunogenicity and induction of the cellular immune response, making them effective against <italic toggle="yes">P. aeruginosa</italic>. However, challenges such as toxicity from the bacterial LPS remain. Protein-based vaccines, especially those targeting OMPs, represent a promising alternative due to their conservation, ease of production, and surface accessibility. The use of live-attenuated bacterial vectors such as <italic toggle="yes">Salmonella</italic> to boost mucosal immunity is also being explored. However, chronic infections, especially in CF patients, require further study to assess the vaccine effectiveness. To improve vaccine safety, several strategies are being considered, including optimized antigen delivery and novel adjuvants like dmLT, which promote Th17-type responses. Mucoadhesive polymers could enhance antigen retention at mucosal sites, improving the efficacy, reducing the required antigen dose and minimizing the associated side effects. Nanoparticle-based platforms hold great promise for enhancing mucosal immunity by targeting respiratory tissues. These platforms can improve antigen stability, increase presentation to immune cells, and enable the co-delivery of multiple antigens for broader protection. DNA vaccines also offer flexibility in encoding multiple targets and could complement other vaccine strategies. RNA-based vaccines, which proved highly effective during the COVID-19 pandemic, present a novel approach for bacterial infections like <italic toggle="yes">P. aeruginosa</italic>. These vaccines can be rapidly designed to include multiple antigens, providing greater safety and higher efficacy and versatility than traditional vaccine methods. mRNA vaccines could address challenges such as antigen variability and downregulation in chronic infections.</p><p>Developing a vaccine against <italic toggle="yes">P. aeruginosa</italic> presents a significant challenge for researchers due to the wide range of VFs produced by the bacterium, as well as its remarkable adaptability and resistance mechanisms. However, the growing threat of multidrug-resistant strains and the vulnerability of high-risk populations highlight the urgent need for a solution. Producing a successful vaccine against <italic toggle="yes">P. aeruginosa</italic> may be possible in the near future by the use of multivalent strategies, including advanced technologies such as nanotechnology and RNA-based platforms, and by obtaining a more detailed understanding of host&#8211;pathogen interactions.</p></sec></body><back><ack><title>Acknowledgments</title><p>The artwork was created with BioRender scientific illustration software (2024) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorender.com/">https://www.biorender.com/</uri>). We sincerely thank the Fundaci&#243;n P&#250;blica Galega de Investigaci&#243;n Biom&#233;dica INIBIC for their grant supporting the publication costs of this open-access article.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-26-02012"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms26052012/s1">https://www.mdpi.com/article/10.3390/ijms26052012/s1</uri>.</p><supplementary-material id="ijms-26-02012-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-26-02012-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, R.S.-F., V.F.-V., M.M. and G.B.; writing&#8212;original draft preparation, R.S.-F., V.F.-V., A.S-R. and M.M.; writing&#8212;review and editing, R.S.-F., V.F.-V., A.S.-R., P.G., M.M. and G.B.; visualization, R.S-F., M.M. and V.F.-V.; supervision, M.M. and G.B.; funding acquisition, G.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-26-02012"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Ten Threats to Global Health in 2019</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2019</year></element-citation></ref><ref id="B2-ijms-26-02012"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>C.J.L.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sharara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Swetschinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bisignano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wool</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></element-citation></ref><ref id="B3-ijms-26-02012"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2022</year><fpage>82</fpage></element-citation></ref><ref id="B4-ijms-26-02012"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirnay</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Bilocq</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pot</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cornelis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zizi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Eldere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deschaght</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vaneechoutte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jennes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitt</surname><given-names>T.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Population Structure Revisited</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7740</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007740</pub-id><pub-id pub-id-type="pmid">19936230</pub-id><pub-id pub-id-type="pmcid">PMC2777410</pub-id></element-citation></ref><ref id="B5-ijms-26-02012"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner-Lastinger</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Abner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kallen</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magill</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>D.</given-names></name><name name-style="western"><surname>See</surname><given-names>I.</given-names></name><name name-style="western"><surname>Soe</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Antimicrobial-Resistant Pathogens Associated with Adult Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network, 2015&#8211;2017</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2020</year><volume>41</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1017/ice.2019.296</pub-id><pub-id pub-id-type="pmid">31767041</pub-id><pub-id pub-id-type="pmcid">PMC8276252</pub-id></element-citation></ref><ref id="B6-ijms-26-02012"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raoofi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pashazadeh Kan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rafiei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hosseinipalangi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Noorani Mejareh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seyghalani Talab</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zarabi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Global Prevalence of Nosocomial Infection: A Systematic Review and Meta-Analysis</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0274248</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0274248</pub-id><pub-id pub-id-type="pmid">36706112</pub-id><pub-id pub-id-type="pmcid">PMC9882897</pub-id></element-citation></ref><ref id="B7-ijms-26-02012"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irek</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Amupitan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Obadare</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Aboderin</surname><given-names>A.O.</given-names></name></person-group><article-title>A Systematic Review of Healthcare-Associated Infections in Africa: An Antimicrobial Resistance Perspective</article-title><source>Afr. J. Lab. Med.</source><year>2018</year><volume>7</volume><elocation-id>796</elocation-id><pub-id pub-id-type="doi">10.4102/ajlm.v7i2.796</pub-id><pub-id pub-id-type="pmid">30568902</pub-id><pub-id pub-id-type="pmcid">PMC6296034</pub-id></element-citation></ref><ref id="B8-ijms-26-02012"><label>8.</label><element-citation publication-type="webpage"><article-title>MSD Manual. <italic toggle="yes">Pseudomonas</italic> and Related Infections</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.msdmanuals.com/professional/infectious-diseases/gram-negative-bacilli/pseudomonas-and-related-infections" ext-link-type="uri">https://www.msdmanuals.com/professional/infectious-diseases/gram-negative-bacilli/pseudomonas-and-related-infections</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-17">(accessed on 17 September 2024)</date-in-citation></element-citation></ref><ref id="B9-ijms-26-02012"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killough</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>R.J.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic>: Recent Advances in Vaccine Development</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1100</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10071100</pub-id><pub-id pub-id-type="pmid">35891262</pub-id><pub-id pub-id-type="pmcid">PMC9320790</pub-id></element-citation></ref><ref id="B10-ijms-26-02012"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hortal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cuerpo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Litvan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rosseel</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E.</given-names></name></person-group><article-title>Ventilator-Associated Pneumonia in Patients Undergoing Major Heart Surgery: An Incidence Study in Europe</article-title><source>Crit. Care</source><year>2009</year><volume>13</volume><elocation-id>R80</elocation-id><pub-id pub-id-type="doi">10.1186/cc7896</pub-id><pub-id pub-id-type="pmid">19463176</pub-id><pub-id pub-id-type="pmcid">PMC2717444</pub-id></element-citation></ref><ref id="B11-ijms-26-02012"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiener-Kronish</surname><given-names>J.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic>: Acute Lung Injury or Ventilator-Associated Pneumonia?</article-title><source>Minerva Anestesiol.</source><year>2010</year><volume>76</volume><fpage>824</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">20935618</pub-id></element-citation></ref><ref id="B12-ijms-26-02012"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.-S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.-C.</given-names></name><etal/></person-group><article-title>Recommendations and Guidelines for the Treatment of Pneumonia in Taiwan</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2019</year><volume>52</volume><fpage>172</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2018.11.004</pub-id><pub-id pub-id-type="pmid">30612923</pub-id></element-citation></ref><ref id="B13-ijms-26-02012"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jean</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.-S.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>P.-R.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.-W.</given-names></name></person-group><article-title>Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>275</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9010275</pub-id><pub-id pub-id-type="pmid">31963877</pub-id><pub-id pub-id-type="pmcid">PMC7019939</pub-id></element-citation></ref><ref id="B14-ijms-26-02012"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luyt</surname><given-names>C.-E.</given-names></name><name name-style="western"><surname>Hekimian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koulenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chastre</surname><given-names>J.</given-names></name></person-group><article-title>Microbial Cause of ICU-Acquired Pneumonia: Hospital-Acquired Pneumonia versus Ventilator-Associated Pneumonia</article-title><source>Curr. Opin. Crit. Care</source><year>2018</year><volume>24</volume><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1097/MCC.0000000000000526</pub-id><pub-id pub-id-type="pmid">30036192</pub-id></element-citation></ref><ref id="B15-ijms-26-02012"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Zahid</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>C.-R.</given-names></name></person-group><article-title>Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies</article-title><source>Adv. Respir. Med.</source><year>2024</year><volume>92</volume><fpage>263</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.3390/arm92040026</pub-id><pub-id pub-id-type="pmid">39051188</pub-id><pub-id pub-id-type="pmcid">PMC11270331</pub-id></element-citation></ref><ref id="B16-ijms-26-02012"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name></person-group><article-title>Cystic Fibrosis</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>2519</fpage><lpage>2531</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00576-6</pub-id><pub-id pub-id-type="pmid">27140670</pub-id></element-citation></ref><ref id="B17-ijms-26-02012"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A.</given-names></name></person-group><article-title>Opportunistic Infections in Lung Disease: <italic toggle="yes">Pseudomonas</italic> Infections in Cystic Fibrosis</article-title><source>Curr. Opin. Pharmacol.</source><year>2007</year><volume>7</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2006.12.005</pub-id><pub-id pub-id-type="pmid">17418640</pub-id></element-citation></ref><ref id="B18-ijms-26-02012"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarych</surname><given-names>D.</given-names></name><name name-style="western"><surname>Augustynowicz-Kopec</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iwanska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parniewski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Majchrzak</surname><given-names>M.</given-names></name></person-group><article-title>Molecular Analysis of <italic toggle="yes">Pseudomonas aeruginosa</italic> Strains Isolated from Cystic Fibrosis Patients</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>15460</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-95034-2</pub-id><pub-id pub-id-type="pmid">34326452</pub-id><pub-id pub-id-type="pmcid">PMC8322141</pub-id></element-citation></ref><ref id="B19-ijms-26-02012"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strateva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mitov</surname><given-names>I.</given-names></name></person-group><article-title>Contribution of an Arsenal of Virulence Factors to Pathogenesis of <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections</article-title><source>Ann. Microbiol.</source><year>2011</year><volume>61</volume><fpage>717</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1007/s13213-011-0273-y</pub-id></element-citation></ref><ref id="B20-ijms-26-02012"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadal Jimenez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Cool</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Quax</surname><given-names>W.J.</given-names></name></person-group><article-title>The Multiple Signaling Systems Regulating Virulence in <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2012</year><volume>76</volume><fpage>46</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1128/MMBR.05007-11</pub-id><pub-id pub-id-type="pmid">22390972</pub-id><pub-id pub-id-type="pmcid">PMC3294424</pub-id></element-citation></ref><ref id="B21-ijms-26-02012"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balasubramanian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schneper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mathee</surname><given-names>K.</given-names></name></person-group><article-title>A Dynamic and Intricate Regulatory Network Determines <italic toggle="yes">Pseudomonas aeruginosa</italic> Virulence</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1039</pub-id><pub-id pub-id-type="pmid">23143271</pub-id><pub-id pub-id-type="pmcid">PMC3592444</pub-id></element-citation></ref><ref id="B22-ijms-26-02012"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurado-Mart&#237;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sainz-Mej&#237;as</surname><given-names>M.</given-names></name><name name-style="western"><surname>McClean</surname><given-names>S.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic>: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>3128</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22063128</pub-id><pub-id pub-id-type="pmid">33803907</pub-id><pub-id pub-id-type="pmcid">PMC8003266</pub-id></element-citation></ref><ref id="B23-ijms-26-02012"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huszczynski</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Khursigara</surname><given-names>C.M.</given-names></name></person-group><article-title>The Role of <italic toggle="yes">Pseudomonas aeruginosa</italic> Lipopolysaccharide in Bacterial Pathogenesis and Physiology</article-title><source>Pathogens</source><year>2019</year><volume>9</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9010006</pub-id><pub-id pub-id-type="pmid">31861540</pub-id><pub-id pub-id-type="pmcid">PMC7168646</pub-id></element-citation></ref><ref id="B24-ijms-26-02012"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.S.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Biofilm, a Programmed Bacterial Life for Fitness</article-title><source>J. Microbiol. Biotechnol.</source><year>2017</year><volume>27</volume><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.4014/jmb.1611.11056</pub-id><pub-id pub-id-type="pmid">28301918</pub-id></element-citation></ref><ref id="B25-ijms-26-02012"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>D.J.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas</italic> Biofilm Matrix Composition and Niche Biology</article-title><source>FEMS Microbiol. Rev.</source><year>2012</year><volume>36</volume><fpage>893</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2011.00322.x</pub-id><pub-id pub-id-type="pmid">22212072</pub-id><pub-id pub-id-type="pmcid">PMC4409827</pub-id></element-citation></ref><ref id="B26-ijms-26-02012"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>D&#8217;Argenio</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>MacCoss</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S.I.</given-names></name></person-group><article-title>Aminoglycoside Antibiotics Induce Bacterial Biofilm Formation</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>1171</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1038/nature03912</pub-id><pub-id pub-id-type="pmid">16121184</pub-id></element-citation></ref><ref id="B27-ijms-26-02012"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goltermann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tolker-Nielsen</surname><given-names>T.</given-names></name></person-group><article-title>Importance of the Exopolysaccharide Matrix in Antimicrobial Tolerance of <italic toggle="yes">Pseudomonas aeruginosa</italic> Aggregates</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><elocation-id>e02696-16</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.02696-16</pub-id><pub-id pub-id-type="pmid">28137803</pub-id><pub-id pub-id-type="pmcid">PMC5365683</pub-id></element-citation></ref><ref id="B28-ijms-26-02012"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams McMackin</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Djapgne</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yahr</surname><given-names>T.L.</given-names></name></person-group><article-title>Fitting Pieces into the Puzzle of <italic toggle="yes">Pseudomonas aeruginosa</italic> Type III Secretion System Gene Expression</article-title><source>J. Bacteriol.</source><year>2019</year><volume>201</volume><elocation-id>e00209-19</elocation-id><pub-id pub-id-type="doi">10.1128/JB.00209-19</pub-id><pub-id pub-id-type="pmid">31010903</pub-id><pub-id pub-id-type="pmcid">PMC6560140</pub-id></element-citation></ref><ref id="B29-ijms-26-02012"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>A.R.</given-names></name></person-group><article-title>The Type III Secretion System of <italic toggle="yes">Pseudomonas aeruginosa</italic>: Infection by Injection</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>654</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2199</pub-id><pub-id pub-id-type="pmid">19680249</pub-id><pub-id pub-id-type="pmcid">PMC2766515</pub-id></element-citation></ref><ref id="B30-ijms-26-02012"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sana</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Berni</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bleves</surname><given-names>S.</given-names></name></person-group><article-title>The T6SSs of <italic toggle="yes">Pseudomonas aeruginosa</italic> Strain PAO1 and Their Effectors: Beyond Bacterial-Cell Targeting</article-title><source>Front. Cell Infect. Microbiol.</source><year>2016</year><volume>6</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2016.00061</pub-id><pub-id pub-id-type="pmid">27376031</pub-id><pub-id pub-id-type="pmcid">PMC4899435</pub-id></element-citation></ref><ref id="B31-ijms-26-02012"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Machen</surname><given-names>T.E.</given-names></name></person-group><article-title>Chemotaxis and Binding of <italic toggle="yes">Pseudomonas aeruginosa</italic> to Scratch-Wounded Human Cystic Fibrosis Airway Epithelial Cells</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0150109</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0150109</pub-id><pub-id pub-id-type="pmid">27031335</pub-id><pub-id pub-id-type="pmcid">PMC4816407</pub-id></element-citation></ref><ref id="B32-ijms-26-02012"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haiko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Westerlund-Wikstr&#246;m</surname><given-names>B.</given-names></name></person-group><article-title>The Role of the Bacterial Flagellum in Adhesion and Virulence</article-title><source>Biology</source><year>2013</year><volume>2</volume><fpage>1242</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.3390/biology2041242</pub-id><pub-id pub-id-type="pmid">24833223</pub-id><pub-id pub-id-type="pmcid">PMC4009794</pub-id></element-citation></ref><ref id="B33-ijms-26-02012"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bardiaux</surname><given-names>B.</given-names></name><name name-style="western"><surname>Francetic</surname><given-names>O.</given-names></name><name name-style="western"><surname>Izadi-Pruneyre</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nilges</surname><given-names>M.</given-names></name></person-group><article-title>Structure and Function of Minor Pilins of Type IV Pili</article-title><source>Med. Microbiol. Immunol.</source><year>2020</year><volume>209</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1007/s00430-019-00642-5</pub-id><pub-id pub-id-type="pmid">31784891</pub-id><pub-id pub-id-type="pmcid">PMC7248040</pub-id></element-citation></ref><ref id="B34-ijms-26-02012"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perraud</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>V.</given-names></name><name name-style="western"><surname>Normant</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hammann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mislin</surname><given-names>G.L.A.</given-names></name><name name-style="western"><surname>Ehret-Sabatier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schalk</surname><given-names>I.J.</given-names></name></person-group><article-title>Phenotypic Adaption of <italic toggle="yes">Pseudomonas aeruginosa</italic> by Hacking Siderophores Produced by Other Microorganisms</article-title><source>Mol. Cell Proteom.</source><year>2020</year><volume>19</volume><fpage>589</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1074/mcp.RA119.001829</pub-id><pub-id pub-id-type="pmid">32024770</pub-id><pub-id pub-id-type="pmcid">PMC7124469</pub-id></element-citation></ref><ref id="B35-ijms-26-02012"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paola</surname><given-names>T.P.</given-names></name></person-group><article-title>Visi&#243;n panor&#225;mica del sistema inmune</article-title><source>Rev. Medica Clin. Las Condes</source><year>2012</year><volume>23</volume><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/S0716-8640(12)70335-8</pub-id></element-citation></ref><ref id="B36-ijms-26-02012"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sainz-Mej&#237;as</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jurado-Mart&#237;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>McClean</surname><given-names>S.</given-names></name></person-group><article-title>Understanding <italic toggle="yes">Pseudomonas aeruginosa</italic>&#8211;Host Interactions: The Ongoing Quest for an Efficacious Vaccine</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>2617</elocation-id><pub-id pub-id-type="doi">10.3390/cells9122617</pub-id><pub-id pub-id-type="pmid">33291484</pub-id><pub-id pub-id-type="pmcid">PMC7762141</pub-id></element-citation></ref><ref id="B37-ijms-26-02012"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavoie</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Wangdi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kazmierczak</surname><given-names>B.I.</given-names></name></person-group><article-title>Innate Immune Responses to <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>Microbes Infect.</source><year>2011</year><volume>13</volume><fpage>1133</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2011.07.011</pub-id><pub-id pub-id-type="pmid">21839853</pub-id><pub-id pub-id-type="pmcid">PMC3221798</pub-id></element-citation></ref><ref id="B38-ijms-26-02012"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Liggitt</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Hawn</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Skerrett</surname><given-names>S.J.</given-names></name></person-group><article-title>Role of Toll-like Receptor 5 in the Innate Immune Response to Acute <italic toggle="yes">P. aeruginosa</italic> Pneumonia</article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2009</year><volume>297</volume><elocation-id>L1112</elocation-id><pub-id pub-id-type="doi">10.1152/ajplung.00155.2009</pub-id><pub-id pub-id-type="pmid">19801452</pub-id><pub-id pub-id-type="pmcid">PMC2793188</pub-id></element-citation></ref><ref id="B39-ijms-26-02012"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Grinstein</surname><given-names>S.</given-names></name></person-group><article-title>Phagocytosis by Neutrophils</article-title><source>Microbes Infect.</source><year>2003</year><volume>5</volume><fpage>1299</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2003.09.014</pub-id><pub-id pub-id-type="pmid">14613773</pub-id></element-citation></ref><ref id="B40-ijms-26-02012"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jouault</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Touqui</surname><given-names>L.</given-names></name></person-group><article-title>Modulation of the Immune Response by the <italic toggle="yes">Pseudomonas aeruginosa</italic> Type-III Secretion System</article-title><source>Front. Cell Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>1064010</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.1064010</pub-id><pub-id pub-id-type="pmid">36519135</pub-id><pub-id pub-id-type="pmcid">PMC9742435</pub-id></element-citation></ref><ref id="B41-ijms-26-02012"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>P.&#216;.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kolpen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rybtke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lauland</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tr&#248;strup</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tolker-Nielsen</surname><given-names>T.</given-names></name></person-group><article-title>Immune Responses to <italic toggle="yes">Pseudomonas aeruginosa</italic> Biofilm Infections</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>625597</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.625597</pub-id><pub-id pub-id-type="pmid">33692800</pub-id><pub-id pub-id-type="pmcid">PMC7937708</pub-id></element-citation></ref><ref id="B42-ijms-26-02012"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Himmler</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>C.N.H.</given-names></name></person-group><article-title>Immune Response Modulation by <italic toggle="yes">Pseudomonas aeruginosa</italic> Persister Cells</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e00056-23</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.00056-23</pub-id><pub-id pub-id-type="pmid">36920189</pub-id><pub-id pub-id-type="pmcid">PMC10128020</pub-id></element-citation></ref><ref id="B43-ijms-26-02012"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>B.D.</given-names></name></person-group><article-title>Chapter 12&#8212;Mucosal and Cutaneous Immunity</article-title><source>Primer to the Immune Response</source><edition>2nd ed.</edition><publisher-name>Academic Cell</publisher-name><publisher-loc>Burlington, MA, USA</publisher-loc><year>2014</year><fpage>269</fpage><lpage>292</lpage><isbn>978-0-12-385245-8</isbn></element-citation></ref><ref id="B44-ijms-26-02012"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayes</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>T.J.</given-names></name></person-group><article-title>Interleukin-17 Is Required for Control of Chronic Lung Infection Caused by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>3507</fpage><lpage>3516</lpage><pub-id pub-id-type="doi">10.1128/IAI.00717-16</pub-id><pub-id pub-id-type="pmid">27698020</pub-id><pub-id pub-id-type="pmcid">PMC5116727</pub-id></element-citation></ref><ref id="B45-ijms-26-02012"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>B.D.</given-names></name></person-group><article-title>Chapter 9&#8212;T Cell Development, Activation and Effector Functions</article-title><source>Primer to the Immune Response</source><edition>2nd ed.</edition><publisher-name>Academic Cell</publisher-name><publisher-loc>Burlington, MA, USA</publisher-loc><year>2014</year><fpage>197</fpage><lpage>226</lpage><isbn>978-0-12-385245-8</isbn></element-citation></ref><ref id="B46-ijms-26-02012"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>F.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>IL-17 Aggravates <italic toggle="yes">Pseudomonas aeruginosa</italic> Airway Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease</article-title><source>Front. Immunol.</source><year>2022</year><volume>12</volume><elocation-id>811803</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.811803</pub-id><pub-id pub-id-type="pmid">35095906</pub-id><pub-id pub-id-type="pmcid">PMC8792752</pub-id></element-citation></ref><ref id="B47-ijms-26-02012"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wonnenberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beisswenger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bals</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tschernig</surname><given-names>T.</given-names></name></person-group><article-title>The Role of IL-1&#946; in <italic toggle="yes">Pseudomonas aeruginosa</italic> in Lung Infection</article-title><source>Cell Tissue Res.</source><year>2016</year><volume>364</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1007/s00441-016-2387-9</pub-id><pub-id pub-id-type="pmid">26984603</pub-id></element-citation></ref><ref id="B48-ijms-26-02012"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lovewell</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Patankar</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Berwin</surname><given-names>B.</given-names></name></person-group><article-title>Mechanisms of Phagocytosis and Host Clearance of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2014</year><volume>306</volume><elocation-id>L591</elocation-id><pub-id pub-id-type="doi">10.1152/ajplung.00335.2013</pub-id><pub-id pub-id-type="pmid">24464809</pub-id><pub-id pub-id-type="pmcid">PMC4116407</pub-id></element-citation></ref><ref id="B49-ijms-26-02012"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Don Hayes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>D.J.</given-names></name></person-group><article-title>Cystic Fibrosis and <italic toggle="yes">Pseudomonas aeruginosa</italic>: The Host-Microbe Interface</article-title><source>Clin. Microbiol. Rev.</source><year>2019</year><volume>32</volume><elocation-id>e00138-18</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00138-18</pub-id><pub-id pub-id-type="pmid">31142499</pub-id><pub-id pub-id-type="pmcid">PMC6589863</pub-id></element-citation></ref><ref id="B50-ijms-26-02012"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajj Hussein</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chams</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chams</surname><given-names>S.</given-names></name><name name-style="western"><surname>El Sayegh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Badran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerges-Geagea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jurjus</surname><given-names>A.</given-names></name></person-group><article-title>Vaccines Through Centuries: Major Cornerstones of Global Health</article-title><source>Front. Public Health</source><year>2015</year><volume>3</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2015.00269</pub-id><pub-id pub-id-type="pmid">26636066</pub-id><pub-id pub-id-type="pmcid">PMC4659912</pub-id></element-citation></ref><ref id="B51-ijms-26-02012"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="B52-ijms-26-02012"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ziwawo</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>DiPiazza</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmid">32756549</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id></element-citation></ref><ref id="B53-ijms-26-02012"><label>53.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>B.D.</given-names></name></person-group><article-title>Chapter 14&#8212;Vaccination</article-title><source>Primer to the Immune Response</source><edition>2nd ed.</edition><publisher-name>Academic Cell</publisher-name><publisher-loc>Burlington, MA, USA</publisher-loc><year>2014</year><fpage>333</fpage><lpage>375</lpage><isbn>978-0-12-385245-8</isbn></element-citation></ref><ref id="B54-ijms-26-02012"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coutinho-Sledge</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Mucosal Vaccination with a Multivalent, Live-Attenuated Vaccine Induces Multifactorial Immunity against <italic toggle="yes">Pseudomonas aeruginosa</italic> Acute Lung Infection</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>1289</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1128/IAI.01139-10</pub-id><pub-id pub-id-type="pmid">21149583</pub-id><pub-id pub-id-type="pmcid">PMC3067523</pub-id></element-citation></ref><ref id="B55-ijms-26-02012"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes-Valverde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bou</surname><given-names>G.</given-names></name></person-group><article-title>Double Auxotrophy to Improve the Safety of a Live Anti-<italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1622</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10101622</pub-id><pub-id pub-id-type="pmid">36298487</pub-id><pub-id pub-id-type="pmcid">PMC9610692</pub-id></element-citation></ref><ref id="B56-ijms-26-02012"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vilanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#228;rtner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vallejo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Francisco-Tom&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuentes-Valverde</surname><given-names>V.</given-names></name><etal/></person-group><article-title>A Live Auxotrophic Vaccine Confers Mucosal Immunity and Protection against Lethal Pneumonia Caused by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008311</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008311</pub-id><pub-id pub-id-type="pmid">32040500</pub-id><pub-id pub-id-type="pmcid">PMC7034913</pub-id></element-citation></ref><ref id="B57-ijms-26-02012"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Meluleni</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Protection against Fatal <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia in Mice after Nasal Immunization with a Live, Attenuated <italic toggle="yes">aroA</italic> Deletion Mutant</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>1453</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.3.1453-1461.2003</pub-id><pub-id pub-id-type="pmid">12595463</pub-id><pub-id pub-id-type="pmcid">PMC148856</pub-id></element-citation></ref><ref id="B58-ijms-26-02012"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Brinig</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name></person-group><article-title>Construction and Characterization of a Live, Attenuated <italic toggle="yes">aroA</italic> Deletion Mutant of <italic toggle="yes">Pseudomonas aeruginosa</italic> as a Candidate Intranasal Vaccine</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><elocation-id>1507</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.70.3.1507-1517.2002</pub-id><pub-id pub-id-type="pmid">11854239</pub-id><pub-id pub-id-type="pmcid">PMC127764</pub-id></element-citation></ref><ref id="B59-ijms-26-02012"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Cederroth</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kamei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coutinho-Sledge</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>IL-17 Is a Critical Component of Vaccine-Induced Protection against Lung Infection by LPS-Heterologous Strains of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>4965</fpage><lpage>4975</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4965</pub-id><pub-id pub-id-type="pmid">18802100</pub-id><pub-id pub-id-type="pmcid">PMC2597098</pub-id></element-citation></ref><ref id="B60-ijms-26-02012"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Beceiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bou</surname><given-names>G.</given-names></name></person-group><article-title>Design of Live Attenuated Bacterial Vaccines Based on D-Glutamate Auxotrophy</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><elocation-id>15480</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15480</pub-id><pub-id pub-id-type="pmid">28548079</pub-id><pub-id pub-id-type="pmcid">PMC5458566</pub-id></element-citation></ref><ref id="B61-ijms-26-02012"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pigula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diercks</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Dik</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>P.G.</given-names></name></person-group><article-title>An Unnatural Amino Acid Dependent, Conditional <italic toggle="yes">Pseudomonas</italic> Vaccine Prevents Bacterial Infection</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><elocation-id>6766</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-50843-7</pub-id><pub-id pub-id-type="pmid">39117651</pub-id><pub-id pub-id-type="pmcid">PMC11310302</pub-id></element-citation></ref><ref id="B62-ijms-26-02012"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name></person-group><article-title>Oral Vaccination of BALB/c Mice with <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing <italic toggle="yes">Pseudomonas aeruginosa</italic> O Antigen Promotes Increased Survival in an Acute Fatal Pneumonia Model</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>7012</fpage><lpage>7021</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.12.7012-7021.2004</pub-id><pub-id pub-id-type="pmid">15557624</pub-id><pub-id pub-id-type="pmcid">PMC529127</pub-id></element-citation></ref><ref id="B63-ijms-26-02012"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harcher</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name></person-group><article-title>Intranasal Immunization with Heterologously Expressed Polysaccharide Protects against Multiple <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>4624</fpage><lpage>4629</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608657104</pub-id><pub-id pub-id-type="pmid">17360574</pub-id><pub-id pub-id-type="pmcid">PMC1838651</pub-id></element-citation></ref><ref id="B64-ijms-26-02012"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scarff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name></person-group><article-title>Vaccination against <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia in Immunocompromised Mice</article-title><source>Clin. Vaccine Immunol.</source><year>2008</year><volume>15</volume><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1128/CVI.00419-07</pub-id><pub-id pub-id-type="pmid">18094113</pub-id><pub-id pub-id-type="pmcid">PMC2238050</pub-id></element-citation></ref><ref id="B65-ijms-26-02012"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moustafa</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raghuram</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schulman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Michael R Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.B.</given-names></name></person-group><article-title>Efficacy of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Serogroup O9 Vaccine</article-title><source>Infect. Immun.</source><year>2023</year><volume>91</volume><elocation-id>e00247</elocation-id><pub-id pub-id-type="doi">10.1128/iai.00247-23</pub-id><pub-id pub-id-type="pmid">37991349</pub-id><pub-id pub-id-type="pmcid">PMC10715167</pub-id></element-citation></ref><ref id="B66-ijms-26-02012"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bridge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Whitmire</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Makobongo</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Merrell</surname><given-names>D.S.</given-names></name></person-group><article-title>Heterologous <italic toggle="yes">Pseudomonas aeruginosa</italic> O-Antigen Delivery Using a <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium <italic toggle="yes">wecA</italic> Mutant Strain</article-title><source>Int. J. Med. Microbiol.</source><year>2016</year><volume>306</volume><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2016.06.005</pub-id><pub-id pub-id-type="pmid">27476047</pub-id></element-citation></ref><ref id="B67-ijms-26-02012"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubensky</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Skoble</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lauer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brockstedt</surname><given-names>D.G.</given-names></name></person-group><article-title>Killed but Metabolically Active Vaccines</article-title><source>Curr. Opin. Biotechnol.</source><year>2012</year><volume>23</volume><fpage>917</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2012.04.005</pub-id><pub-id pub-id-type="pmid">22608846</pub-id></element-citation></ref><ref id="B68-ijms-26-02012"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meynet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Laurin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lenormand</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Camara</surname><given-names>B.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>B.</given-names></name><name name-style="western"><surname>Le Gou&#235;llec</surname><given-names>A.</given-names></name></person-group><article-title>Killed but Metabolically Active <italic toggle="yes">Pseudomonas aeruginosa</italic>-Based Vaccine Induces Protective Humoral- and Cell-Mediated Immunity against <italic toggle="yes">Pseudomonas aeruginosa</italic> Pulmonary Infections</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1893</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.040</pub-id><pub-id pub-id-type="pmid">29506924</pub-id></element-citation></ref><ref id="B69-ijms-26-02012"><label>69.</label><element-citation publication-type="gov"><collab>Office of Infectious Disease and HIV/AIDS</collab><article-title>Vaccine Types</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/immunization/basics/types/index.html" ext-link-type="uri">https://www.hhs.gov/immunization/basics/types/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B70-ijms-26-02012"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Dunkley</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>R.L.</given-names></name></person-group><article-title>Mucosal and Systemic Immunizations with Killed <italic toggle="yes">Pseudomonas aeruginosa</italic> Protect against Acute Respiratory Infection in Rats</article-title><source>Infect. Immun.</source><year>1994</year><volume>62</volume><fpage>1427</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1128/iai.62.4.1427-1436.1994</pub-id><pub-id pub-id-type="pmid">8132349</pub-id><pub-id pub-id-type="pmcid">PMC186298</pub-id></element-citation></ref><ref id="B71-ijms-26-02012"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Dunkley</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kyd</surname><given-names>J.</given-names></name></person-group><article-title>Vaccine Strategies against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection in the Lung</article-title><source>Behring Inst. Mitt.</source><year>1997</year><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">9382749</pub-id></element-citation></ref><ref id="B72-ijms-26-02012"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Peek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dunkley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vento</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marjason</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sizer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Croft</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sedlak-Weinstein</surname><given-names>L.</given-names></name></person-group><article-title>Safety and Immunogenicity of an Oral Inactivated Whole-Cell <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine Administered to Healthy Human Subjects</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>968</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1128/IAI.74.2.968-974.2006</pub-id><pub-id pub-id-type="pmid">16428742</pub-id><pub-id pub-id-type="pmcid">PMC1360303</pub-id></element-citation></ref><ref id="B73-ijms-26-02012"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodgers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>McCrudden</surname><given-names>M.T.C.</given-names></name><name name-style="western"><surname>Vincente-Perez</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Larra&#241;eta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kissenpfennig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Design and Characterisation of a Dissolving Microneedle Patch for Intradermal Vaccination with Heat-Inactivated Bacteria: A Proof of Concept Study</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>549</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.07.049</pub-id><pub-id pub-id-type="pmid">30048778</pub-id><pub-id pub-id-type="pmcid">PMC6127419</pub-id></element-citation></ref><ref id="B74-ijms-26-02012"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackwood</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Varney</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Damron</surname><given-names>F.H.</given-names></name><etal/></person-group><article-title>Innate and Adaptive Immune Responses against <italic toggle="yes">Bordetella pertussis</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> in a Murine Model of Mucosal Vaccination against Respiratory Infection</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>647</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8040647</pub-id><pub-id pub-id-type="pmid">33153066</pub-id><pub-id pub-id-type="pmcid">PMC7712645</pub-id></element-citation></ref><ref id="B75-ijms-26-02012"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Huckaby</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Horspool</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Malkowski</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Damron</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Barbier</surname><given-names>M.</given-names></name></person-group><article-title>Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against <italic toggle="yes">Pseudomonas aeruginosa</italic> Acute Murine Pneumonia</article-title><source>Infect. Immun.</source><year>2021</year><volume>89</volume><elocation-id>e00451</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00451-20</pub-id><pub-id pub-id-type="pmid">33199354</pub-id><pub-id pub-id-type="pmcid">PMC7822147</pub-id></element-citation></ref><ref id="B76-ijms-26-02012"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hydrogen Peroxide-Inactivated Bacteria Induces Potent Humoral and Cellular Immune Responses and Releases Nucleic Acids</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>69</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.01.055</pub-id><pub-id pub-id-type="pmid">30780019</pub-id></element-citation></ref><ref id="B77-ijms-26-02012"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amara</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Salem-Bekhit</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Alanazi</surname><given-names>F.K.</given-names></name></person-group><article-title>Sponge-Like: A New Protocol for Preparing Bacterial Ghosts</article-title><source>Sci. World J.</source><year>2013</year><volume>2013</volume><elocation-id>545741</elocation-id><pub-id pub-id-type="doi">10.1155/2013/545741</pub-id><pub-id pub-id-type="pmcid">PMC3614036</pub-id><pub-id pub-id-type="pmid">23576904</pub-id></element-citation></ref><ref id="B78-ijms-26-02012"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheweita</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gamal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghazy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bahey-El-Din</surname><given-names>M.</given-names></name></person-group><article-title>Bacterial Ghosts of <italic toggle="yes">Pseudomonas aeruginosa</italic> as a Promising Candidate Vaccine and Its Application in Diabetic Rats</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>910</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10060910</pub-id><pub-id pub-id-type="pmid">35746518</pub-id><pub-id pub-id-type="pmcid">PMC9228170</pub-id></element-citation></ref><ref id="B79-ijms-26-02012"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>An X-Ray Inactivated Vaccine against <italic toggle="yes">Pseudomonas aeruginosa</italic> Keratitis in Mice</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>4700</fpage><lpage>4709</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.05.066</pub-id><pub-id pub-id-type="pmid">37353454</pub-id></element-citation></ref><ref id="B80-ijms-26-02012"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Gnabasik</surname><given-names>F.J.</given-names></name></person-group><article-title>New Immunotype Schema for <italic toggle="yes">Pseudomonas aeruginosa</italic> Based on Protective Antigens</article-title><source>J. Bacteriol.</source><year>1969</year><volume>98</volume><fpage>835</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1128/jb.98.2.835-836.1969</pub-id><pub-id pub-id-type="pmid">4977486</pub-id><pub-id pub-id-type="pmcid">PMC284896</pub-id></element-citation></ref><ref id="B81-ijms-26-02012"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanessian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Regan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haskell</surname><given-names>T.H.</given-names></name></person-group><article-title>Isolation and Characterization of Antigenic Components of a New Heptavalent <italic toggle="yes">Pseudomonas</italic> Vaccine</article-title><source>Nat. New Biol.</source><year>1971</year><volume>229</volume><fpage>209</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/newbio229209a0</pub-id><pub-id pub-id-type="pmid">5281014</pub-id></element-citation></ref><ref id="B82-ijms-26-02012"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Altemeier</surname><given-names>W.A.</given-names></name></person-group><article-title>Prevention of Invasive <italic toggle="yes">Pseudomonas</italic> Infection in Burns with a New Vaccine</article-title><source>Arch. Surg.</source><year>1969</year><volume>99</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1001/archsurg.1969.01340140121018</pub-id><pub-id pub-id-type="pmid">4978523</pub-id></element-citation></ref><ref id="B83-ijms-26-02012"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M.W.</given-names></name></person-group><article-title>Immunological Determinants of <italic toggle="yes">Pseudomonas</italic> Infections of Man Accompanying Severe Burn Injury</article-title><source>J. Trauma.</source><year>1970</year><volume>10</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1097/00005373-197007000-00005</pub-id><pub-id pub-id-type="pmid">4986708</pub-id></element-citation></ref><ref id="B84-ijms-26-02012"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M.W.</given-names></name></person-group><article-title>Vaccination for <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Am. J. Surg.</source><year>1970</year><volume>120</volume><elocation-id>512</elocation-id><pub-id pub-id-type="doi">10.1016/S0002-9610(70)80019-8</pub-id><pub-id pub-id-type="pmid">4990276</pub-id></element-citation></ref><ref id="B85-ijms-26-02012"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>B.G.</given-names></name></person-group><article-title>Immunological Control of <italic toggle="yes">Pseudomonas</italic> Infection in Burn Patients: A Clinical Evaluation</article-title><source>Arch. Surg.</source><year>1971</year><volume>102</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1001/archsurg.1971.01350010033008</pub-id><pub-id pub-id-type="pmid">4992359</pub-id></element-citation></ref><ref id="B86-ijms-26-02012"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>D.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine in Cancer Patients</article-title><source>Ann. Intern. Med.</source><year>1973</year><volume>79</volume><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-79-4-518</pub-id><pub-id pub-id-type="pmid">4201225</pub-id></element-citation></ref><ref id="B87-ijms-26-02012"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennington</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>A.S.</given-names></name></person-group><article-title>Use of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine in Pateints with Acute Leukemia and Cystic Fibrosis</article-title><source>Am. J. Med.</source><year>1975</year><volume>58</volume><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(75)90498-2</pub-id><pub-id pub-id-type="pmid">805535</pub-id></element-citation></ref><ref id="B88-ijms-26-02012"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haghbin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.L.</given-names></name></person-group><article-title>Controlled Prospective Trial of <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine in Children with Acute Leukemia</article-title><source>Cancer</source><year>1973</year><volume>32</volume><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(197310)32:4&amp;#x0003c;761::AID-CNCR2820320405&amp;#x0003e;3.0.CO;2-H</pub-id><pub-id pub-id-type="pmid">4201654</pub-id></element-citation></ref><ref id="B89-ijms-26-02012"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennington</surname><given-names>J.E.</given-names></name></person-group><article-title>Preliminary Investigations of <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine in Patients with Leukemia and Cystic Fibrosis</article-title><source>J. Infect. Dis.</source><year>1974</year><volume>130</volume><fpage>S159</fpage><lpage>S162</lpage><pub-id pub-id-type="doi">10.1093/infdis/130.Supplement.S159</pub-id><pub-id pub-id-type="pmid">4213986</pub-id></element-citation></ref><ref id="B90-ijms-26-02012"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Spilbury</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ror</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Lowbury</surname><given-names>E.J.L.</given-names></name></person-group><article-title>A New Polyvalent <italic toggle="yes">Pseudomonas</italic> Vaccine</article-title><source>J. Med. Microbiol.</source><year>1977</year><volume>10</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1099/00222615-10-1-19</pub-id><pub-id pub-id-type="pmid">402473</pub-id></element-citation></ref><ref id="B91-ijms-26-02012"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roe</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.J.</given-names></name></person-group><article-title>Immunization of Burned Patients against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection at Safdarjang Hospital, New Delhi</article-title><source>Rev. Infect. Dis.</source><year>1983</year><volume>5</volume><issue>(Suppl. 5)</issue><fpage>S922</fpage><lpage>S930</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_5.S922</pub-id><pub-id pub-id-type="pmid">6419315</pub-id></element-citation></ref><ref id="B92-ijms-26-02012"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Lowbury</surname><given-names>E.J.L.</given-names></name><name name-style="western"><surname>Miler</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Spilsbury</surname><given-names>J.F.</given-names></name></person-group><article-title>A New <italic toggle="yes">Pseudomonas</italic> Vaccine: Preliminary Trial on Human Volunteers</article-title><source>Epidemiol. Infect.</source><year>1976</year><volume>76</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1017/S0022172400055364</pub-id><pub-id pub-id-type="pmcid">PMC2129666</pub-id><pub-id pub-id-type="pmid">819576</pub-id></element-citation></ref><ref id="B93-ijms-26-02012"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langford</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Hiller</surname><given-names>J.</given-names></name></person-group><article-title>Prospective, Controlled Study of a Polyvalent <italic toggle="yes">Pseudomonas</italic> Vaccine in Cystic Fibrosis&#8212;Three Year Results</article-title><source>Arch. Dis. Child.</source><year>1984</year><volume>59</volume><fpage>1131</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1136/adc.59.12.1131</pub-id><pub-id pub-id-type="pmid">6441523</pub-id><pub-id pub-id-type="pmcid">PMC1628912</pub-id></element-citation></ref><ref id="B94-ijms-26-02012"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Furer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Germanier</surname><given-names>R.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Immunotype 5 Polysaccharide-Toxin A Conjugate Vaccine</article-title><source>Infect. Immun.</source><year>1986</year><volume>52</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1128/iai.52.1.161-165.1986</pub-id><pub-id pub-id-type="pmid">3082756</pub-id><pub-id pub-id-type="pmcid">PMC262213</pub-id></element-citation></ref><ref id="B95-ijms-26-02012"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Germanier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J.C.</given-names></name></person-group><article-title>Safety and Immunogenicity of a <italic toggle="yes">Pseudomonas aeruginosa</italic> O-Polysaccharide Toxin A Conjugate Vaccine in Humans</article-title><source>J. Clin. Investig.</source><year>1987</year><volume>80</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1172/JCI113062</pub-id><pub-id pub-id-type="pmid">3110215</pub-id><pub-id pub-id-type="pmcid">PMC442200</pub-id></element-citation></ref><ref id="B96-ijms-26-02012"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.</given-names></name><name name-style="western"><surname>R&#252;deberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wedgwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schaad</surname><given-names>U.</given-names></name></person-group><article-title>Immunization of Cystic Fibrosis Patients with a <italic toggle="yes">Pseudomonas aeruginosa</italic> O-Polysaccharide-Toxin A Conjugate Vaccine</article-title><source>Behring Inst. Mitt.</source><year>1997</year><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">9382759</pub-id></element-citation></ref><ref id="B97-ijms-26-02012"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaad</surname><given-names>U.B.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Wedgwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruedeberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name></person-group><article-title>Safety and Immunogenicity of <italic toggle="yes">Pseudomonas aeruginosa</italic> Conjugate A Vaccine in Cystic Fibrosis</article-title><source>Lancet</source><year>1991</year><volume>338</volume><fpage>1236</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(91)92103-9</pub-id><pub-id pub-id-type="pmid">1682645</pub-id></element-citation></ref><ref id="B98-ijms-26-02012"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name></person-group><article-title>Immunization with a <italic toggle="yes">Pseudomonas aeruginosa</italic> Immunotype 5 O Polysaccharide-Toxin A Conjugate Vaccine: Effect of a Booster Dose on Antibody Levels in Humans</article-title><source>Infect. Immun.</source><year>1988</year><volume>56</volume><fpage>1829</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1128/iai.56.7.1829-1830.1988</pub-id><pub-id pub-id-type="pmid">2454893</pub-id><pub-id pub-id-type="pmcid">PMC259485</pub-id></element-citation></ref><ref id="B99-ijms-26-02012"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;ring</surname><given-names>G.</given-names></name></person-group><article-title>Prevention of <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection in Cystic Fibrosis Patients</article-title><source>Int. J. Med. Microbiol.</source><year>2010</year><volume>300</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2010.08.010</pub-id><pub-id pub-id-type="pmid">20940108</pub-id></element-citation></ref><ref id="B100-ijms-26-02012"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fatyan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saafan</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>El-Gebaly</surname><given-names>E.A.E.A.</given-names></name></person-group><article-title>Preparation and Evaluation of a New Combined Conjugated Vaccine against <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Appl. Microbiol.</source><year>2022</year><volume>133</volume><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1111/jam.15646</pub-id><pub-id pub-id-type="pmid">35652238</pub-id></element-citation></ref><ref id="B101-ijms-26-02012"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Promises and Pitfalls of <italic toggle="yes">Pseudomonas aeruginosa</italic> Lipopolysaccharide as a Vaccine Antigen</article-title><source>Carbohydr. Res.</source><year>2003</year><volume>338</volume><fpage>2549</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1016/S0008-6215(03)00312-4</pub-id><pub-id pub-id-type="pmid">14670716</pub-id></element-citation></ref><ref id="B102-ijms-26-02012"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Boisot</surname><given-names>S.</given-names></name><name name-style="western"><surname>DesJardins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Brisker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Immunogenic and Antigenic Properties of a Heptavalent High-Molecular-Weight O-Polysaccharide Vaccine Derived from <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Infect. Immun.</source><year>1994</year><volume>62</volume><fpage>3608</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1128/iai.62.9.3608-3616.1994</pub-id><pub-id pub-id-type="pmid">7520416</pub-id><pub-id pub-id-type="pmcid">PMC303009</pub-id></element-citation></ref><ref id="B103-ijms-26-02012"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saylor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gillam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lohneis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>283</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00283</pub-id><pub-id pub-id-type="pmid">32153587</pub-id><pub-id pub-id-type="pmcid">PMC7050619</pub-id></element-citation></ref><ref id="B104-ijms-26-02012"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuon</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Dantas</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Suss</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Tasca Ribeiro</surname><given-names>V.S.</given-names></name></person-group><article-title>Pathogenesis of the <italic toggle="yes">Pseudomonas aeruginosa</italic> Biofilm: A Review</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11030300</pub-id><pub-id pub-id-type="pmid">35335624</pub-id><pub-id pub-id-type="pmcid">PMC8950561</pub-id></element-citation></ref><ref id="B105-ijms-26-02012"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>H.B.</given-names></name></person-group><article-title>Protection against Mucoid <italic toggle="yes">Pseudomonas aeruginosa</italic> in Rodent Models of Endobronchial Infections</article-title><source>Science</source><year>1990</year><volume>249</volume><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1126/science.2116663</pub-id><pub-id pub-id-type="pmid">2116663</pub-id></element-citation></ref><ref id="B106-ijms-26-02012"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>DesJardin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Pekoe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Harkonen</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>H.C.</given-names></name></person-group><article-title>Human Immune Response to <italic toggle="yes">Pseudomonas aeruginosa</italic> Mucoid Exopolysaccharide (Alginate) Vaccine</article-title><source>Infect. Immun.</source><year>1994</year><volume>62</volume><fpage>3972</fpage><lpage>3979</lpage><pub-id pub-id-type="doi">10.1128/iai.62.9.3972-3979.1994</pub-id><pub-id pub-id-type="pmid">8063415</pub-id><pub-id pub-id-type="pmcid">PMC303055</pub-id></element-citation></ref><ref id="B107-ijms-26-02012"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>F&#252;rer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.U.</given-names></name></person-group><article-title>Synthesis and Characterization of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Alginate-Toxin A Conjugate Vaccine</article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1128/iai.59.1.45-50.1991</pub-id><pub-id pub-id-type="pmid">1898901</pub-id><pub-id pub-id-type="pmcid">PMC257703</pub-id></element-citation></ref><ref id="B108-ijms-26-02012"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Mueschenborn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Llosa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Construction and Characterization of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Mucoid Exopolysaccharide-Alginate Conjugate Vaccine</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3875</fpage><lpage>3884</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.7.3875-3884.2003</pub-id><pub-id pub-id-type="pmid">12819072</pub-id><pub-id pub-id-type="pmcid">PMC162014</pub-id></element-citation></ref><ref id="B109-ijms-26-02012"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azimi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Safari Zanjani</surname><given-names>L.</given-names></name></person-group><article-title>Immunization against <italic toggle="yes">Pseudomonas aeruginosa</italic> Using Alg-PLGA Nano-Vaccine</article-title><source>Iran. J. Basic. Med. Sci.</source><year>2021</year><volume>24</volume><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.22038/ijbms.2021.52217.11813</pub-id><pub-id pub-id-type="pmid">34094029</pub-id><pub-id pub-id-type="pmcid">PMC8143718</pub-id></element-citation></ref><ref id="B110-ijms-26-02012"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afshari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hakimian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanha</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Salouti</surname><given-names>M.</given-names></name></person-group><article-title>Immunogenicity Evaluating of the SLNs-Alginate Conjugate against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Immunol. Methods</source><year>2021</year><volume>488</volume><elocation-id>112938</elocation-id><pub-id pub-id-type="doi">10.1016/j.jim.2020.112938</pub-id><pub-id pub-id-type="pmid">33259781</pub-id></element-citation></ref><ref id="B111-ijms-26-02012"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>A Semisynthetic Oligomannuronic Acid-Based Glycoconjugate Vaccine against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>ACS Cent. Sci.</source><year>2024</year><volume>10</volume><fpage>1515</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.4c00387</pub-id><pub-id pub-id-type="pmid">39220693</pub-id><pub-id pub-id-type="pmcid">PMC11363335</pub-id></element-citation></ref><ref id="B112-ijms-26-02012"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyle</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Modern Subunit Vaccines: Development, Components, and Research Opportunities</article-title><source>ChemMedChem</source><year>2013</year><volume>8</volume><fpage>360</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201200487</pub-id><pub-id pub-id-type="pmid">23316023</pub-id></element-citation></ref><ref id="B113-ijms-26-02012"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duch&#234;ne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Domdey</surname><given-names>H.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name></person-group><article-title>Protection against Experimental <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection by Recombinant <italic toggle="yes">P. aeruginosa</italic> Lipoprotein I Expressed in <italic toggle="yes">Escherichia coli</italic></article-title><source>Infect. Immun.</source><year>1990</year><volume>58</volume><fpage>2241</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1128/iai.58.7.2241-2244.1990</pub-id><pub-id pub-id-type="pmid">2114360</pub-id><pub-id pub-id-type="pmcid">PMC258803</pub-id></element-citation></ref><ref id="B114-ijms-26-02012"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babaluei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farokhi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name></person-group><article-title>Immunostimulatory Chimeric Protein Encapsulated in Gelatin Nanoparticles Elicits Protective Immunity against <italic toggle="yes">Pseudomonas aeruginosa</italic> Respiratory Tract Infection</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>277</volume><elocation-id>133964</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.133964</pub-id><pub-id pub-id-type="pmid">39029853</pub-id></element-citation></ref><ref id="B115-ijms-26-02012"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews-Greer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> Outer Membrane Protein F Produced in <italic toggle="yes">Escherichia coli</italic> Retains Vaccine Efficacy</article-title><source>Curr. Microbiol.</source><year>1990</year><volume>20</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/BF02091993</pub-id></element-citation></ref><ref id="B116-ijms-26-02012"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>M.R.</given-names></name></person-group><article-title>Vaccine Efficacies of Elastase, Exotoxin A, and Outer-Membrane Protein F in Preventing Chronic Pulmonary Infection by <italic toggle="yes">Pseudomonas aeruginosa</italic> in a Rat Model</article-title><source>J. Med. Microbiol.</source><year>1993</year><volume>38</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1099/00222615-38-2-79</pub-id><pub-id pub-id-type="pmid">8429543</pub-id></element-citation></ref><ref id="B117-ijms-26-02012"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peluso</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Luca</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giovannini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lavorgna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Mascolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luna</surname><given-names>L.O.D.</given-names></name><name name-style="western"><surname>Catania</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic> Lung Infection in Mice by Recombinant OprF-Pulsed Dendritic Cell Immunization</article-title><source>BMC Microbiol.</source><year>2010</year><volume>10</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-10-9</pub-id><pub-id pub-id-type="pmid">20070893</pub-id><pub-id pub-id-type="pmcid">PMC2820439</pub-id></element-citation></ref><ref id="B118-ijms-26-02012"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hee</surname><given-names>K.-K.</given-names></name><name name-style="western"><surname>Vintayen</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Roelvink</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Bruder</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Wickham</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Kovesdi</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Protection against <italic toggle="yes">P. aeruginosa</italic> with an Adenovirus Vector Containing an OprF Epitope in the Capsid</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><elocation-id>1281</elocation-id><pub-id pub-id-type="doi">10.1172/JCI23135</pub-id><pub-id pub-id-type="pmid">15841217</pub-id><pub-id pub-id-type="pmcid">PMC1070634</pub-id></element-citation></ref><ref id="B119-ijms-26-02012"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krause</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whu</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wafadari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name></person-group><article-title>RGD Capsid Modification Enhances Mucosal Protective Immunity of a Non-Human Primate Adenovirus Vector Expressing <italic toggle="yes">Pseudomonas aeruginosa</italic> OprF</article-title><source>Clin. Exp. Immunol.</source><year>2013</year><volume>173</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.1111/cei.12101</pub-id><pub-id pub-id-type="pmid">23607394</pub-id><pub-id pub-id-type="pmcid">PMC3722923</pub-id></element-citation></ref><ref id="B120-ijms-26-02012"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>R.G.</given-names></name></person-group><article-title>Protective Immunity to <italic toggle="yes">Pseudomonas aeruginosa</italic> Induced with a Capsid-Modified Adenovirus Expressing <italic toggle="yes">P. aeruginosa</italic> OprF</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><elocation-id>13801</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01246-07</pub-id><pub-id pub-id-type="pmid">17942539</pub-id><pub-id pub-id-type="pmcid">PMC2168865</pub-id></element-citation></ref><ref id="B121-ijms-26-02012"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krause</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whu</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Joh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name></person-group><article-title>Protective Anti-<italic toggle="yes">Pseudomonas aeruginosa</italic> Humoral and Cellular Mucosal Immunity by AdC7-Mediated Expression of the <italic toggle="yes">P. aeruginosa</italic> Protein OprF</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><elocation-id>2131</elocation-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.087</pub-id><pub-id pub-id-type="pmid">21215829</pub-id><pub-id pub-id-type="pmcid">PMC3061442</pub-id></element-citation></ref><ref id="B122-ijms-26-02012"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahey-El-Din</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sheweita</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Haroun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zaghloul</surname><given-names>T.I.</given-names></name></person-group><article-title>Recombinant N-Terminal Outer Membrane Porin (OprF) of <italic toggle="yes">Pseudomonas aeruginosa</italic> Is a Promising Vaccine Candidate against Both <italic toggle="yes">P. aeruginosa</italic> and Some Strains of <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Int. J. Med. Microbiol.</source><year>2020</year><volume>310</volume><elocation-id>151415</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijmm.2020.151415</pub-id><pub-id pub-id-type="pmid">32156509</pub-id></element-citation></ref><ref id="B123-ijms-26-02012"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayeux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gayet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Odier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Cort&#232;s</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaack</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lenormand</surname><given-names>J.-L.</given-names></name></person-group><article-title>Cell-Free Expression of the Outer Membrane Protein OprF of <italic toggle="yes">Pseudomonas aeruginosa</italic> for Vaccine Purposes</article-title><source>Life Sci. Alliance</source><year>2021</year><volume>4</volume><elocation-id>e202000958</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202000958</pub-id><pub-id pub-id-type="pmid">33972378</pub-id><pub-id pub-id-type="pmcid">PMC8127326</pub-id></element-citation></ref><ref id="B124-ijms-26-02012"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanvi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dissanayake</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vartak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sebilleau</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Alom</surname><given-names>N.-E.</given-names></name><name name-style="western"><surname>Prestwich</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sucheck</surname><given-names>S.J.</given-names></name></person-group><article-title>Synthesis and Evaluation of a Self-Adjuvanting Pseudomonal Vaccine Based on Major Outer Membrane Porin OprF Epitopes Formulated with Low-Toxicity QS-21-Containing Liposomes</article-title><source>Bioconjugate Chem.</source><year>2023</year><volume>34</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00103</pub-id><pub-id pub-id-type="pmid">37092892</pub-id><pub-id pub-id-type="pmcid">PMC10723056</pub-id></element-citation></ref><ref id="B125-ijms-26-02012"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>B.</given-names></name><name name-style="western"><surname>Worgall</surname><given-names>S.</given-names></name></person-group><article-title>Post-Exposure Immunization by Capsid-Modified AdC7 Vector Expressing <italic toggle="yes">Pseudomonas aeruginosa</italic> OprF Clears <italic toggle="yes">P. Aeruginosa</italic> Respiratory Infection</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>7174</fpage><lpage>7180</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.078</pub-id><pub-id pub-id-type="pmid">29126807</pub-id><pub-id pub-id-type="pmcid">PMC5752147</pub-id></element-citation></ref><ref id="B126-ijms-26-02012"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>H.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.-L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-P.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name></person-group><article-title>Recombinant Protein Composed of <italic toggle="yes">Pseudomonas</italic> Exotoxin A, Outer Membrane Proteins I and F as Vaccine against <italic toggle="yes">P. aeruginosa</italic> Infection</article-title><source>Appl. Microbiol. Biotechnol.</source><year>1999</year><volume>52</volume><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1007/s002530051555</pub-id><pub-id pub-id-type="pmid">10570800</pub-id></element-citation></ref><ref id="B127-ijms-26-02012"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Parlane</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>Bioengineering a Bacterial Pathogen to Assemble Its Own Particulate Vaccine Capable of Inducing Cellular Immunity</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>41607</elocation-id><pub-id pub-id-type="doi">10.1038/srep41607</pub-id><pub-id pub-id-type="pmid">28150705</pub-id><pub-id pub-id-type="pmcid">PMC5288705</pub-id></element-citation></ref><ref id="B128-ijms-26-02012"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Strain Expressing OprF-OprI Protects Mice against Fatal Infection by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Microbiol. Immunol.</source><year>2015</year><volume>59</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12291</pub-id><pub-id pub-id-type="pmid">26249788</pub-id></element-citation></ref><ref id="B129-ijms-26-02012"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name></person-group><article-title>Mannose-Modified Chitosan Microspheres Enhance OprF-OprI-Mediated Protection of Mice against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection via Induction of Mucosal Immunity</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2015</year><volume>99</volume><fpage>667</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-6147-z</pub-id><pub-id pub-id-type="pmid">25381907</pub-id></element-citation></ref><ref id="B130-ijms-26-02012"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>R.</given-names></name><name name-style="western"><surname>El-Naggar</surname><given-names>W.</given-names></name><name name-style="western"><surname>Abd El-Aziz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Shaaban</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kenawy</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Y.M.</given-names></name></person-group><article-title>Immunization with Outer Membrane Proteins (OprF and OprI) and Flagellin B Protects Mice from Pulmonary Infection with Mucoid and Nonmucoid <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Microbiol. Immunol. Infect.</source><year>2018</year><volume>51</volume><fpage>312</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2016.08.014</pub-id><pub-id pub-id-type="pmid">28291719</pub-id></element-citation></ref><ref id="B131-ijms-26-02012"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Oligomerization of IC43 Resulted in Improved Immunogenicity and Protective Efficacy against <italic toggle="yes">Pseudomonas aeruginosa</italic> Lung Infection</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>159</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.05.057</pub-id><pub-id pub-id-type="pmid">32413471</pub-id></element-citation></ref><ref id="B132-ijms-26-02012"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westritschnig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wallner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Firbas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schwameis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B.</given-names></name></person-group><article-title>A Randomized, Placebo-Controlled Phase I Study Assessing the Safety and Immunogenicity of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Hybrid Outer Membrane Protein OprF/I Vaccine (IC43) in Healthy Volunteers</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>170</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.4161/hv.26565</pub-id><pub-id pub-id-type="pmid">24064511</pub-id><pub-id pub-id-type="pmcid">PMC4181012</pub-id></element-citation></ref><ref id="B133-ijms-26-02012"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gabelsberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hundt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hungerer</surname><given-names>K.-D.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Staczek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domdey</surname><given-names>H.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.-U.</given-names></name></person-group><article-title>Safety and Immunogenicity of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers</article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>1461</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.3.1461-1470.1999</pub-id><pub-id pub-id-type="pmid">10024596</pub-id><pub-id pub-id-type="pmcid">PMC96482</pub-id></element-citation></ref><ref id="B134-ijms-26-02012"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blome-Eberwein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gabelsberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Germann</surname><given-names>G.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name></person-group><article-title>Clinical Study to Assess the Immunogenicity and Safety of a Recombinant <italic toggle="yes">Pseudomonas aeruginosa</italic> OprF-OprI Vaccine in Burn Patients</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2003</year><volume>37</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S0928-8244(03)00072-5</pub-id><pub-id pub-id-type="pmid">12832120</pub-id></element-citation></ref><ref id="B135-ijms-26-02012"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krenn</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Locker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pilger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Madl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balica</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dugernier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laterre</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A Randomized Placebo-Controlled Phase II Study of a <italic toggle="yes">Pseudomonas</italic> Vaccine in Ventilated ICU Patients</article-title><source>Crit. Care</source><year>2017</year><volume>21</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-017-1601-9</pub-id><pub-id pub-id-type="pmid">28159015</pub-id><pub-id pub-id-type="pmcid">PMC5291979</pub-id></element-citation></ref><ref id="B136-ijms-26-02012"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adlbrecht</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Spapen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lorente</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Creteur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meier-Hellmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eller</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Efficacy, Immunogenicity, and Safety of IC43 Recombinant <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine in Mechanically Ventilated Intensive Care Patients-a Randomized Clinical Trial</article-title><source>Crit. Care</source><year>2020</year><volume>24</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-020-2792-z</pub-id><pub-id pub-id-type="pmid">32131866</pub-id><pub-id pub-id-type="pmcid">PMC7057595</pub-id></element-citation></ref><ref id="B137-ijms-26-02012"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larbig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Freihorst</surname><given-names>J.</given-names></name><name name-style="western"><surname>T&#252;mmler</surname><given-names>B.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Domdey</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hungerer</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Hundt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gabelsberger</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of an Intranasal <italic toggle="yes">Pseudomonas aeruginosa</italic> Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>2291</fpage><lpage>2297</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00550-8</pub-id><pub-id pub-id-type="pmid">11257350</pub-id></element-citation></ref><ref id="B138-ijms-26-02012"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumann</surname><given-names>U.</given-names></name><name name-style="western"><surname>G&#246;cke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gewecke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Freihorst</surname><given-names>J.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name></person-group><article-title>Assessment of Pulmonary Antibodies with Induced Sputum and Bronchoalveolar Lavage Induced by Nasal Vaccination against <italic toggle="yes">Pseudomonas aeruginosa</italic>: A Clinical Phase I/II Study</article-title><source>Respir. Res.</source><year>2007</year><volume>8</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1186/1465-9921-8-57</pub-id><pub-id pub-id-type="pmid">17683588</pub-id><pub-id pub-id-type="pmcid">PMC1973076</pub-id></element-citation></ref><ref id="B139-ijms-26-02012"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#246;cke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hagemann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gabelsberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Freihorst</surname><given-names>J.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name></person-group><article-title>Mucosal Vaccination with a Recombinant OprF-I Vaccine of <italic toggle="yes">Pseudomonas aeruginosa</italic> in Healthy Volunteers: Comparison of a Systemic vs. a Mucosal Booster Schedule</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2003</year><volume>37</volume><fpage>167</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0928-8244(03)00094-4</pub-id><pub-id pub-id-type="pmid">12832121</pub-id></element-citation></ref><ref id="B140-ijms-26-02012"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzaga</surname><given-names>Z.J.C.</given-names></name><name name-style="western"><surname>Merakou</surname><given-names>C.</given-names></name><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>A <italic toggle="yes">Pseudomonas aeruginosa</italic>-Derived Particulate Vaccine Protects against <italic toggle="yes">P. aeruginosa</italic> Infection</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>803</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9070803</pub-id><pub-id pub-id-type="pmid">34358220</pub-id><pub-id pub-id-type="pmcid">PMC8309987</pub-id></element-citation></ref><ref id="B141-ijms-26-02012"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzaga</surname><given-names>Z.J.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>Intranasal Delivery of Antigen-Coated Polymer Particles Protects against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>ACS Infect. Dis.</source><year>2022</year><volume>8</volume><fpage>744</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00434</pub-id><pub-id pub-id-type="pmid">35238554</pub-id></element-citation></ref><ref id="B142-ijms-26-02012"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>M.O.F.</given-names></name><name name-style="western"><surname>Schaefers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Merakou</surname><given-names>C.</given-names></name><name name-style="western"><surname>DiBlasi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zurakowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kehl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabor</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>DiGiandomenico</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multicomponent <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice</article-title><source>Infect. Immun.</source><year>2022</year><volume>90</volume><elocation-id>e00203</elocation-id><pub-id pub-id-type="doi">10.1128/iai.00203-22</pub-id><pub-id pub-id-type="pmid">36069593</pub-id><pub-id pub-id-type="pmcid">PMC9584304</pub-id></element-citation></ref><ref id="B143-ijms-26-02012"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabzehali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chirani</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Izad</surname><given-names>M.H.Y.</given-names></name></person-group><article-title>Immunopotentiating properties of chimeric OprF-OprI-PopB protein against <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1 in the infected burned rat model</article-title><source>Iran. J. Basic. Med. Sci.</source><year>2022</year><volume>25</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.22038/IJBMS.2022.61448.13595</pub-id><pub-id pub-id-type="pmid">35656187</pub-id><pub-id pub-id-type="pmcid">PMC9148398</pub-id></element-citation></ref><ref id="B144-ijms-26-02012"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Traficante</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Risech</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lory</surname><given-names>S.</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name></person-group><article-title>Th17-Stimulating Protein Vaccines Confer Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2012</year><volume>186</volume><elocation-id>420</elocation-id><pub-id pub-id-type="doi">10.1164/rccm.201202-0182OC</pub-id><pub-id pub-id-type="pmid">22723292</pub-id><pub-id pub-id-type="pmcid">PMC3443805</pub-id></element-citation></ref><ref id="B145-ijms-26-02012"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name></person-group><article-title>Vaccination with a Recombinant OprL Fragment Induces a Th17 Response and Confers Serotype-Independent Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection in Mice</article-title><source>Clin. Immunol.</source><year>2017</year><volume>183</volume><fpage>354</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2017.09.022</pub-id><pub-id pub-id-type="pmid">28970186</pub-id></element-citation></ref><ref id="B146-ijms-26-02012"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name></person-group><article-title>Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous <italic toggle="yes">Pseudomonas aeruginosa</italic> Strains Based on Expression Profiling of Outer Membrane Proteins During Infection</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>1737</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01737</pub-id><pub-id pub-id-type="pmid">30093906</pub-id><pub-id pub-id-type="pmcid">PMC6070602</pub-id></element-citation></ref><ref id="B147-ijms-26-02012"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Pociask</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Morici</surname><given-names>L.A.</given-names></name></person-group><article-title>Intradermal Vaccination with a <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine Adjuvanted with a Mutant Bacterial ADP-Ribosylating Enterotoxin Protects against Acute Pneumonia</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.12.053</pub-id><pub-id pub-id-type="pmid">30638799</pub-id></element-citation></ref><ref id="B148-ijms-26-02012"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Extracellular Polysaccharide of Lactobacillus Plantarum Enhance Immune Efficacy of oprH Gene Recombinant Subunit Vaccine from <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Vet. Med. Sci.</source><year>2023</year><volume>85</volume><elocation-id>1210</elocation-id><pub-id pub-id-type="doi">10.1292/jvms.23-0320</pub-id><pub-id pub-id-type="pmid">37779090</pub-id><pub-id pub-id-type="pmcid">PMC10686767</pub-id></element-citation></ref><ref id="B149-ijms-26-02012"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golpasha</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Owlia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Irani</surname><given-names>S.</given-names></name></person-group><article-title>Immunization with 3-Oxododecanoyl-L-Homoserine Lactone-r-PcrV Conjugate Enhances Survival of Mice against Lethal Burn Infections Caused by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Bosn. J. Basic. Med. Sci.</source><year>2015</year><volume>15</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.17305/bjbms.2015.292</pub-id><pub-id pub-id-type="pmid">26042508</pub-id><pub-id pub-id-type="pmcid">PMC4469931</pub-id></element-citation></ref><ref id="B150-ijms-26-02012"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Badmasti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name></person-group><article-title>Vaccination of Mice with Hybrid Protein Containing Exotoxin S and PcrV with Adjuvants Alum and MPL Protects <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>1325</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-05157-3</pub-id><pub-id pub-id-type="pmid">35079054</pub-id><pub-id pub-id-type="pmcid">PMC8789797</pub-id></element-citation></ref><ref id="B151-ijms-26-02012"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakoor</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Mousavi Gargari</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Owlia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sabokbar</surname><given-names>A.</given-names></name></person-group><article-title>Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against <italic toggle="yes">Pseudomonas aeruginosa</italic> in the Burned BALB/c Mouse Model</article-title><source>Infect. Drug Resist.</source><year>2020</year><volume>13</volume><fpage>1651</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.2147/IDR.S244081</pub-id><pub-id pub-id-type="pmid">32606816</pub-id><pub-id pub-id-type="pmcid">PMC7294051</pub-id></element-citation></ref><ref id="B152-ijms-26-02012"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalantari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferdousi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asadi Karam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Mohammadian</surname><given-names>T.</given-names></name></person-group><article-title>Development of a Multi-Epitope Vaccine Candidate against <italic toggle="yes">Pseudomonas aeruginosa</italic> Causing Urinary Tract Infection and Evaluation of Its Immunoreactivity in a Rabbit Model</article-title><source>J. Biomol. Struct. Dyn.</source><year>2024</year><volume>42</volume><fpage>6212</fpage><lpage>6227</lpage><pub-id pub-id-type="doi">10.1080/07391102.2023.2239915</pub-id><pub-id pub-id-type="pmid">37489041</pub-id></element-citation></ref><ref id="B153-ijms-26-02012"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yahr</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gropper</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wiener-Kronish</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D.W.</given-names></name></person-group><article-title>Active and Passive Immunization with the <italic toggle="yes">Pseudomonas</italic> V Antigen Protects against Type III Intoxication and Lung Injury</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/7391</pub-id><pub-id pub-id-type="pmid">10202927</pub-id></element-citation></ref><ref id="B154-ijms-26-02012"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Protective Efficacy of the Trivalent <italic toggle="yes">Pseudomonas aeruginosa</italic> Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>3957</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-04029-5</pub-id><pub-id pub-id-type="pmid">28638106</pub-id><pub-id pub-id-type="pmcid">PMC5479855</pub-id></element-citation></ref><ref id="B155-ijms-26-02012"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hamaoka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kainuma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>T.</given-names></name></person-group><article-title>The Protective Effects of Nasal PcrV-CpG Oligonucleotide Vaccination against <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia</article-title><source>Microbiol. Immunol.</source><year>2018</year><volume>62</volume><fpage>774</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12658</pub-id><pub-id pub-id-type="pmid">30378708</pub-id></element-citation></ref><ref id="B156-ijms-26-02012"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name></person-group><article-title>Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>781</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00781</pub-id><pub-id pub-id-type="pmid">31068928</pub-id><pub-id pub-id-type="pmcid">PMC6491502</pub-id></element-citation></ref><ref id="B157-ijms-26-02012"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howlader</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whittier</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Nagel</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varisco</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Development of a nano-emulsion based multivalent protein subunit vaccine against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1372349</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1372349</pub-id><pub-id pub-id-type="pmid">38698863</pub-id><pub-id pub-id-type="pmcid">PMC11063228</pub-id></element-citation></ref><ref id="B158-ijms-26-02012"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Howlader</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ratnakaram</surname><given-names>S.S.K.</given-names></name><name name-style="western"><surname>Whittier</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Picking</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Birket</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Picking</surname><given-names>W.L.</given-names></name></person-group><article-title>Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>583008</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.583008</pub-id><pub-id pub-id-type="pmid">33281815</pub-id><pub-id pub-id-type="pmcid">PMC7705240</pub-id></element-citation></ref><ref id="B159-ijms-26-02012"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howlader</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Varisco</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Ratnakaram</surname><given-names>S.S.K.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>706157</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.706157</pub-id><pub-id pub-id-type="pmid">34483911</pub-id><pub-id pub-id-type="pmcid">PMC8416447</pub-id></element-citation></ref><ref id="B160-ijms-26-02012"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howlader</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Varisco</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Ratnakaram</surname><given-names>S.S.K.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Picking</surname><given-names>W.D.</given-names></name><etal/></person-group><article-title>A Protein Subunit Vaccine Elicits a Balanced Immune Response That Protects against <italic toggle="yes">Pseudomonas</italic> Pulmonary Infection</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1038/s41541-023-00618-w</pub-id><pub-id pub-id-type="pmid">36918600</pub-id><pub-id pub-id-type="pmcid">PMC10012293</pub-id></element-citation></ref><ref id="B161-ijms-26-02012"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Development of a Chimeric Vaccine Against <italic toggle="yes">Pseudomonas aeruginosa</italic> Based on the Th17-Stimulating Epitopes of PcrV and AmpC</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><elocation-id>601601</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.601601</pub-id><pub-id pub-id-type="pmid">33552056</pub-id><pub-id pub-id-type="pmcid">PMC7859429</pub-id></element-citation></ref><ref id="B162-ijms-26-02012"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Q.</given-names></name></person-group><article-title>Intranasal Vaccination with rePcrV Protects against <italic toggle="yes">Pseudomonas aeruginosa</italic> and Generates Lung Tissue-Resident Memory T Cells</article-title><source>J. Immunol. Res.</source><year>2022</year><volume>2022</volume><elocation-id>1403788</elocation-id><pub-id pub-id-type="doi">10.1155/2022/1403788</pub-id><pub-id pub-id-type="pmid">36471700</pub-id><pub-id pub-id-type="pmcid">PMC9719435</pub-id></element-citation></ref><ref id="B163-ijms-26-02012"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free <italic toggle="yes">Pseudomonas aeruginosa</italic> vaccine</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1184863</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1184863</pub-id><pub-id pub-id-type="pmid">37415986</pub-id><pub-id pub-id-type="pmcid">PMC10321299</pub-id></element-citation></ref><ref id="B164-ijms-26-02012"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muranishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sudo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>T.</given-names></name></person-group><article-title>Effect of a Novel Trivalent Vaccine Formulation against Acute Lung Injury Caused by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1088</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11061088</pub-id><pub-id pub-id-type="pmid">37376477</pub-id><pub-id pub-id-type="pmcid">PMC10304393</pub-id></element-citation></ref><ref id="B165-ijms-26-02012"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#246;ms</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Forslund</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>M.S.</given-names></name></person-group><article-title>PcrH of <italic toggle="yes">Pseudomonas aeruginosa</italic> Is Essential for Secretion and Assembly of the Type III Translocon</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>1909</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1086/379898</pub-id><pub-id pub-id-type="pmid">14673772</pub-id></element-citation></ref><ref id="B166-ijms-26-02012"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaefers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reznor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>G.P.</given-names></name></person-group><article-title>PLGA-Encapsulation of the <italic toggle="yes">Pseudomonas aeruginosa</italic> PopB Vaccine Antigen Improves Th17 Responses and Confers Protection against Experimental Acute Pneumonia</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><elocation-id>6926</elocation-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.10.010</pub-id><pub-id pub-id-type="pmid">30314911</pub-id><pub-id pub-id-type="pmcid">PMC6279603</pub-id></element-citation></ref><ref id="B167-ijms-26-02012"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Structural and Biological Insights into Outer Membrane Protein Lipotoxin F of <italic toggle="yes">Pseudomonas aeruginosa</italic>: Implications for Vaccine Application</article-title><source>Int. J. Biol. Macromol.</source><year>2023</year><volume>253</volume><elocation-id>127634</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.127634</pub-id><pub-id pub-id-type="pmid">37884248</pub-id></element-citation></ref><ref id="B168-ijms-26-02012"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askarian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Cordara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zurich</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Bj&#229;nes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Golten</surname><given-names>O.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Kousha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chikwati</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Immunization with Lytic Polysaccharide Monooxygenase CbpD Induces Protective Immunity against <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><elocation-id>e2301538120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2301538120</pub-id><pub-id pub-id-type="pmid">37459522</pub-id><pub-id pub-id-type="pmcid">PMC10372616</pub-id></element-citation></ref><ref id="B169-ijms-26-02012"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banadkoki</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Keshavarzmehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Aleyasin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>F.B.</given-names></name></person-group><article-title>Protective Effect of Pilin Protein with Alum+naloxone Adjuvant against Acute Pulmonary <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>Biologicals</source><year>2016</year><volume>44</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2016.06.009</pub-id><pub-id pub-id-type="pmid">27427517</pub-id></element-citation></ref><ref id="B170-ijms-26-02012"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A Novel Structurally Identified Epitope Delivered by Macrophage Membrane-Coated PLGA Nanoparticles Elicits Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Nanobiotechnol.</source><year>2022</year><volume>20</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/s12951-022-01725-x</pub-id><pub-id pub-id-type="pmid">36517801</pub-id><pub-id pub-id-type="pmcid">PMC9750051</pub-id></element-citation></ref><ref id="B171-ijms-26-02012"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Churchill</surname><given-names>M.E.A.</given-names></name><name name-style="western"><surname>Irvin</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>R.S.</given-names></name></person-group><article-title>Animal Protection and Structural Studies of a Consensus Sequence VaccineTargeting the Receptor Binding Domain of the Type IV Pilus of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Mol. Biol.</source><year>2007</year><volume>374</volume><fpage>426</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.09.032</pub-id><pub-id pub-id-type="pmid">17936788</pub-id><pub-id pub-id-type="pmcid">PMC3493149</pub-id></element-citation></ref><ref id="B172-ijms-26-02012"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>R.S.</given-names></name></person-group><article-title>Advantages of a Synthetic Peptide Immunogen Over a Protein Immunogen in the Development of an Anti-Pilus Vaccine for <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Chem. Biol. Drug Des.</source><year>2009</year><volume>74</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2009.00825.x</pub-id><pub-id pub-id-type="pmid">19519742</pub-id><pub-id pub-id-type="pmcid">PMC2756486</pub-id></element-citation></ref><ref id="B173-ijms-26-02012"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korpi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Laghaei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name></person-group><article-title>Flagellin and Pilin Immunization against Multi-Drug Resistant <italic toggle="yes">Pseudomonas aeruginosa</italic> Protects Mice in the Burn Wound Sepsis Model</article-title><source>Immunol. Lett.</source><year>2016</year><volume>176</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2016.04.002</pub-id><pub-id pub-id-type="pmid">27210422</pub-id></element-citation></ref><ref id="B174-ijms-26-02012"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Irajianm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korpi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Motamedifar</surname><given-names>M.</given-names></name></person-group><article-title>Passive immunization against <italic toggle="yes">Pseudomonas aeruginosa</italic> recombinant PilA in a murine burn wound model</article-title><source>Microb Pathog.</source><year>2016</year><volume>101</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2016.10.027</pub-id><pub-id pub-id-type="pmid">27836762</pub-id></element-citation></ref><ref id="B175-ijms-26-02012"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laghaei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Korpi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amirmozafari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name></person-group><article-title>Immunogenicity and Protective Efficacy of <italic toggle="yes">Pseudomonas aeruginosa</italic> Type a and b Flagellin Vaccines in a Burned Mouse Model</article-title><source>Mol. Immunol.</source><year>2016</year><volume>74</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2016.04.008</pub-id><pub-id pub-id-type="pmid">27152476</pub-id></element-citation></ref><ref id="B176-ijms-26-02012"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saffari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Behbood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khorshidi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moniri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name></person-group><article-title>Antibodies Raised against Divalent Type b Flagellin and Pilin Provide Effective Immunotherapy against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection of Mice with Burn Wounds</article-title><source>Biologicals</source><year>2017</year><volume>45</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2016.10.007</pub-id><pub-id pub-id-type="pmid">27836582</pub-id></element-citation></ref><ref id="B177-ijms-26-02012"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakht azad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nikokar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Faezi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rasooly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the Immune Responses Following Co-Administration of PilQ and Type b-Flagellin from <italic toggle="yes">Pseudomonas aeruginosa</italic> in the Burn Mouse Model</article-title><source>Microb. Pathog.</source><year>2018</year><volume>123</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2018.07.042</pub-id><pub-id pub-id-type="pmid">30075242</pub-id></element-citation></ref><ref id="B178-ijms-26-02012"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashemi</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Laghaei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Korpi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>M.J.</given-names></name></person-group><article-title>A Trivalent Vaccine Consisting of &#8220;Flagellin A+B and Pilin&#8221; Protects against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection in a Murine Burn Model</article-title><source>Microb. Pathog.</source><year>2020</year><volume>138</volume><elocation-id>103697</elocation-id><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103697</pub-id><pub-id pub-id-type="pmid">31465785</pub-id></element-citation></ref><ref id="B179-ijms-26-02012"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heurtault</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gentine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thomann</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Baehr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frisch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pons</surname><given-names>F.</given-names></name></person-group><article-title>Design of a Liposomal Candidate Vaccine Against <italic toggle="yes">Pseudomonas aeruginosa</italic> and Its Evaluation in Triggering Systemic and Lung Mucosal Immunity</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><fpage>276</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9724-y</pub-id><pub-id pub-id-type="pmid">18781377</pub-id></element-citation></ref><ref id="B180-ijms-26-02012"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chirani</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Razavi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Falak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name></person-group><article-title>Immunogenicity of a Fusion Protein Containing PilQ and Disulphide Turn Region of PilA from <italic toggle="yes">Pseudomonas aeruginosa</italic> in Mice</article-title><source>Lett. Appl. Microbiol.</source><year>2017</year><volume>65</volume><fpage>439</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1111/lam.12796</pub-id><pub-id pub-id-type="pmid">28857243</pub-id></element-citation></ref><ref id="B181-ijms-26-02012"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadbeigi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chirani</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>M.</given-names></name></person-group><article-title>Immunopotentiation of the Engineered Low-Molecular-Weight Pilin Targeting <italic toggle="yes">Pseudomonas aeruginosa</italic>: A Combination of Immunoinformatics Investigation and Active Immunization</article-title><source>Mol. Immunol.</source><year>2020</year><volume>124</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2020.05.009</pub-id><pub-id pub-id-type="pmid">32540517</pub-id></element-citation></ref><ref id="B182-ijms-26-02012"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chirani</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Hajikhani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ebrahimipour</surname><given-names>G.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>M.</given-names></name></person-group><article-title>Unraveling the Immunopotentiation of <italic toggle="yes">P. aeruginosa</italic> PAPI-1 Encoded Pilin: From Immunoinformatics Survey to Active Immunization</article-title><source>Int. Immunopharmacol.</source><year>2023</year><volume>125</volume><elocation-id>111197</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2023.111197</pub-id><pub-id pub-id-type="pmid">37951200</pub-id></element-citation></ref><ref id="B183-ijms-26-02012"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hajikhani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ebrahimipour</surname><given-names>G.</given-names></name></person-group><article-title>Exploiting Immunopotential PAPI-1 Encoded Type IVb Major Pilin Targeting <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Heliyon</source><year>2024</year><volume>10</volume><elocation-id>e36859</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e36859</pub-id><pub-id pub-id-type="pmid">39281519</pub-id><pub-id pub-id-type="pmcid">PMC11401190</pub-id></element-citation></ref><ref id="B184-ijms-26-02012"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amirmozafari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Naghavi</surname><given-names>S.</given-names></name></person-group><article-title>Bivalent Flagellin Immunotherapy Protects Mice against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections in Both Acute Pneumonia and Burn Wound Models</article-title><source>Biologicals</source><year>2017</year><volume>46</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2016.12.005</pub-id><pub-id pub-id-type="pmid">28065582</pub-id></element-citation></ref><ref id="B185-ijms-26-02012"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holder</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Naglich</surname><given-names>J.G.</given-names></name></person-group><article-title>Experimental Studies of the Pathogenesis of Infections Due to <italic toggle="yes">Pseudomonas aeruginosa</italic>: Immunization Using Divalent Flagella Preparations</article-title><source>J. Trauma.</source><year>1986</year><volume>26</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1097/00005373-198602000-00003</pub-id><pub-id pub-id-type="pmid">2418208</pub-id></element-citation></ref><ref id="B186-ijms-26-02012"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holder</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montie</surname><given-names>T.C.</given-names></name></person-group><article-title>Flagellar Preparations from <italic toggle="yes">Pseudomonas aeruginosa</italic>: Animal Protection Studies</article-title><source>Infect. Immun.</source><year>1982</year><volume>35</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1128/iai.35.1.276-280.1982</pub-id><pub-id pub-id-type="pmid">6797948</pub-id><pub-id pub-id-type="pmcid">PMC351026</pub-id></element-citation></ref><ref id="B187-ijms-26-02012"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montie</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Craven</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Holder</surname><given-names>I.A.</given-names></name></person-group><article-title>Flagellar Preparations from <italic toggle="yes">Pseudomonas aeruginosa</italic>: Isolation and Characterization</article-title><source>Infect. Immun.</source><year>1982</year><volume>35</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1128/iai.35.1.281-288.1982</pub-id><pub-id pub-id-type="pmid">6797949</pub-id><pub-id pub-id-type="pmcid">PMC351027</pub-id></element-citation></ref><ref id="B188-ijms-26-02012"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faezi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bahrmand</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Sardari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nikokar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Khanaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mirzajani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>G.</given-names></name></person-group><article-title>Preparation of <italic toggle="yes">Pseudomonas aeruginosa</italic> Alginate-Flagellin Immunoconjugate</article-title><source>Biologicals</source><year>2017</year><volume>47</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2017.04.001</pub-id><pub-id pub-id-type="pmid">28404459</pub-id></element-citation></ref><ref id="B189-ijms-26-02012"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weimer</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kock</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>A Fusion Protein Vaccine Containing OprF Epitope 8, OprI, and Type A and B Flagellins Promotes Enhanced Clearance of Nonmucoid <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>2356</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1128/IAI.00054-09</pub-id><pub-id pub-id-type="pmid">19349426</pub-id><pub-id pub-id-type="pmcid">PMC2687341</pub-id></element-citation></ref><ref id="B190-ijms-26-02012"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campod&#243;nico</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Llosa</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Grout</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#246;ring</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maira-Litr&#225;n</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Evaluation of Flagella and Flagellin of <italic toggle="yes">Pseudomonas aeruginosa</italic> as Vaccines</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1128/IAI.00806-09</pub-id><pub-id pub-id-type="pmid">19995892</pub-id><pub-id pub-id-type="pmcid">PMC2812208</pub-id></element-citation></ref><ref id="B191-ijms-26-02012"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campod&#243;nico</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Llosa</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Bentancor</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Maira-Litran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Efficacy of a Conjugate Vaccine Containing Polymannuronic Acid and Flagellin against Experimental <italic toggle="yes">Pseudomonas aeruginosa</italic> Lung Infection in Mice</article-title><source>Infect. Immun.</source><year>2011</year><volume>79</volume><fpage>3455</fpage><lpage>3464</lpage><pub-id pub-id-type="doi">10.1128/IAI.00157-11</pub-id><pub-id pub-id-type="pmid">21628521</pub-id><pub-id pub-id-type="pmcid">PMC3147594</pub-id></element-citation></ref><ref id="B192-ijms-26-02012"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behrouz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Fatemi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Naghavi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Halabian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Imani Fooladi</surname><given-names>A.A.</given-names></name></person-group><article-title>Immunization with Bivalent Flagellin Protects Mice against Fatal <italic toggle="yes">Pseudomonas aeruginosa</italic> Pneumonia</article-title><source>J. Immunol. Res.</source><year>2017</year><volume>2017</volume><elocation-id>5689709</elocation-id><pub-id pub-id-type="doi">10.1155/2017/5689709</pub-id><pub-id pub-id-type="pmid">29201922</pub-id><pub-id pub-id-type="pmcid">PMC5671732</pub-id></element-citation></ref><ref id="B193-ijms-26-02012"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korpi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Irajian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Forouhi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mohammadian</surname><given-names>T.</given-names></name></person-group><article-title>A Chimeric Vaccine Targeting <italic toggle="yes">Pseudomonas aeruginosa</italic> Virulence Factors Protects Mice against Lethal Infection</article-title><source>Microb. Pathog.</source><year>2023</year><volume>178</volume><elocation-id>106033</elocation-id><pub-id pub-id-type="doi">10.1016/j.micpath.2023.106033</pub-id><pub-id pub-id-type="pmid">36813005</pub-id></element-citation></ref><ref id="B194-ijms-26-02012"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Flagella Hook Protein FlgE Is a Novel Vaccine Candidate of <italic toggle="yes">Pseudomonas aeruginosa</italic> Identified by a Genomic Approach</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2386</fpage><lpage>2395</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.051</pub-id><pub-id pub-id-type="pmid">33775439</pub-id></element-citation></ref><ref id="B195-ijms-26-02012"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Recombinant <italic toggle="yes">Pseudomonas aeruginosa</italic> Flagellin Delivered Using Ferritin Nanoparticles Provides Enhanced Cross-Protection against Lung Infection in Mice</article-title><source>Mol. Immunol.</source><year>2023</year><volume>163</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2023.10.005</pub-id><pub-id pub-id-type="pmid">37866168</pub-id></element-citation></ref><ref id="B196-ijms-26-02012"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Tennant</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>A.S.</given-names></name></person-group><article-title>The O-Glycan Is Essential for the Induction of Protective Antibodies against Lethal Infection by Flagella A-Bearing <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Infect. Immun.</source><year>2024</year><volume>92</volume><elocation-id>e00427</elocation-id><pub-id pub-id-type="doi">10.1128/iai.00427-23</pub-id><pub-id pub-id-type="pmid">38391207</pub-id><pub-id pub-id-type="pmcid">PMC10929410</pub-id></element-citation></ref><ref id="B197-ijms-26-02012"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;ring</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>U.</given-names></name><name name-style="western"><surname>Mohr-Pennert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dorner</surname><given-names>F.</given-names></name></person-group><article-title>Parenteral Application of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Flagella Vaccine Elicits Specific Anti-Flagella Antibodies in the Airways of Healthy Individuals</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1995</year><volume>151</volume><fpage>983</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.151.4.7697276</pub-id><pub-id pub-id-type="pmid">7697276</pub-id></element-citation></ref><ref id="B198-ijms-26-02012"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowe</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Enzersberger</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schober-Bendixen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitterer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mundt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Livey</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pabst</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eibl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eibl</surname><given-names>J.</given-names></name></person-group><article-title>The First Clinical Trial of Immuno&#8217;s Experimental <italic toggle="yes">Pseudomonas aeruginosa</italic> Flagellar Vaccines</article-title><source>Antibiot Chemother</source><year>1991</year><volume>44</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1159/000420309</pub-id><pub-id pub-id-type="pmid">1801633</pub-id></element-citation></ref><ref id="B199-ijms-26-02012"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;ring</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meisner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M.</given-names></name></person-group><article-title>A Double-Blind Randomized Placebo-Controlled Phase III Study of a <italic toggle="yes">Pseudomonas aeruginosa</italic> Flagella Vaccine in Cystic Fibrosis Patients</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>11020</fpage><lpage>11025</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702403104</pub-id><pub-id pub-id-type="pmid">17585011</pub-id><pub-id pub-id-type="pmcid">PMC1904125</pub-id></element-citation></ref><ref id="B200-ijms-26-02012"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokol</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kooi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Cachia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>D.E.</given-names></name></person-group><article-title>Immunization with a <italic toggle="yes">Pseudomonas aeruginosa</italic> Elastase Peptide Reduces Severity of Experimental Lung Infections Due to <italic toggle="yes">P. aeruginosa</italic> or <italic toggle="yes">Burkholderia cepacia</italic></article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>1682</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1086/315470</pub-id><pub-id pub-id-type="pmid">10823769</pub-id></element-citation></ref><ref id="B201-ijms-26-02012"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shibano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name></person-group><article-title>Site-Directed Mutagenesis of Glu-141 and His-223 in <italic toggle="yes">Pseudomonas aeruginosa</italic> Elastase: Catalytic Activity, Processing, and Protective Activity of the Elastase against <italic toggle="yes">Pseudomonas</italic> Infection</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><elocation-id>1400</elocation-id><pub-id pub-id-type="doi">10.1128/iai.61.4.1400-1405.1993</pub-id><pub-id pub-id-type="pmid">8454342</pub-id><pub-id pub-id-type="pmcid">PMC281377</pub-id></element-citation></ref><ref id="B202-ijms-26-02012"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Dunkley</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bastin</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kyd</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name></person-group><article-title>Catalase Immunization from <italic toggle="yes">Pseudomonas aeruginosa</italic> Enhances Bacterial Clearance in the Rat Lung</article-title><source>Vaccine</source><year>2000</year><volume>19</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00146-8</pub-id><pub-id pub-id-type="pmid">10930690</pub-id></element-citation></ref><ref id="B203-ijms-26-02012"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Kyd</surname><given-names>J.M.</given-names></name></person-group><article-title>Immune Response Mechanisms against <italic toggle="yes">Pseudomonas aeruginosa</italic> Associated with Mucosal Immunization with Protein Antigens in a Rat Model of Acute Lung Infection</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3324</fpage><lpage>3330</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.085</pub-id><pub-id pub-id-type="pmid">19200832</pub-id></element-citation></ref><ref id="B204-ijms-26-02012"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen-Kilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Malkowski</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bevere</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Varney</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice from <italic toggle="yes">Pseudomonas aeruginosa</italic> Acute Murine Pneumonia</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>2497</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02497</pub-id><pub-id pub-id-type="pmid">31708925</pub-id><pub-id pub-id-type="pmcid">PMC6819369</pub-id></element-citation></ref><ref id="B205-ijms-26-02012"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michalska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas</italic> Exotoxin A: Optimized by Evolution for Effective Killing</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><elocation-id>963</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.00963</pub-id><pub-id pub-id-type="pmid">26441897</pub-id><pub-id pub-id-type="pmcid">PMC4584936</pub-id></element-citation></ref><ref id="B206-ijms-26-02012"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukac</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>R.J.</given-names></name></person-group><article-title>Toxoid of <italic toggle="yes">Pseudomonas aeruginosa</italic> Exotoxin A Generated by Deletion of an Active-Site Residue</article-title><source>Infect. Immun.</source><year>1988</year><volume>56</volume><fpage>3095</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.1128/iai.56.12.3095-3098.1988</pub-id><pub-id pub-id-type="pmid">2460407</pub-id><pub-id pub-id-type="pmcid">PMC259707</pub-id></element-citation></ref><ref id="B207-ijms-26-02012"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Loa</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.-L.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>H.-F.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>C.-F.</given-names></name></person-group><article-title>A Nontoxic <italic toggle="yes">Pseudomonas</italic> Exotoxin A Induces Active Immunity and Passive Protective Antibody against <italic toggle="yes">Pseudomonas</italic> Exotoxin a Intoxication</article-title><source>J. Biomed. Sci.</source><year>1999</year><volume>6</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1159/000025408</pub-id><pub-id pub-id-type="pmid">10494043</pub-id></element-citation></ref><ref id="B208-ijms-26-02012"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Embaie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hertle</surname><given-names>R.</given-names></name><name name-style="western"><surname>FitzGerald</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mrsny</surname><given-names>R.J.</given-names></name></person-group><article-title>Intranasal Immunization Strategy To Impede Pilin-Mediated Binding of <italic toggle="yes">Pseudomonas aeruginosa</italic> to Airway Epithelial Cells</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>7705</fpage><lpage>7717</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.11.7705-7717.2005</pub-id><pub-id pub-id-type="pmid">16239575</pub-id><pub-id pub-id-type="pmcid">PMC1273878</pub-id></element-citation></ref><ref id="B209-ijms-26-02012"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farajnia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peerayeh</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Tanomand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majidi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Naghili</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rahbarnia</surname><given-names>L.</given-names></name></person-group><article-title>Protective Efficacy of Recombinant Exotoxin A&#8212;Flagellin Fusion Protein against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>Can. J. Microbiol.</source><year>2015</year><volume>61</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1139/cjm-2014-0501</pub-id><pub-id pub-id-type="pmid">25496361</pub-id></element-citation></ref><ref id="B210-ijms-26-02012"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elhosary</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bahey-El-Din</surname><given-names>M.</given-names></name><name name-style="western"><surname>AbdelBary</surname><given-names>A.</given-names></name><name name-style="western"><surname>El Guink</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aboushleib</surname><given-names>H.M.</given-names></name></person-group><article-title>Immunization with the Ferric Iron-Binding Periplasmic Protein HitA Provides Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic> in the Murine Infection Model</article-title><source>Microb. Pathog.</source><year>2019</year><volume>131</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2019.04.014</pub-id><pub-id pub-id-type="pmid">30978430</pub-id></element-citation></ref><ref id="B211-ijms-26-02012"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamad</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Edward</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Sheta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aboushleib</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bahey-El-Din</surname><given-names>M.</given-names></name></person-group><article-title>Iron Acquisition Proteins of <italic toggle="yes">Pseudomonas aeruginosa</italic> as Potential Vaccine Targets: In Silico Analysis and In Vivo Evaluation of Protective Efficacy of the Hemophore HasAp</article-title><source>Vaccines</source><year>2022</year><volume>11</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11010028</pub-id><pub-id pub-id-type="pmid">36679873</pub-id><pub-id pub-id-type="pmcid">PMC9864456</pub-id></element-citation></ref><ref id="B212-ijms-26-02012"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safari Zanjani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shapouri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dezfulian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shafiee Ardestani</surname><given-names>M.</given-names></name></person-group><article-title>Exotoxin A-PLGA Nanoconjugate Vaccine against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection: Protectivity in Murine Model</article-title><source>World J. Microbiol. Biotechnol.</source><year>2019</year><volume>35</volume><elocation-id>94</elocation-id><pub-id pub-id-type="doi">10.1007/s11274-019-2669-y</pub-id><pub-id pub-id-type="pmid">31187291</pub-id></element-citation></ref><ref id="B213-ijms-26-02012"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanomand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kafilzadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zolghadri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hosainzadegan</surname><given-names>H.</given-names></name></person-group><article-title>Preparation and Evaluation of the Exotoxin A Nano-Gold Conjugate as a Vaccine Candidate for <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections</article-title><source>Iran. J. Basic. Med. Sci.</source><year>2021</year><volume>24</volume><elocation-id>1366</elocation-id><pub-id pub-id-type="doi">10.22038/IJBMS.2021.58367.12960</pub-id><pub-id pub-id-type="pmid">35096294</pub-id><pub-id pub-id-type="pmcid">PMC8769522</pub-id></element-citation></ref><ref id="B214-ijms-26-02012"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najafzadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tanomand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haddadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majidi</surname><given-names>J.</given-names></name></person-group><article-title>Immunological Properties of Exotoxin A Toxoid&#8212;Detoxified Lipopolysaccharide&#8212;Gold Nanoparticles Conjugate Against <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>Iran. J. Immunol.</source><year>2021</year><volume>18</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.22034/IJI.2021.87816.1832</pub-id><pub-id pub-id-type="pmid">34931615</pub-id></element-citation></ref><ref id="B215-ijms-26-02012"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamshidi</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>S.</given-names></name><name name-style="western"><surname>St Michael</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vinogradov</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Sauvageau</surname><given-names>J.</given-names></name></person-group><article-title>Synthesis and Immunogenicity of a Methyl Rhamnan Pentasaccharide Conjugate from <italic toggle="yes">Pseudomonas aeruginosa</italic> A-Band Polysaccharide</article-title><source>ACS Infect. Dis.</source><year>2022</year><volume>8</volume><fpage>1347</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.2c00184</pub-id><pub-id pub-id-type="pmid">35674342</pub-id></element-citation></ref><ref id="B216-ijms-26-02012"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cairns</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Jamshidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Faassen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hussack</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sauvageau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vinogradov</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>A.D.</given-names></name></person-group><article-title>Structural Characterization and Evaluation of an Epitope at the Tip of the A-Band Rhamnan Polysaccharide of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>ACS Infect. Dis.</source><year>2022</year><volume>8</volume><fpage>1336</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.2c00183</pub-id><pub-id pub-id-type="pmid">35653593</pub-id></element-citation></ref><ref id="B217-ijms-26-02012"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamshidi</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khieu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sauvageau</surname><given-names>J.</given-names></name></person-group><article-title>Optimization of the Synthesis and Conjugation of the Methyl Rhamnan Tip of <italic toggle="yes">Pseudomonas aeruginosa</italic> A-Band Polysaccharide and Immunogenicity Evaluation for the Continued Development of a Potential Glycoconjugate Vaccine</article-title><source>ACS Infect. Dis.</source><year>2024</year><volume>10</volume><elocation-id>1361</elocation-id><pub-id pub-id-type="doi">10.1021/acsinfecdis.4c00049</pub-id><pub-id pub-id-type="pmid">38447154</pub-id><pub-id pub-id-type="pmcid">PMC11019553</pub-id></element-citation></ref><ref id="B218-ijms-26-02012"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zavan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Whitchurch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greening</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Kaparakis-Liaskos</surname><given-names>M.</given-names></name></person-group><article-title>The Mechanism of <italic toggle="yes">Pseudomonas aeruginosa</italic> Outer Membrane Vesicle Biogenesis Determines Their Protein Composition</article-title><source>Proteomics</source><year>2023</year><volume>23</volume><elocation-id>2200464</elocation-id><pub-id pub-id-type="doi">10.1002/pmic.202200464</pub-id><pub-id pub-id-type="pmid">36781972</pub-id></element-citation></ref><ref id="B219-ijms-26-02012"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomberger</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>MacEachran</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Coutermarsh</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Toole</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>B.A.</given-names></name></person-group><article-title>Long-Distance Delivery of Bacterial Virulence Factors by <italic toggle="yes">Pseudomonas aeruginosa</italic> Outer Membrane Vesicles</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000382</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000382</pub-id><pub-id pub-id-type="pmid">19360133</pub-id><pub-id pub-id-type="pmcid">PMC2661024</pub-id></element-citation></ref><ref id="B220-ijms-26-02012"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name></person-group><article-title>Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>mSphere</source><year>2021</year><volume>6</volume><elocation-id>e00699-21</elocation-id><pub-id pub-id-type="doi">10.1128/mSphere.00699-21</pub-id><pub-id pub-id-type="pmid">34612675</pub-id><pub-id pub-id-type="pmcid">PMC8510544</pub-id></element-citation></ref><ref id="B221-ijms-26-02012"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cimino</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name></person-group><article-title>Recombinant <italic toggle="yes">Pseudomonas</italic> Bionanoparticles Induce Protection against Pneumonic <italic toggle="yes">Pseudomonas aeruginosa</italic> Infection</article-title><source>Infect. Immun.</source><year>2021</year><volume>89</volume><elocation-id>e0039621</elocation-id><pub-id pub-id-type="doi">10.1128/IAI.00396-21</pub-id><pub-id pub-id-type="pmid">34310892</pub-id><pub-id pub-id-type="pmcid">PMC8519289</pub-id></element-citation></ref><ref id="B222-ijms-26-02012"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zare Banadkoki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rasooli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ghazanfari</surname><given-names>T.</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Shafiee Ardestani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Owlia</surname><given-names>P.</given-names></name></person-group><article-title><italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1 Outer Membrane Vesicles-Diphtheria Toxoid Conjugate as a Vaccine Candidate in a Murine Burn Model</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>22324</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-26846-z</pub-id><pub-id pub-id-type="pmid">36566282</pub-id><pub-id pub-id-type="pmcid">PMC9789887</pub-id></element-citation></ref><ref id="B223-ijms-26-02012"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Cellular Nanodiscs Made from Bacterial Outer Membrane as a Platform for Antibacterial Vaccination</article-title><source>ACS Nano</source><year>2022</year><volume>17</volume><fpage>1120</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c08360</pub-id><pub-id pub-id-type="pmcid">PMC10225015</pub-id><pub-id pub-id-type="pmid">36441916</pub-id></element-citation></ref><ref id="B224-ijms-26-02012"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Outer Membrane Vesicles from X-ray-Irradiated <italic toggle="yes">Pseudomonas aeruginosa</italic> Alleviate Lung Injury Caused by <italic toggle="yes">P. aeruginosa</italic> Infection-Mediated Sepsis</article-title><source>APMIS</source><year>2024</year><volume>132</volume><fpage>646</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1111/apm.13444</pub-id><pub-id pub-id-type="pmid">38837446</pub-id></element-citation></ref><ref id="B225-ijms-26-02012"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.-B.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>A Multiantigenic Antibacterial Nanovaccine Utilizing Hybrid Membrane Vesicles for Combating <italic toggle="yes">Pseudomonas aeruginosa</italic> Infections</article-title><source>J. Extracell. Vesicles</source><year>2024</year><volume>13</volume><elocation-id>e12524</elocation-id><pub-id pub-id-type="doi">10.1002/jev2.12524</pub-id><pub-id pub-id-type="pmid">39400457</pub-id><pub-id pub-id-type="pmcid">PMC11472236</pub-id></element-citation></ref><ref id="B226-ijms-26-02012"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Futamata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>Y.</given-names></name></person-group><article-title>Biofilm-Derived Membrane Vesicles Exhibit Potent Immunomodulatory Activity in <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1</article-title><source>Microbiol. Immunol.</source><year>2024</year><volume>68</volume><fpage>224</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.13156</pub-id><pub-id pub-id-type="pmid">38797913</pub-id></element-citation></ref><ref id="B227-ijms-26-02012"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papenfort</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bassler</surname><given-names>B.</given-names></name></person-group><article-title>Quorum-Sensing Signal-Response Systems in Gram-Negative Bacteria</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>576</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.89</pub-id><pub-id pub-id-type="pmid">27510864</pub-id><pub-id pub-id-type="pmcid">PMC5056591</pub-id></element-citation></ref><ref id="B228-ijms-26-02012"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyairi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tateda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fuse</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takabatake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Horikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Standiford</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Immunization with 3-Oxododecanoyl-l-Homoserine Lactone&#8211;Protein Conjugate Protects Mice from Lethal <italic toggle="yes">Pseudomonas aeruginosa</italic> Lung Infection</article-title><source>J. Med. Microbiol.</source><year>2006</year><volume>55</volume><fpage>1381</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46658-0</pub-id><pub-id pub-id-type="pmid">17005787</pub-id></element-citation></ref><ref id="B229-ijms-26-02012"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F.</given-names></name></person-group><article-title>A Comprehensive Comparison of DNA and RNA Vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2024</year><volume>210</volume><elocation-id>115340</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2024.115340</pub-id><pub-id pub-id-type="pmid">38810703</pub-id><pub-id pub-id-type="pmcid">PMC11181159</pub-id></element-citation></ref><ref id="B230-ijms-26-02012"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Galloway</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Staczek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gilleland</surname><given-names>H.E.</given-names></name></person-group><article-title>Protection against <italic toggle="yes">Pseudomonas aeruginosa</italic> Chronic Lung Infection in Mice by Genetic Immunization against Outer Membrane Protein F (OprF) of <italic toggle="yes">P. aeruginosa</italic></article-title><source>Infect. Immun.</source><year>2001</year><volume>69</volume><fpage>3510</fpage><lpage>3515</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.5.3510-3515.2001</pub-id><pub-id pub-id-type="pmid">11292786</pub-id><pub-id pub-id-type="pmcid">PMC98322</pub-id></element-citation></ref><ref id="B231-ijms-26-02012"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tozuka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takase</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Multivalent DNA Vaccine Protects Mice against Pulmonary Infection Caused by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>6240</fpage><lpage>6249</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.077</pub-id><pub-id pub-id-type="pmid">16806598</pub-id></element-citation></ref><ref id="B232-ijms-26-02012"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name></person-group><article-title>Enhanced Protective Efficacy of an OprF/PcrV Bivalent DNA Vaccine against <italic toggle="yes">Pseudomonas aeruginosa</italic> Using a Hydrogel Delivery System</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>172</volume><elocation-id>116264</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116264</pub-id><pub-id pub-id-type="pmid">38359491</pub-id></element-citation></ref><ref id="B233-ijms-26-02012"><label>233.</label><element-citation publication-type="gov"><article-title>PubChem TLR5&#8212;Toll Like Receptor 5 (Human)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/gene/TLR5/human" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/gene/TLR5/human</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-30">(accessed on 30 September 2024)</date-in-citation></element-citation></ref><ref id="B234-ijms-26-02012"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jounai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>K.-Q.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Blocking of the TLR5 Activation Domain Hampers Protective Potential of Flagellin DNA Vaccine</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>1147</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.2.1147</pub-id><pub-id pub-id-type="pmid">17617608</pub-id></element-citation></ref><ref id="B235-ijms-26-02012"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J.</given-names></name></person-group><article-title>A DNA Vaccine Encoding VP22 of Herpes Simplex Virus Type I (HSV-1) and <italic toggle="yes">OprF</italic> Confers Enhanced Protection from <italic toggle="yes">Pseudomonas aeruginosa</italic> in Mice</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>4399</fpage><lpage>4405</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.07.017</pub-id><pub-id pub-id-type="pmid">27449680</pub-id></element-citation></ref><ref id="B236-ijms-26-02012"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.Z.</given-names></name></person-group><article-title>Immune Efficacy of DNA Vaccines Based on <italic toggle="yes">oprL</italic> and <italic toggle="yes">oprF</italic> Genes of <italic toggle="yes">Pseudomonas aeruginosa</italic> in Chickens</article-title><source>Poult. Sci.</source><year>2018</year><volume>97</volume><fpage>4219</fpage><lpage>4227</lpage><pub-id pub-id-type="doi">10.3382/ps/pey307</pub-id><pub-id pub-id-type="pmid">30053150</pub-id></element-citation></ref><ref id="B237-ijms-26-02012"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>Immune Efficacy of Different Immunization Doses of Divalent Combination DNA Vaccine pOPRL+pOPRF of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Vet. Med. Sci.</source><year>2021</year><volume>83</volume><elocation-id>1959</elocation-id><pub-id pub-id-type="doi">10.1292/jvms.21-0036</pub-id><pub-id pub-id-type="pmid">34759080</pub-id><pub-id pub-id-type="pmcid">PMC8762422</pub-id></element-citation></ref><ref id="B238-ijms-26-02012"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.</given-names></name></person-group><article-title>Immune Responses and Protective Efficacy of a Trivalent Combination DNA Vaccine Based on <italic toggle="yes">oprL</italic>, <italic toggle="yes">oprF</italic> and <italic toggle="yes">flgE</italic> Genes of <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Veterin&#225;rn&#237; Medic&#237;na</source><year>2022</year><volume>67</volume><elocation-id>611</elocation-id><pub-id pub-id-type="doi">10.17221/86/2021-VETMED</pub-id><pub-id pub-id-type="pmid">38845784</pub-id><pub-id pub-id-type="pmcid">PMC11154874</pub-id></element-citation></ref><ref id="B239-ijms-26-02012"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rcheulishvili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Papukashvili</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Strong Immune Responses and Protection of PcrV and OprF-I mRNA Vaccine Candidates against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><elocation-id>76</elocation-id><pub-id pub-id-type="doi">10.1038/s41541-023-00672-4</pub-id><pub-id pub-id-type="pmid">37231060</pub-id><pub-id pub-id-type="pmcid">PMC10209580</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-02012-f001" orientation="portrait"><label>Figure 1</label><caption><p>Progression of <italic toggle="yes">P. aeruginosa</italic> infection in host cells. Infection progresses through adhesion, invasion, and dissemination. Flagella, pili, and OMPs mediate adhesion and biofilm formation. The T3SS injects cytotoxins (ExoS, ExoU) that disrupt the cytoskeleton, while proteases and phospholipases degrade the epithelial barriers. Dissemination, driven by flagella, rhamnolipids, and quorum-sensing systems, promotes immune evasion and bacterial spread, leading to acute infections with severe tissue damage or chronic infections, where <italic toggle="yes">P. aeruginosa</italic> undergoes adaptive changes and downregulates VFs to enhance biofilm formation. LPS, lipopolysaccharide; OMPs, outer membrane proteins; T3SS, type III secretion system; VFs, virulence factors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-02012-g001.jpg"/></fig><fig position="float" id="ijms-26-02012-f002" orientation="portrait"><label>Figure 2</label><caption><p>Major virulence factors as targets for vaccine development against <italic toggle="yes">P. aeruginosa</italic>. IM, inner membrane; LPS, lipopolysaccharides; OM, outer membrane; OMP, outer membrane protein; OMV, outer membrane vesicle; OPS, O-antigen; PG, peptidoglycan; QS, quorum sensing; T3SS, type III secretory system.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-02012-g002.jpg"/></fig><fig position="float" id="ijms-26-02012-f003" orientation="portrait"><label>Figure 3</label><caption><p><bold>Upper panel</bold>: Activation pathways of M1 and M2 macrophages. The pro-inflammatory cascade triggered by M1 macrophage activation is shown on the left. The anti-inflammatory cascade resulting from M2 macrophage activation is depicted on the right. The arrows represent connections between pathways. ECM, extracellular matrix; I, inflammasome; IL, interleukin; N, neutrophil; ROS, reactive oxygen species. <bold>Lower panel</bold>: Cytokines and factors released during the inflammatory and anti-inflammatory phases. Pro-inflammatory molecules are shown with a red background and anti-inflammatory molecules are shown with a green background.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-02012-g003.jpg"/></fig><fig position="float" id="ijms-26-02012-f004" orientation="portrait"><label>Figure 4</label><caption><p>Distribution of vaccine designs by base components. Graphical representation of the number of vaccine designs categorized by their primary base components. LPS, lipopolysaccharide; OMP, outer membrane protein; OMV, outer membrane vesicle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-02012-g004.jpg"/></fig></floats-group></article></pmc-articleset>